

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
**WO 02/12294 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 14/315**,  
A61K 39/09, C07K 16/12, C12N 5/12, A61K 39/40,  
C12N 15/12, 15/63, A61K 48/00, C12Q 1/68, G01N  
33/53, C07K 14/34

Elisabeth [CA/US]; 1041 Murray Hill Lane S., Memphis,  
TN 38120 (US). **BOHNSACK, John** [US/US]; 760 South  
1200 East, Salt Lake City, UT 84102 (US).

(21) International Application Number: PCT/US01/24795

(74) Agent: **DIETZEL, Christine, E.**; Klauber & Jackson, 411  
Hackensack Avenue, Hackensack, NJ 07601 (US).

(22) International Filing Date: 8 August 2001 (08.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/634,341 8 August 2000 (08.08.2000) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 09/634,341 (CON)  
Filed on 8 August 2000 (08.08.2000)

(71) Applicants (for all designated States except US): **ST.  
JUDE CHILDREN'S RESEARCH HOSPITAL**  
[US/US]; 332 North Lauderdale Street, Memphis, TN  
38105-2794 (US). **UNIVERSITY OF UTAH RE-  
SEARCH FOUNDATION** [US/US]; 615 Arapeen Drive,  
Suite 10, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ADDERSON,**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: GROUP B STREPTOCOCCUS POLYPEPTIDES NUCLEIC ACIDS AND THERAPEUTIC COMPOSITIONS AND VACCINES THEREOF

(57) Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of strepto-  
coccal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides  
EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of  
Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and  
fragments thereof. Ema homologous polypeptides from additional bacterial species, including *S. pneumoniae*, *S. pyogenes*, *E. fae-  
calis* and *C. diphtheriae* are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided.  
The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention pro-  
vides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the  
isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present  
invention for use in therapy are also provided.



**WO 02/12294 A2**

## GROUP B STREPTOCOCCUS POLYPEPTIDES NUCLEIC ACIDS AND THERAPEUTIC COMPOSITIONS AND VACCINES THEREOF

5

### GOVERNMENTAL SUPPORT

The research leading to the present invention was supported, at least in part, by a grant from NAID, Grant No.A140918. Accordingly, the Government may have certain  
10 rights in the invention.

### FIELD OF THE INVENTION

This invention relates generally to extracellular matrix adhesin (Ema) proteins,  
15 antibodies thereto and to vaccines, compositions and therapeutics. The Group B streptococcal Ema polypeptides are EmaA, EmaB, EmaC, EmaD and EmaE. The invention further relates to Ema polypeptides from various species of bacteria, including *S. pneumoniae*, *S. pyogenes*, *E. faecalis* and *C. diphtheriae*. The invention also relates to the identification and prevention of infections by streptococci. Isolated  
20 nucleic acids encoding Group B streptococcal Ema polypeptides, particularly EmaA, EmaB, EmaC, EmaD and EmaE and to other bacterial Ema homologs are included herein. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.

25

### BACKGROUND OF THE INVENTION

Streptococci are catalase negative gram positive cocci. They may be classified by the type of hemolysis exhibited on blood agar, by the serologic detection of carbohydrate antigens, or by certain biochemical reactions. Medically important streptococci include  
30 Groups A, B, D, *S. pneumoniae* and the viridans group of streptococci. Lancefield type A (GroupA) *Streptococcus pyogenes* is an important human pathogen - the cause of streptococcal pharyngitis, impetigo and more severe infections such as bacteremia

and necrotizing fascitis. The immunologic sequelae of Group A Streptococcal infections are also important health problems - rheumatic carditis is the most common cause of acquired cardiac disease worldwide and post-streptococcal glomerulonephritis is a cause of hypertension and renal dysfunction. Group B Streptococcus agalactiae are the most common cause of serious bacterial infections in newborns, and important pathogens in pregnant women and nonpregnant adults with underlying medical problems such as diabetes and cardiovascular disease. Group D streptococci include the enterococci (*Streptococcus faecalis* and *faecium*) and the "nonenterococcal" Group D streptococci. *Streptococcus pneumoniae* (pneumococcus) is not classified by group in the Lancefield system. Pneumococci are extremely important human pathogens, the most common cause of bacterial pneumonia, middle ear infections and meningitis beyond the newborn period. The viridans group of streptococci include *S. milleri*, *S. mitis*, *S. sanguis* and others. They cause bacteremia, endocarditis, and dental infections. Enterococci are important causes of urinary tract infections, bacteremia and wound infections (predominantly as nosocomial infections in hospitalized patients), and endocarditis. Over the past decade enterococci have developed resistance to many conventional antibiotics and there are some strains resistant to all known antibiotics.

Group B streptococci (GBS) are the most common cause of serious bacterial disease in neonates, and are important pathogens in pregnant women and adults with underlying illnesses (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis*. (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237). Common manifestations of these infections include bacteremia, pneumonia, meningitis, endocarditis, and osteoarticular infections (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis*. (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237; Blumberg H.M. et al. (1996) *J Infect Dis* 173:365-373). The incidence of invasive GBS disease is approximately 2.6 in 1000 live births and 7.7 in 100,000 in the overall population, with mortality rates that vary from 6 to 30% (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections*.

*Clinical aspects, microbiology, and molecular pathogenesis.* (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237; Blumberg H.M. et al. (1996) *J Infect Dis* **173**:365-373). Although much neonatal disease is preventable by administration of prophylactic antibiotics to women in labor, antibiotic prophylaxis  
5 programs can be inefficient, suffer from poor compliance, or fail if antibiotic resistance emerges. No effective prophylaxis strategy for adult infections has been established.

During childbirth, GBS can pass from the mother to the newborn. By one estimate, up to 30% of pregnant women carry GBS at least temporarily in the vagina or rectum  
10 without symptoms. Infants born to these women become colonized with GBS during delivery (Baker, C.J. and Edwards, M.S. (1995) "Group B Streptococcal Infections" in *Infectious Disease of the Fetus and Newborn Infant* (J.S. Remington and J.O Klein), 980-1054). Aspiration of infected amniotic fluid or vaginal secretions allow GBS to gain access to the lungs. Adhesion to, and invasion of, respiratory epithelium and  
15 endothelium appear to be critical factors in early onset neonatal infection. (Baker, C.J. and Edwards, M.S. (1995) "Group B Streptococcal Infections" in *Infectious Disease of the Fetus and Newborn Infant* (J.S. Remington and J.O Klein), 980-1054; Rubens, C.E. et al. (1991) *J Inf Dis* **164**:320-330). Subsequent steps in infection, such as blood stream invasion and the establishment of metastatic local infections have not been  
20 clarified. The pathogenesis of neonatal infection occurring after the first week of life is also not well understood. Gastrointestinal colonization may be more important than a respiratory focus in late onset neonatal disease (Baker, C.J. and Edwards, M.S. (1995) "Group B Streptococcal Infections" in *Infectious Disease of the Fetus and Newborn Infant* (J.S. Remington and J.O Klein), 980-1054). Considerable evidence suggests that  
25 invasion of brain microvascular endothelial cells by GBS is the initial step in the pathogenesis of meningitis. GBS are able to invade human brain microvascular endothelial cells and type III GBS, which are responsible for the majority of meningitis, accomplish this 2-6 times more efficiently than other serotypes (Nizet, V. et al. (1997) *Infect Immun* **65**:5074-5081).



- Because GBS is widely distributed among the population and is an important pathogen in newborns, pregnant women are commonly tested for GBS at 35-37 weeks of pregnancy. Much of GBS neonatal disease is preventable by administration of prophylactic antibiotics during labor to women who test positive or display known risk factors. However, these antibiotics programs do not prevent all GBS disease. The programs are deficient for a number of reasons. First, the programs can be inefficient. Second, it is difficult to ensure that all healthcare providers and patients comply with the testing and treatment. And finally, if new serotypes or antibiotic resistance emerges, the antibiotic programs may fail altogether. Currently available tests for GBS are inefficient. These tests may provide false negatives. Furthermore, the tests are not specific to virulent strains of GBS. Thus, antibiotic treatment may be given unnecessarily and add to the problem of antibiotic resistance. Although a vaccine would be advantageous, none are yet commercially available.
- Traditionally, GBS are divided into 9 serotypes according to the immunologic reactivity of the polysaccharide capsule (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis*. (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237; Blumberg H.M. et al. (1996) *J Infect Dis* 173:365-373; Kogan, G. et al. (1996) *J Biol Chem* 271:8786-8790). Serotype III GBS are particularly important in human neonates, causing 60-70% of all infections and almost all meningitis (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis*. (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237). Type III GBS can be subdivided into three groups of related strains based on the analysis of restriction digest patterns (RDPs) produced by digestion of chromosomal DNA with *Hind* III and *Sse*8387 (I. Y. Nagano et al. (1991) *J Med Micro* 35:297-303; S. Takahashi et al. (1998) *J Inf Dis* 177:1116-1119).
- Over 90% of invasive type III GBS neonatal disease in Tokyo, Japan and in Salt Lake City, Utah is caused by bacteria from one of three RDP types, termed RDP type III-3,

while RDP type III-2 are significantly more likely to be isolated from vagina than from blood or CSF. These results suggest that this genetically-related cluster of type III-3 GBS are more virulent than III-2 strains and could be responsible for the majority of invasive type III disease globally.

5

- Preliminary vaccines for GBS used unconjugated purified polysaccharide. GBS poly - and oligosaccharides are poorly immunogenic and fail to elicit significant memory and booster responses. Baker et al immunized 40 pregnant women with purified serotype III capsular polysaccharide (Baker, C.J. et al. (1998) *New Engl J of Med* 319:1180-1185). Overall, only 57% of women with low levels of specific antibody responded to the vaccine. The poor immunogenicity of purified polysaccharide antigen was further demonstrated in a study in which thirty adult volunteers were immunized with a tetravalent vaccine composed of purified polysaccharide from serotypes Ia, Ib, II, and III (Kotloff, K.L. et al. (1996) *Vaccine* 14:446-450). Although safe, this vaccine was only modestly immunogenic, with only 13% of subjects responding to type Ib, 17% to type II, 33% responding to type Ia, and 70% responding to type III polysaccharide. The poor immunogenicity of polysaccharide antigens prompted efforts to develop polysaccharide conjugate vaccines, whereby these poly - or oligosaccharides are conjugated to protein carriers. Ninety percent of healthy adult women immunized with a type III polysaccharide-tetanus toxoid conjugate vaccine responded with a 4-fold rise in antibody concentration, compared to 50% immunized with plain polysaccharide (Kasper, D.L. et al (1996) *J of Clin Invest* 98:2308-2314). A type Ia/Ib polysaccharide-tetanus toxoid conjugate vaccine was similarly more immunogenic in healthy adults than plain polysaccharide (Baker, C.J. et al (1999) *J Infect Dis* 179:142-150).

- The disadvantage of polysaccharide-protein conjugate vaccines is that the process of purifying and conjugating polysaccharides is difficult, time-consuming and expensive. A protein antigen which could be cheaply and easily produced would be an improvement.

30

If one were to make a polysaccharide-protein conjugate vaccine, a GBS-specific carrier protein may be preferable to one of the commonly used carriers such as tetanus or diphtheria toxoids because of the potential problems associated with some of these carrier proteins, particularly variable immunogenicity and the problems associated with repeated vaccination with the same carrier protein. Selection of appropriate carrier proteins is important for the development of polysaccharide-protein vaccine formulations. For example, *Haemophilus influenzae* type b poly- or oligosaccharide conjugated to different protein carriers has variable immunogenicity and elicits antibody with varying avidity (Decker, M.D. et al (1992) *J Pediatrics* 120:184-189; Schlesinger, Y. (1992) *JAMA* 267:1489-1494). Repeated immunization with the same carrier protein may also suppress immune responses by competition for specific B cells (epitopic suppression) or other mechanisms. This is of particular concern for the development of GBS vaccines since recently developed poly/oligosaccharide-protein conjugate vaccines against the bacteria *H. influenzae*, *S. pneumoniae*, and *N. meningitidis* all utilize a restricted number of carrier proteins (tetanus toxoid, CRM197, diphtheria toxoid), increasing the number of exposures to these carriers an individual is likely to receive. Additionally, using tetanus as a carrier protein offers no specific advantage beyond the improved immunogenicity of the vaccine. A second-generation vaccine containing a GBS-specific carrier protein would enhance immunogenicity and have an advantage in that a GBS-specific immune response would be generated against both the carrier protein and the poly/oligosaccharide.

Therefore, in view of the aforementioned deficiencies attendant with prior art vaccines and methods, it should be apparent that there still exists a need in the art for an effective and immunogenic GBS vaccine. The availability and use of a GBS polypeptide in a conjugate vaccine is desirable. A GBS polypeptide which is present or expressed in all GBS serotypes would have the added advantage of providing broad, general immunity across many GBS serotypes. It would be particularly relevant and useful to provide a streptococcal vaccine or immunogen which is expressed broadly in various streptococcal species, whereby broad or general immunity against multiple and unique groups of streptococci (for instance, Group A, Group B and *S. pneumoniae*),

particularly against distinct virulent and clinically relevant streptococcal bacteria, could thereby be generated.

The citation of references herein shall not be construed as an admission that such is  
5 prior art to the present invention.

### SUMMARY OF THE INVENTION

In accordance with the present invention, streptococcal polypeptides termed  
10 extracellular matrix adhesins (Ema) are provided which are particularly useful in the identification and prevention of infections by streptococci.

In its broadest aspect, the present invention encompasses isolated polypeptides comprising an amino acid sequence of a streptococcal polypeptide selected from the  
15 group of EmaA, EmaB, EmaC, EmaD and EmaE. The isolated peptides, including combinations of one or more thereof, are suitable for use in immunizing animals and humans against bacterial infection, particularly streptococci.

The present invention is directed to an isolated streptococcal EmaA polypeptide which  
20 comprises the amino acid sequence set out in SEQ ID NO: 2, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaB polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 4, and analogs, variants and  
25 immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaC polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 6, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaD polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 8, and analogs, variants and immunogenic fragments thereof.

- 5 The present invention is directed to an isolated streptococcal EmaE polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 10, and analogs, variants and immunogenic fragments thereof.

The present invention also provides Ema polypeptide homologs from distinct bacterial  
10 species, particularly including distinct streptococcal species, more particularly including Group B streptococcus, Group A streptococcus (particularly *S. pyogenes*) and *S. pneumoniae*. The present invention also provides Ema polypeptides from additional distinct bacterial species, particularly including *Enterococcus faecalis* and *Corynebacterium diphtheriae*. Nucleic acids encoding Ema polypeptide homologs from  
15 distinct bacterial species are also provided.

The present invention thus provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:23. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:23 is further  
20 provided.

The invention thus further provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:26. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:26 is further  
25 provided.

The present invention further provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:37. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:37 is further  
30 provided.

An enterococcal Ema polypeptide is further provided comprising the amino acid sequence set out in SEQ ID NO:29. An isolated isolated nucleic acid which encodes the enterococcal polypeptide set out in SEQ ID NO:29 is also provided.

- 5 The invention provides an isolated *Corynebacterium* Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO: 32. Also provided is an isolated nucleic acid which encodes the *Corynebacterium* polypeptide set out in SEQ ID NO: 32.

The invention provides an isolated bacterial polypeptide comprising the amino acid  
10 sequence TLLTCTPYMINS/THRLVR/KG (SEQ ID NO: 34), wherein the polypeptide is not isolated from *Actinomyces*.

The invention further provides an isolated streptococcal polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLVR/KG (SEQ ID NO: 34).

15

Also provided is an isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGINTHRLVTA (SEQ ID NO: 35).

The present invention includes an isolated bacterial polypeptide comprising the amino  
20 acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36). An isolated streptococcal polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36) is also provided.

The invention further includes an isolated polypeptide having the amino acid sequence  
25 selected from the group of TLLTCTPYMINS/THRLVR/KG (SEQ ID NO: 34), TLVTCTPYGINTHRLVTA (SEQ ID NO: 35), and TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36).

The present invention contemplates the use of the polypeptides of the present invention  
30 in diagnostic tests and methods for determining and/or monitoring of streptococcal infection. Thus, the present invention provides an isolated Ema polypeptide,

particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, labeled with a detectable label.

5 In the instance where a radioactive label, such as the isotopes  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$  are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

10

The present invention extends to an immunogenic Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, or a fragment thereof. The present invention also extends to immunogenic Ema polypeptides wherein such polypeptides comprise a combination of at least one immunogenic Ema  
15 polypeptide, selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, or immunogenic polypeptide fragment thereof, and a GBS polypeptide selected from the group of Spb1, Spb2, C protein alpha antigen, Rib, Lmb, C5a-ase, or immunogenic fragments thereof.

20 In a further aspect, the present invention extends to vaccines based on the Ema proteins described herein. The present invention provides a vaccine comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant. The present invention provides a vaccine comprising one or more streptococcal polypeptides selected from  
25 the group of the polypeptide of SEQ ID NO: 23, 26, and 37, and a pharmaceutically acceptable adjuvant.

The present invention further provides a streptococcal vaccine comprising one or more Group B streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC,  
30 EmaD and EmaE, further comprising one or more additional streptococcal antigens. The present invention further provides a GBS vaccine comprising one or more Group

- B streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more additional GBS antigens. In a particular embodiment, the GBS antigen is selected from the group of the polypeptide Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof Lmb or an immunogenic fragment thereof, C5a-ase or an immunogenic fragment thereof and Group B streptococcal polysaccharides or oligosaccharides.
- 10 In another aspect, the invention is directed to a vaccine for protection of an animal subject from infection with streptococci comprising an immunogenic amount of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. Such a vaccine may contain the protein conjugated covalently to a GBS bacterial polysaccharide or oligosaccharide or polysaccharide or oligosaccharide from one or more GBS serotypes.
- In a still further aspect, the present invention provides an immunogenic composition comprising one of more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant.
- 20 The present invention further provides an immunogenic composition comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more antigens selected from the group of the polypeptide Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof Lmb or an immunogenic fragment thereof, C5a-ase or an immunogenic fragment thereof, and Group B streptococcal polysaccharides or oligosaccharides.
- 25 30 The invention further provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use thereof.



- The invention provides pharmaceutical compositions comprising a bacterial Ema polypeptide and a pharmaceutically acceptable carrier. The invention provides pharmaceutical compositions comprising a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, the polypeptide of SEQ ID NO:23, the polypeptide of SEQ ID NO: 26, the polypeptide of SEQ ID NO:37, and a pharmaceutically acceptable carrier. The invention provides pharmaceutical compositions comprising a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The present invention further provides pharmaceutical compositions comprising one or more GBS Ema polypeptide, or a fragment thereof, in combination with one or more of GBS polypeptide Spb1, Spb2, C protein alpha antigen, Rib, Lmb, C5a-ase, a Group B streptococcal polysaccharide or oligosaccharide vaccine, and an anti-streptococcal vaccine.
- In a still further aspect, the present invention provides a purified antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a still further aspect, the present invention provides a purified antibody to a streptococcal polypeptide selected from the group of the polypeptide of SEQ ID NO:23, the polypeptide of SEQ ID NO: 26, and the polypeptide of SEQ ID NO:37.
- Antibodies against the isolated polypeptides of the present invention include naturally raised and recombinantly prepared antibodies. These may include both polyclonal and monoclonal antibodies prepared by known genetic techniques, as well as bi-specific (chimeric) antibodies, and antibodies including other functionalities suiting them for diagnostic use. Such antibodies can be used in immunoassays to diagnose infection with a particular strain or species of bacteria. The antibodies can also be used for passive immunization to treat an infection with streptococcal bacteria including Group B streptococcus, Group A streptococcus, and *S. pneumoniae*. These antibodies may also be suitable for modulating bacterial adherence and/or invasion including but not limited to acting as competitive agents.

The present invention provides a monoclonal antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The invention thereby extends to an immortal cell line that produces a monoclonal antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and  
5 EmaE.

An antibody to a streptococcal Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE labeled with a detectable label is further provided. In particular embodiments, the label may be selected from the group consisting of an enzyme, a chemical which  
10 fluoresces, and a radioactive element.

The present invention provides a pharmaceutical composition comprising one or more antibodies to a streptococcal protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The invention further  
15 provides a pharmaceutical composition comprising a combination of at least two antibodies to Group B streptococcal proteins and a pharmaceutically acceptable carrier, wherein at least one antibody to a protein selected from the group of EmaA, EmaB, EmaC, EmaD, and EmaE is combined with at least one antibody to a protein selected from the group of Spb1, Spb2, Rib, Lmb, C5a-ase and a C protein alpha  
20 antigen.

The present invention also relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode the isolated polypeptide of the present invention or  
25 which competitively inhibit the activity of the polypeptide. The present invention further relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode a bacterial Ema polypeptide. The present invention further relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate  
30 variants thereof, mutants, analogs, or fragments thereof, which encode a streptococcal Ema polypeptide. The present invention further relates to isolated nucleic acids, such

as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode a streptococcal Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. Preferably, the isolated nucleic acid, which includes degenerates, variants, mutants, analogs, or fragments thereof, has a sequence as set forth in SEQ ID NOS: 1, 3, 5, 7 or 9. In a further embodiment of the invention, the DNA sequence of the recombinant DNA molecule or cloned gene may be operatively linked to an expression control sequence which may be introduced into an appropriate host. The invention accordingly extends to unicellular hosts transformed with the cloned gene or recombinant DNA molecule comprising a DNA sequence encoding an Ema protein, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and more particularly, the DNA sequences or fragments thereof determined from the sequences set forth above.

In a particular embodiment, the nucleic acid encoding the EmaA polypeptide has the sequence selected from the group comprising SEQ ID NO:1; a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:1 or a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof, and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaA polypeptide has the sequence selected from the group comprising SEQ ID NO:1; a sequence complementary to SEQ ID NO:1; or a homologous sequence which is substantially similar to SEQ ID NO:1. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:1.

In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:3 or a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization

conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence complementary to SEQ ID NO:3; or a homologous sequence which is substantially  
5 similar to SEQ ID NO:3. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:3.

In a particular embodiment, the nucleic acid encoding the EmaC polypeptide has the sequence selected from the group comprising SEQ ID NO:5; a sequence that  
10 hybridizes to SEQ ID NO:5 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:5 or a sequence that hybridizes to SEQ ID NO:5 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaC polypeptide  
15 has the sequence selected from the group comprising SEQ ID NO:5; a sequence complementary to SEQ ID NO:5; or a homologous sequence which is substantially similar to SEQ ID NO:5. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:5.

20 In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:7 or a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization  
25 conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence complementary to SEQ ID NO:7; or a homologous sequence which is substantially similar to SEQ ID NO:7. In a further embodiment, the nucleic acid has the sequence  
30 consisting of SEQ ID NO:7.

In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the sequence selected from the group comprising SEQ ID NO:9; a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:9 or  
5 a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the sequence selected from the group comprising SEQ ID NO:9; a sequence complementary to SEQ ID NO:9; or a homologous sequence which is substantially  
10 similar to SEQ ID NO:9. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:9.

In a further embodiment, the nucleic acid encoding the bacterial Ema polypeptide comprises the sequence selected from the group comprising SEQ ID NO: 24, 27, 30  
15 and 33. In a further embodiment, the nucleic acid encoding the bacterial Ema polypeptide has the sequence selected from the group comprising SEQ ID NO: 24, 27, 30 and 33.

A nucleic acid capable of encoding a streptococcal polypeptide EmaA, EmaB, EmaC, EmaD or EmaE which is a recombinant DNA molecule is further provided. Such a recombinant DNA molecule wherein the DNA molecule is operatively linked to an expression control sequence is also provided herein.  
20

The present invention relates to nucleic acid vaccines or DNA vaccines comprising  
25 nucleic acids encoding immunogenic streptococcal Ema polypeptides, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding one or more immunogenic Ema polypeptide or a fragment thereof or any combination of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE  
30 with at least one other polypeptide, particularly a GBS polypeptide, more particularly wherein said other GBS polypeptide is selected from the group of Spb1, Spb2, C

protein alpha antigen, Rib, Lmb, C5a-ase, and immunogenic polypeptide fragments thereof.

The invention further relates to a vaccine for protection of an animal subject from  
5 infection with a streptococcal bacterium comprising a vector containing a gene  
encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC,  
EmaD and EmaE operatively associated with a promoter capable of directing  
expression of the gene in the subject. The present invention further provides a nucleic  
acid vaccine comprising a recombinant DNA molecule capable of encoding a GBS  
10 polypeptide EmaA, EmaB, EmaC, EmaD or EmaE.

The invention further relates to a vaccine for protection of an animal subject from  
infection with a Group B streptococcal bacterium comprising a vector containing a  
gene encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC,  
15 EmaD and EmaE operatively associated with a promoter capable of directing  
expression of the gene in the subject. The present invention further provides a nucleic  
acid vaccine comprising a recombinant DNA molecule capable of encoding a GBS  
polypeptide EmaA, EmaB, EmaC, EmaD or EmaE.

20 The present invention provides a vector which comprises the nucleic acid capable of  
encoding encoding an Ema polypeptide selected from the group of EmaA, EmaB,  
EmaC, EmaD and EmaE and a promoter. The present invention provides a vector  
which comprises the nucleic acid of any of SEQ ID NO: 1, 3, 5, 7 or 9 and a  
promoter. The invention contemplates a vector wherein the promoter comprises a  
25 bacterial, yeast, insect or mammalian promoter. The invention contemplates a vector  
wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC),  
bacteriophage or eukaryotic viral DNA.

The present invention further provides a host vector system for the production of a  
30 polypeptide which comprises the vector capable of encoding an Ema polypeptide,  
particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE in a

suitable host cell. A host vector system is provided wherein the suitable host cell comprises a prokaryotic or eukaryotic cell. A unicellular host transformed with a recombinant DNA molecule or vector capable of encoding encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is  
5 thereby provided.

The present invention includes methods for determining and monitoring infection by streptococci by detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the  
10 streptococcal Ema polypeptide is measured by:

a. contacting a sample in which the presence or activity of a Streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal polypeptide under conditions that allow binding of the  
15 streptococcal polypeptide to the antibody to occur; and

b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;

20 wherein the detection of binding indicates the presence or activity of the streptococcal polypeptide in the sample.

The present invention includes methods for determining and monitoring infection by streptococci by detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the  
25 streptococcal Ema polypeptide is measured by:

a. contacting a sample in which the presence or activity of a Streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal polypeptide under conditions that allow binding of the  
30 streptococcal polypeptide to the antibody to occur; and

- b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;

wherein the detection of binding indicates the presence or activity of the streptococcal polypeptide in the sample.

The present invention includes methods for determining and monitoring infection by Group B streptococci by detecting the presence of a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the streptococcal Ema polypeptide is measured by:

- a. contacting a sample in which the presence or activity of a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said Group B streptococcal polypeptide under conditions that allow binding of the Group B streptococcal polypeptide to the antibody to occur; and

- b. detecting whether binding has occurred between the Group B streptococcal polypeptide from the sample and the antibody;

wherein the detection of binding indicates the presence or activity of the Group B streptococcal polypeptide in the sample.

The present invention further provides a method for detecting the presence of a bacterium having a gene encoding a streptococcal polypeptide selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, comprising:

- a. contacting a sample in which the presence or activity of the bacterium is suspected with an oligonucleotide which hybridizes to a streptococcal polypeptide gene selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, under conditions that allow specific hybridization of the oligonucleotide to the gene to occur; and



- b. detecting whether hybridization has occurred between the oligonucleotide and the gene;

wherein the detection of hybridization indicates that presence or activity of the  
5 bacterium in the sample.

The invention includes an assay system for screening of potential compounds effective to modulate the activity of a streptococcal protein EmaA, EmaB, EmaC, EmaD or EmaE of the present invention. In one instance, the test compound, or an extract  
10 containing the compound, could be administered to a cellular sample expressing the particular Ema protein to determine the compound's effect upon the activity of the protein by comparison with a control. In a further instance the test compound, or an extract containing the compound, could be administered to a cellular sample expressing the Ema protein to determine the compound's effect upon the activity of  
15 the protein, and thereby on adherence of said cellular sample to host cells, by comparison with a control.

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of streptococci,  
20 so as to treat or prevent the adverse consequences of invasive, spontaneous, or idiopathic pathological states.

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of Group B streptococci, so as to treat or prevent the adverse consequences of invasive,  
25 spontaneous, or idiopathic pathological states.

The invention provides a method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine comprising an Ema polypeptide selected  
30 from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

The invention further provides a method for preventing infection with a bacterium that expresses a Group B streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

5

The present invention is directed to a method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a  
10 pharmaceutically acceptable carrier to a subject.

The invention further provides a method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an antibody to an Ema  
15 polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier to a subject.

In a further aspect, the invention provides a method of inducing an immune response in a subject which has been exposed to or infected with a streptococcal bacterium  
20 comprising administering to the subject an amount of the pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier, thereby inducing an immune response.

25 The invention still further provides a method for preventing infection by a streptococcal bacterium in a subject comprising administering to the subject an amount of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a  
30 streptococcal bacterium.

In a further aspect, the invention provides a method of inducing an immune response in a subject which has been exposed to or infected with a Group B streptococcal bacterium comprising administering to the subject an amount of the pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier, thereby inducing an immune response.

The invention still further provides a method for preventing infection by a Group B streptococcal bacterium in a subject comprising administering to the subject an amount of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a streptococcal bacterium.

The invention further provides an *ema* mutant bacteria which is non-adherent and/or non-invasive to cells, particularly which is mutated in one or more genes selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*. Particularly, such *ema* mutant is a streptococcal bacteria. More particularly, such *ema* mutant is a Group B streptococcal bacteria. Such non-adherent and/or non-invasive *ema* mutant bacteria can further be utilized in expressing other immunogenic or therapeutic proteins for the purposes of eliciting immune responses to any such other proteins in the context of vaccines and in other forms of therapy.

Other objects and advantages will become apparent to those skilled in the art from a review of the following description which proceeds with reference to the following illustrative drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**FIGURE 1** depicts the restriction digest pattern (RDP) type III-3 specific probes. Dot blot hybridization of probe DY1-1 with genomic DNA isolated from type III

GBS. 10 ug of genomic DNA from each of 62 type III GBS strains was transferred to nylon membrane. Radiolabeled probe DY1-1 hybridized with DNA from all III-3 strains (rows A-D) including the original type III-3 strain (well E-1). The probe failed to hybridize with DNA from III-2 strains (F1- F10, G1-7) including the original strain used in the subtraction hybridization (well E 10) and III-1 strains (wells H1-3; cf. Figure 3). The same pattern of hybridization was observed using probe DY1-11.

**FIGURE 2** depicts the nucleic acid and predicted amino acid sequence of *emaA*.

10 **FIGURE 3** depicts the nucleic acid and predicted amino acid sequence of *emaB*.

**FIGURE 4** depicts the nucleic acid and predicted amino acid sequence of *emaC*.

**FIGURE 5** depicts the nucleic acid and predicted amino acid sequence of *emaD*.

15

**FIGURE 6 A-D** depicts the nucleic acid and predicted amino acid sequence of *emaE*.

#### DETAILED DESCRIPTION

20 The present invention provides novel Group B streptococcal Ema polypeptides and their Ema homologs in distinct bacterial species, including distinct streptococcal species. The present invention relates to novel streptococcal Ema polypeptides, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and fragments thereof. Nucleic acids encoding Ema polypeptides, and diagnostic and  
25 therapeutic compositions and methods based thereon for identification and prevention of infections by virulent forms of streptococci are provided. In particular, the present invention includes Group B streptococcal Ema polypeptides. The invention further includes polypeptide homologs of the GBS Ema polypeptides, particularly streptococcal homologs, more particularly Ema homologs of *S. pneumoniae* and *S.*  
30 *pyogenes*. Bacterial Ema polypeptide homologs in *E. faecalis* and *C. diphtheriae* are also provided.

*Polypeptides*

The present invention is directed to an isolated polypeptide comprising an amino acid  
5 sequence of a bacterial Ema polypeptide. Bacterial Ema polypeptides are provided  
from streptococcus, enterococcus and corynebacterium. The present invention is  
particularly directed to an isolated polypeptide comprising an amino acid sequence of a  
streptococcal Ema polypeptide selected from the group of EmaA, EmaB, EmaC,  
EmaD and EmaE. The present invention is particularly directed to an isolated  
10 polypeptide comprising an amino acid sequence of a Group streptococcal Ema  
polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.  
Additional *S. pneumoniae* and *S. pyogenes* Ema polypeptides are included in the  
invention. *E. faecalis* and *C. diphtheriae* Ema polypeptides are also included in the  
invention.

15

The polypeptides of the present invention are suitable for use in immunizing animals  
broadly against streptococcal infection. The polypeptides of the present invention are  
suitable for use in immunizing animals broadly against Group B, Group A, and *S.*  
*pneumoniae* streptococcal infection. The polypeptides of the present invention are  
20 suitable for use in immunizing animals against Group B streptococci. These  
polypeptide or peptide fragments thereof, when formulated with an appropriate  
adjuvant, are used in vaccines for protection against streptococci, particularly Group B  
streptococci, and against other bacteria with cross-reactive proteins.

25 GBS proteins with streptococcal homologs outside of Group B have been previously  
identified (Lachenauer CS and Madoff LC (1997) *Adv Exp Med Biol.* **418**:615-8;  
Brady L.J. et al (1991) *Infect Immun* **59**(12):4425-35; Stahlhammer-Carlemalm M. et  
al (2000) *J Infect Dis* **182**(1):142-129). Stahlhammer-Carlemalm et al have  
demonstrated cross-protection between Group A and Group B streptococci due to  
30 cross-reacting surface proteins (Stahlhammer-Carlemalm M. et al (2000) *J Infect Dis*  
**182**(1):142-129). The R28 protein of group A streptococcus (GAS) and the Rib

protein of group B streptococcus (GBS) are surface molecules that elicit protective immunity to experimental infection. These proteins are members of the same family and cross-react immunologically. In spite of extensive amino acid residue identity, the cross-reactivity between R28 and Rib was found to be limited, as shown by analysis  
5 with highly purified proteins and specific antisera. Nevertheless, immunization of mice with purified R28 conferred protection against lethal infection with Rib-expressing GBS strains, and immunization with Rib conferred protection against R28-expressing GAS. Thus, R28 and Rib elicited cross-protective immunity.

10 The present invention is directed to an isolated streptococcal EmaA polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 2, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaB polypeptide which  
15 comprises the amino acid sequence set out in SEQ ID NO: 4, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaC polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 6, and analogs, variants  
20 and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaD polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 8, and analogs, variants and immunogenic fragments thereof.

25

The identity or location of one or more amino acid residues may be changed or modified to include variants such as, for example, deletions containing less than all of the residues specified for the protein, substitutions wherein one or more residues specified are replaced by other residues and additions wherein one or more amino acid  
30 residues are added to a terminal or medial portion of the polypeptide. These molecules include: the incorporation of codons "preferred" for expression by selected

non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.

- 5 The present invention is directed to an isolated Group B streptococcal EmaE polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 10, and analogs, variants and immunogenic fragments thereof.

- 10 The present invention thus provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:23. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:23 is further provided.

- 15 The invention thus further provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:26. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:26 is further provided.

- 20 The present invention further provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:37. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:37 is further provided.

- 25 An enterococcal Ema polypeptide is further provided comprising the amino acid sequence set out in SEQ ID NO:29. An isolated isolated nucleic acid which encodes the enterococcal polypeptide set out in SEQ ID NO:29 is also provided.

- 30 The invention provides an isolated *Corynebacterium* Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO: 32. Also provided is an isolated nucleic acid which encodes the *Corynebacterium* polypeptide set out in SEQ ID NO: 32.

The invention provides an isolated bacterial polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), wherein the polypeptide is not isolated from *Actinomyces*.

- 5 The invention further provides an isolated streptococcal polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34).

Also provided is an isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35).

10

The present invention includes an isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36). An isolated streptococcal polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36) is also provided.

15

The invention further includes an isolated polypeptide having the amino acid sequence selected from the group of TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35), and TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36).

20

The present invention contemplates the use of the streptococcal polypeptides of the present invention in diagnostic tests and methods for determining and/or monitoring of streptococcal infection. Thus, the present invention provides an isolated GBS Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and  
25 EmaE, labeled with a detectable label.

In the instance where a radioactive label, such as the isotopes  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$  are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme,  
30 detection may be accomplished by any of the presently utilized colorimetric,



spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

The present invention extends to an immunogenic bacterial Ema polypeptide. The  
5 present invention extends to an immunogenic streptococcal Ema polypeptide,  
particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, or a  
fragment thereof. The present invention also extends to immunogenic GBS Ema  
polypeptides wherein such polypeptides comprise a combination of at least one  
immunogenic GBS Ema polypeptide, selected from the group of EmaA, EmaB, EmaC,  
10 EmaD and EmaE, or immunogenic polypeptide fragment thereof and GBS polypeptide  
Spb1, Spb2, C protein alpha antigen, Rib or immunogenic fragments thereof.

As defined herein, "adhesion" means noncovalent binding of a bacteria to a human cell  
or secretion that is stable enough to withstand washing.

15

The term "extracellular matrix adhesin", "Ema", "ema" and any variants not specifically  
listed, may be used herein interchangeably, and as used throughout the present  
application and claims refer to proteinaceous material including single or multiple  
proteins, and extends to those proteins having the amino acid sequence data described  
20 herein and particularly identified by (SEQ ID NOS: 2, 4, 6, 8, 10, 23, 26, 29, 32 and  
37), and the profile of activities set forth herein and in the Claims. In particular the  
Ema proteins provided herein include EmaA, EmaB, EmaC, EmaD and EmaE. The  
Ema proteins include bacterial Ema homologs. Bacterial Ema homologs include those  
from streptococcal species and other bacterial species. Accordingly, proteins and  
25 polypeptides displaying substantially equivalent or altered activity are likewise  
contemplated. These modifications may be deliberate, for example, such as  
modifications obtained through site-directed mutagenesis, or may be accidental, such  
as those obtained through mutations in hosts that are producers of one or more Ema  
polypeptide. Also, the term "extracellular matrix adhesin (Ema)" is intended to include  
30 within its scope proteins specifically recited herein as well as all substantially  
homologous analogs and allelic variations.

- This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a bacterial Ema polypeptide. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a streptococcal Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and
- 5 EmaE. It is contemplated by this invention that the immunogenic polypeptide has the amino acid sequence set forth in any of SEQ ID NOS: 2, 4, 6, 8, 10, 23, 26, 29, 32 and 37, including immunogenic fragments, mutants, variants, analogs, or derivatives, thereof.
- 10 This invention is directed to analogs of the polypeptide which comprise the amino acid sequence as set forth above. The analog polypeptide may have an N-terminal methionine or a polyhistidine optionally attached to the N or COOH terminus of the polypeptide which comprise the amino acid sequence.
- 15 In another embodiment, this invention contemplates peptide fragments of the polypeptide which result from proteolytic digestion products of the polypeptide. In another embodiment, the derivative of the polypeptide has one or more chemical moieties attached thereto. In another embodiment the chemical moiety is a water soluble polymer. In another embodiment the chemical moiety is polyethylene glycol.
- 20 In another embodiment the chemical moiety is mon-, di-, tri- or tetrapegylated. In another embodiment the chemical moiety is N-terminal monopegylated.
- Attachment of polyethylene glycol (PEG) to compounds is particularly useful because PEG has very low toxicity in mammals (Carpenter et al., 1971). For example, a PEG
- 25 adduct of adenosine deaminase was approved in the United States for use in humans for the treatment of severe combined immunodeficiency syndrome. A second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds. For example, a PEG adduct of a human protein might be useful for the treatment of disease in other
- 30 mammalian species without the risk of triggering a severe immune response. The compound of the present invention may be delivered in a microencapsulation device

so as to reduce or prevent an host immune response against the compound or against cells which may produce the compound. The compound of the present invention may also be delivered microencapsulated in a membrane, such as a liposome.

- 5 Numerous activated forms of PEG suitable for direct reaction with proteins have been described. Useful PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives containing maleimido or haloacetyl groups  
10 are useful reagents for the modification of protein free sulfhydryl groups. Likewise, PEG reagents containing amino hydrazine or hydrazide groups are useful for reaction with aldehydes generated by periodate oxidation of carbohydrate groups in proteins.

- In one embodiment, the amino acid residues of the polypeptide described herein are  
15 preferred to be in the "L" isomeric form. In another embodiment, the residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property of lectin activity is retained by the polypeptide. NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide.  
20 Abbreviations used herein are in keeping with standard polypeptide nomenclature, *J. Biol. Chem.*, 243:3552-59 (1969).

- It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-  
25 terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues.

- Synthetic polypeptide, prepared using the well known techniques of solid phase, liquid  
30 phase, or peptide condensation techniques, or any combination thereof, can include natural and unnatural amino acids. Amino acids used for peptide synthesis may be

standard Boc ( $N^{\alpha}$ -amino protected  $N^{\alpha}$ -t-butyloxycarbonyl) amino acid resin with the standard deprotecting, neutralization, coupling and wash protocols of the original solid phase procedure of Merrifield (1963, *J. Am. Chem. Soc.* 85:2149-2154), or the base-labile  $N^{\alpha}$ -amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids first  
5 described by Carpino and Han (1972, *J. Org. Chem.* 37:3403-3409). Thus, polypeptide of the invention may comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (*e.g.*,  $\beta$ -methyl amino acids,  $C\alpha$ -methyl amino acids, and  $N\alpha$ -methyl amino acids, etc.) to convey special properties. Synthetic amino acids include ornithine for lysine, fluorophenylalanine for  
10 phenylalanine, and norleucine for leucine or isoleucine. Additionally, by assigning specific amino acids at specific coupling steps,  $\alpha$ -helices,  $\beta$  turns,  $\beta$  sheets,  $\gamma$ -turns, and cyclic peptides can be generated.

In one aspect of the invention, the peptides may comprise a special amino acid at the  
15 C-terminus which incorporates either a  $CO_2H$  or  $CONH_2$  side chain to simulate a free glycine or a glycine-amide group. Another way to consider this special residue would be as a D or L amino acid analog with a side chain consisting of the linker or bond to the bead. In one embodiment, the pseudo-free C-terminal residue may be of the D or the L optical configuration; in another embodiment, a racemic mixture of D and L-  
20 isomers may be used.

In an additional embodiment, pyroglutamate may be included as the N-terminal residue of the peptide. Although pyroglutamate is not amenable to sequence by Edman degradation, by limiting substitution to only 50% of the peptides on a given bead with  
25 N-terminal pyroglutamate, there will remain enough non-pyroglutamate peptide on the bead for sequencing. One of ordinary skill would readily recognize that this technique could be used for sequencing of any peptide that incorporates a residue resistant to Edman degradation at the N-terminus. Other methods to characterize individual peptides that demonstrate desired activity are described in detail *infra*. Specific  
30 activity of a peptide that comprises a blocked N-terminal group, *e.g.*, pyroglutamate, when the particular N-terminal group is present in 50% of the peptides, would readily

be demonstrated by comparing activity of a completely (100%) blocked peptide with a non-blocked (0%) peptide.

In addition, the present invention envisions preparing peptides that have more well  
5 defined structural properties, and the use of peptidomimetics, and peptidomimetic  
bonds, such as ester bonds, to prepare peptides with novel properties. In another  
embodiment, a peptide may be generated that incorporates a reduced peptide bond,  
i.e.,  $R_1-CH_2-NH-R_2$ , where  $R_1$  and  $R_2$  are amino acid residues or sequences. A  
reduced peptide bond may be introduced as a dipeptide subunit. Such a molecule  
10 would be resistant to peptide bond hydrolysis, *e.g.*, protease activity. Such peptides  
would provide ligands with unique function and activity, such as extended half-lives *in vivo*  
due to resistance to metabolic breakdown, or protease activity. Furthermore, it is  
well known that in certain systems constrained peptides show enhanced functional  
activity (Hruby, 1982, *Life Sciences* 31:189-199; Hruby et al., 1990, *Biochem J.*  
15 268:249-262); the present invention provides a method to produce a constrained  
peptide that incorporates random sequences at all other positions.

A constrained, cyclic or rigidized peptide may be prepared synthetically, provided that  
in at least two positions in the sequence of the peptide an amino acid or amino acid  
20 analog is inserted that provides a chemical functional group capable of cross-linking to  
constrain, cyclise or rigidize the peptide after treatment to form the cross-link.  
Cyclization will be favored when a turn-inducing amino acid is incorporated.  
Examples of amino acids capable of cross-linking a peptide are cysteine to form  
disulfide, aspartic acid to form a lactone or a lactase, and a chelator such as  
25  $\gamma$ -carboxyl-glutamic acid (Gla) (Bachem) to chelate a transition metal and form a  
cross-link. Protected  $\gamma$ -carboxyl glutamic acid may be prepared by modifying the  
synthesis described by Zee-Cheng and Olson (1980, *Biophys. Biochem. Res. Commun.*  
94:1128-1132). A peptide in which the peptide sequence comprises at least two  
amino acids capable of cross-linking may be treated, *e.g.*, by oxidation of cysteine  
30 residues to form a disulfide or addition of a metal ion to form a chelate, so as to cross-  
link the peptide and form a constrained, cyclic or rigidized peptide.

The present invention provides strategies to systematically prepare cross-links. For example, if four cysteine residues are incorporated in the peptide sequence, different protecting groups may be used (Hiskey, 1981, in *The Peptides: Analysis, Synthesis, Biology*, Vol. 3, Gross and Meienhofer, eds., Academic Press: New York, pp. 137-167; Ponsanti et al., 1990, *Tetrahedron* 46:8255-8266). The first pair of cysteine may be deprotected and oxidized, then the second set may be deprotected and oxidized. In this way a defined set of disulfide cross-links may be formed. Alternatively, a pair of cysteine and a pair of collating amino acid analogs may be incorporated so that the cross-links are of a different chemical nature.

The following non-classical amino acids may be incorporated in the peptide in order to introduce particular conformational motifs: 1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Kazmierski et al., 1991, *J. Am. Chem. Soc.* 113:2275-2283); (2S,3S)-methyl-phenylalanine, (2S,3R)-methyl-phenylalanine, (2R,3S)-methyl-phenylalanine and (2R,3R)-methyl-phenylalanine (Kazmierski and Hruby, 1991, *Tetrahedron Lett.*); 2-aminotetrahydronaphthalene-2-carboxylic acid (Landis, 1989, Ph.D. Thesis, University of Arizona); hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Miyake et al., 1989, *J. Takeda Res. Labs.* 43:53-76);  $\beta$ -carboline (D and L) (Kazmierski, 1988, Ph.D. Thesis, University of Arizona); HIC (histidine isoquinoline carboxylic acid) (Zechel et al., 1991, *Int. J. Pep. Protein Res.* 43); and HIC (histidine cyclic urea) (Dharanipragada).

The following amino acid analogs and peptidomimetics may be incorporated into a peptide to induce or favor specific secondary structures: LL-Acp (LL-3-amino-2-propenidone-6-carboxylic acid), a  $\beta$ -turn inducing dipeptide analog (Kemp et al., 1985, *J. Org. Chem.* 50:5834-5838);  $\beta$ -sheet inducing analogs (Kemp et al., 1988, *Tetrahedron Lett.* 29:5081-5082);  $\beta$ -turn inducing analogs (Kemp et al., 1988, *Tetrahedron Lett.* 29:5057-5060);  $\alpha$ -helix inducing analogs (Kemp et al., 1988, *Tetrahedron Lett.* 29:4935-4938);  $\gamma$ -turn inducing analogs (Kemp et al., 1989, *J. Org. Chem.* 54:109:115); and analogs provided by the following references: Nagai and

Sato, 1985, *Tetrahedron Lett.* 26:647-650; DiMaio et al., 1989, *J. Chem. Soc. Perkin Trans.* p. 1687; also a Gly-Ala turn analog (Kahn et al., 1989, *Tetrahedron Lett.* 30:2317); amide bond isostere (Jones et al., 1988, *Tetrahedron Lett.* 29:3853-3856); tetrazol (Zabrocki et al., 1988, *J. Am. Chem. Soc.* 110:5875-5880); DTC (Samanen et al., 1990, *Int. J. Protein Pep. Res.* 35:501:509); and analogs taught in Olson et al., 1990, *J. Am. Chem. Sci.* 112:323-333 and Garvey et al., 1990, *J. Org. Chem.* 56:436. Conformationally restricted mimetics of beta turns and beta bulges, and peptides containing them, are described in U.S. Patent No. 5,440,013, issued August 8, 1995 to Kahn.

10

The present invention further provides for modification or derivatization of the polypeptide or peptide of the invention. Modifications of peptides are well known to one of ordinary skill, and include phosphorylation, carboxymethylation, and acylation. Modifications may be effected by chemical or enzymatic means. In another aspect, glycosylated or fatty acylated peptide derivatives may be prepared. Preparation of glycosylated or fatty acylated peptides is well known in the art. Fatty acyl peptide derivatives may also be prepared. For example, and not by way of limitation, a free amino group (N-terminal or lysyl) may be acylated, *e.g.*, myristoylated. In another embodiment an amino acid comprising an aliphatic side chain of the structure -  
(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub> may be incorporated in the peptide. This and other peptide-fatty acid conjugates suitable for use in the present invention are disclosed in U.K. Patent GB-8809162.4, International Patent Application PCT/AU89/00166, and reference 5, *supra*.

25 *Chemical Moieties For Derivatization.* Chemical moieties suitable for derivatization may be selected from among water soluble polymers. The polymer selected should be water soluble so that the component to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.  
30 One skilled in the art will be able to select the desired polymer based on such considerations as whether the polymer/component conjugate will be used

therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis, and other considerations. For the present component or components, these may be ascertained using the assays provided herein.

- 5 The water soluble polymer may be selected from the group consisting of, for example, polyethylene glycol, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or
- 10 poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co- polymers, polyoxyethylated polyols and polyvinyl alcohol. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
- 15 The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 2kDa and about 100kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired
- 20 therapeutic profile (*e.g.*, the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

- The number of polymer molecules so attached may vary, and one skilled in the art will
- 25 be able to ascertain the effect on function. One may mono-derivative, or may provide for a di-, tri-, tetra- or some combination of derivatization, with the same or different chemical moieties (*e.g.*, polymers, such as different weights of polyethylene glycols). The proportion of polymer molecules to component or components molecules will vary, as will their concentrations in the reaction mixture. In general, the optimum ratio
- 30 (in terms of efficiency of reaction in that there is no excess unreacted component or components and polymer) will be determined by factors such as the desired degree of



derivatization (*e.g.*, mono, di-, tri-, etc.), the molecular weight of the polymer selected, whether the polymer is branched or unbranched, and the reaction conditions.

The polyethylene glycol molecules (or other chemical moieties) should be attached to  
5 the component or components with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, *e.g.*, EP 0 401 384 herein incorporated by reference (coupling PEG to G-CSF), *see also* Malik *et al.*, 1992, *Exp. Hematol.* 20:1028-1035 (reporting  
10 pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated  
polyethylene glycol molecule may be bound. The amino acid residues having a free amino group include lysine residues and the – terminal amino acid residues; those  
15 having a free carboxyl group include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s). Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

20

### *Nucleic Acids*

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook et  
25 al, "Molecular Cloning: A Laboratory Manual" (1989); "Current Protocols in Molecular Biology" Volumes I-III [Ausubel, R. M., ed. (1994)]; "Cell Biology: A Laboratory Handbook" Volumes I-III [J. E. Celis, ed. (1994)]; "Current Protocols in Immunology" Volumes I-III [Coligan, J. E., ed. (1994)]; "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds.  
30 (1985)]; "Transcription And Translation" [B.D. Hames & S.J. Higgins, eds. (1984)];

"Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

Mutations can be made in a nucleic acid encoding the polypeptide of the present invention such that a particular codon is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible. A substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. A non-conservative change is more likely to alter the structure, activity or function of the resulting protein. The present invention should be considered to include sequences containing conservative changes which do not significantly alter the activity or binding characteristics of the resulting protein. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;

- Glu for Asp and vice versa such that a negative charge may be maintained;
  - Ser for Thr such that a free -OH can be maintained; and
  - Gln for Asn such that a free NH<sub>2</sub> can be maintained.
- 5 Synthetic DNA sequences allow convenient construction of genes which will express analogs or "muteins". A general method for site-specific incorporation of unnatural amino acids into proteins is described in Noren, et al. *Science*, **244**:182-188 (April 1989). This method may be used to create analogs with unnatural amino acids.
- 10 This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a streptococcal Ema polypeptide. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a streptococcal Ema polypeptide. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a Group B
- 15 streptococcal Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a Group B streptococcal Ema protein selected from the group of Ema proteins EmaA, EmaB, EmaC, EmaD and EmaE as set forth in FIGURES 2-6. The invention provides an isolated nucleic acid
- 20 encoding a polypeptide comprising an amino acid sequence of a bacterial Ema polypeptide selected from the group of SEQ ID NO: 23, 26, 29, 32 and 37. In particular embodiments the nucleic acid is set forth in any of SEQ ID NOS: 1, 3, 5, 7, 9, 24, 27, 30, and 33, including fragments, mutants, variants, analogs, or derivatives, thereof. The nucleic acid is DNA, cDNA, genomic DNA, RNA. Further, the isolated
- 25 nucleic acid may be operatively linked to a promoter of RNA transcription.

The present invention also relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode the isolated polypeptide or which competitively

30 inhibit the activity of the polypeptide. The present invention further relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate

variants thereof, mutants, analogs, or fragments thereof, which encode a GBS Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. Preferably, the isolated nucleic acid, which includes degenerates, variants, mutants, analogs, or fragments thereof, has a sequence as set forth in SEQ ID NOS: 1, 3, 5, 7 or 9. In a further embodiment of the invention, the DNA sequence of the recombinant DNA molecule or cloned gene may be operatively linked to an expression control sequence which may be introduced into an appropriate host. The invention accordingly extends to unicellular hosts transformed with the cloned gene or recombinant DNA molecule comprising a DNA sequence encoding an Ema protein, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and more particularly, the DNA sequences or fragments thereof determined from the sequences set forth above.

In a particular embodiment, the nucleic acid encoding the EmaA polypeptide has the sequence selected from the group comprising SEQ ID NO:1; a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:1 or a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaA polypeptide has the sequence selected from the group comprising SEQ ID NO:1; a sequence complementary to SEQ ID NO:1; or a homologous sequence which is substantially similar to SEQ ID NO:1. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:1.

In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:3 or a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence

complementary to SEQ ID NO:3; or a homologous sequence which is substantially similar to SEQ ID NO:3. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:3.

- 5 In a particular embodiment, the nucleic acid encoding the EmaC polypeptide has the sequence selected from the group comprising SEQ ID NO:5; a sequence that hybridizes to SEQ ID NO:5 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:5 or a sequence that hybridizes to SEQ ID NO:5 under moderate stringency hybridization
- 10 conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaC polypeptide has the sequence selected from the group comprising SEQ ID NO:5; a sequence complementary to SEQ ID NO:5; or a homologous sequence which is substantially similar to SEQ ID NO:5. In a further embodiment, the nucleic acid has the sequence
- 15 consisting of SEQ ID NO:5.

- In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization conditions; DNA
- 20 sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:7 or a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence
- 25 complementary to SEQ ID NO:7; or a homologous sequence which is substantially similar to SEQ ID NO:7. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:7.

- In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the
- 30 sequence selected from the group comprising SEQ ID NO:9; a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:9 or a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization

conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the sequence selected from the group comprising SEQ ID NO:9; a sequence complementary to SEQ ID NO:9; or a homologous sequence which is substantially similar to SEQ ID NO:9. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:9.

A nucleic acid capable of encoding a GBS polypeptide EmaA, EmaB, EmaC, EmaD or EmaE which is a recombinant DNA molecule is further provided. Such a recombinant DNA molecule wherein the DNA molecule is operatively linked to an expression control sequence is also provided herein.

The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding immunogenic bacterial Ema polypeptides, particularly immunogenic streptococcal Ema polypeptides. The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding immunogenic GBS Ema polypeptides, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding one or more immunogenic GBS Ema polypeptide or a fragment thereof or any combination of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE with at least one other GBS polypeptide, particularly wherein said other GBS polypeptide is selected from the group of Spb1, Spb2, C protein alpha antigen, Rib and immunogenic polypeptide fragments thereof.

The invention further relates to a vaccine for protection of an animal subject from infection with a streptococcal bacterium comprising a vector containing a gene encoding an Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, operatively associated with a promoter capable of directing expression of the gene in the subject. The invention further relates to a vaccine for protection of an animal subject from infection with a Group B streptococcal bacterium comprising a vector containing a gene encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE operatively associated with a promoter capable of directing expression of the gene in the subject. The present

invention further provides a nucleic acid vaccine comprising a recombinant DNA molecule capable of encoding a GBS polypeptide EmaA, EmaB, EmaC, EmaD or EmaE.

- 5 The present invention provides a vector which comprises the nucleic acid capable of encoding encoding a bacterial Ema polypeptide, particularly a streptococcal Ema polypeptide. The present invention provides a vector which comprises the nucleic acid capable of encoding encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a promoter. The present invention provides a  
10 vector which comprises the nucleic acid of any of SEQ ID NO: 1, 3, 5, 7, 9, 24, 27, 30, and 33, and a promoter. The invention contemplates a vector wherein the promoter comprises a bacterial, yeast, insect or mammalian promoter. The invention contemplates a vector wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA.

15

- The present invention further provides a host vector system for the production of a polypeptide which comprises the vector capable of encoding encoding an Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, in a suitable host cell. A host vector system is provided wherein the suitable  
20 host cell comprises a prokaryotic or eukaryotic cell. A unicellular host transformed with a recombinant DNA molecule or vector capable of encoding encoding an Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, is thereby provided.

- 25 A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

- A "DNA" or "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-  
30 stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the

structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

5

An "origin of replication" refers to those DNA sequences that participate in DNA synthesis.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed  
10 and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g.,  
15 mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence in the case of eukaryotic mRNA.

Transcriptional and translational control sequences are DNA regulatory sequences,  
20 such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding  
25 sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with  
30 nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.



An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into  
5 the protein encoded by the coding sequence.

A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the  
10 media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

The term "oligonucleotide," as used herein in referring to the probe of the present  
15 invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.

The term "primer" as used herein refers to an oligonucleotide, whether occurring  
20 naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either  
25 single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains  
30 15-25 or more nucleotides, although it may contain fewer nucleotides.

The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be

sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand.

- 5 Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.

- 10 As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

- A cell has been "transformed" by exogenous or heterologous DNA when such DNA  
15 has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has  
20 become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell  
25 that is capable of stable growth *in vitro* for many generations.

- Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are  
30 substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining

appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

5 A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by  
10 the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.

The term "standard hybridization conditions" refers to salt and temperature conditions  
15 substantially equivalent to 5 x SSC and 65°C for both hybridization and wash. However, one skilled in the art will appreciate that such "standard hybridization conditions" are dependent on particular conditions including the concentration of sodium and magnesium in the buffer, nucleotide sequence length and concentration, percent mismatch, percent formamide, and the like. Also important in the  
20 determination of "standard hybridization conditions" is whether the two sequences hybridizing are RNA-RNA, DNA-DNA or RNA-DNA. Such standard hybridization conditions are easily determined by one skilled in the art according to well known formulae, wherein hybridization is typically 10-20°C below the predicted or determined  $T_m$  with washes of higher stringency, if desired.

25

It should be appreciated that also within the scope of the present invention are DNA sequences encoding an Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE which code for an Ema polypeptide having the same amino acid sequence as any of SEQ ID NOS:2, 4, 6, 8 or 10, but which are degenerate to any of SEQ ID NOS:1, 3, 5, 7 or 9.  
30 By "degenerate to" is meant that a different three-letter codon is used to specify a particular amino acid. It is well known in the art that the following codons can be used interchangeably to code for each specific amino acid:

	Phenylalanine (Phe or F)	UUU or UUC
	Leucine (Leu or L)	UUA or UUG or CUU or CUC or CUA or CUG
	Isoleucine (Ile or I)	AUU or AUC or AUA
	Methionine (Met or M)	AUG
5	Valine (Val or V)	GUU or GUC or GUA or GUG
	Serine (Ser or S)	UCU or UCC or UCA or UCG or AGU or AGC
	Proline (Pro or P)	CCU or CCC or CCA or CCG
	Threonine (Thr or T)	ACU or ACC or ACA or ACG
	Alanine (Ala or A)	GCU or GCG or GCA or GCG
10	Tyrosine (Tyr or Y)	UAU or UAC
	Histidine (His or H)	CAU or CAC
	Glutamine (Gln or Q)	CAA or CAG
	Asparagine (Asn or N)	AAU or AAC
	Lysine (Lys or K)	AAA or AAG
15	Aspartic Acid (Asp or D)	GAU or GAC
	Glutamic Acid (Glu or E)	GAA or GAG
	Cysteine (Cys or C)	UGU or UGC
	Arginine (Arg or R)	CGU or CGC or CGA or CGG or AGA or AGG
	Glycine (Gly or G)	GGU or GGC or GGA or GGG
20	Tryptophan (Trp or W)	UGG
	Termination codon	UAA (ochre) or UAG (amber) or UGA (opal)

It should be understood that the codons specified above are for RNA sequences. The corresponding codons for DNA have a T substituted for U.

25

Mutations can be made in SEQ ID NOS: 1, 3, 5, 7 or 9 such that a particular codon is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible. A substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular

30

size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. A non-conservative change is more likely to alter the structure, activity or function of the resulting protein. The present invention should be  
5 considered to include sequences containing conservative changes which do not significantly alter the activity or binding characteristics of the resulting protein.

Two amino acid sequences are "substantially homologous" when at least about 70% of the amino acid residues (preferably at least about 80%, and most preferably at least  
10 about 90 or 95%) are identical, or represent conservative substitutions.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene  
15 will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring  
20 mutational events do not give rise to a heterologous region of DNA as defined herein.

A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate  
25 start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be  
30 inserted in front of the gene.

Further this invention also provides a vector which comprises the above-described nucleic acid molecule. The promoter may be, or is identical to, a bacterial, yeast,

- insect or mammalian promoter. Further, the vector may be a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA. Other numerous vector backbones known in the art as useful for expressing protein may be employed. Such vectors include, but are not limited to: adenovirus, simian virus 40 (SV40), cytomegalovirus (CMV), mouse mammary tumor virus (MMTV), Moloney murine leukemia virus, DNA delivery systems, i.e. liposomes, and expression plasmid delivery systems. Such vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art.
- 10 This invention also provides a host vector system for the production of a polypeptide which comprises the vector of a suitable host cell. A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, fungi such as yeasts, and animal cells, such as
- 15 CHO, RL1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture.

- A wide variety of host/expression vector combinations may be employed in expressing
- 20 the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., *E. coli* plasmids col El, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage  $\lambda$ , M13
- 25 and filamentous single stranded phage DNA; yeast plasmids such as the 2 $\mu$  plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

- 30 Any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence operatively linked to it -- may be used in these vectors to express the DNA sequences of this invention. Such useful expression control

- sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the *LTR* system, the major operator and promoter regions of phage  $\lambda$ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or  
5 other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the promoters of the yeast  $\alpha$ -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
- 10 It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and  
15 hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.
- 20 In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular  
25 hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.
- 30 This invention further provides a method of producing a polypeptide which comprises growing the above-described host vector system under suitable conditions permitting the production of the polypeptide and recovering the polypeptide so produced.

As used herein, "pg" means picogram, "ng" means nanogram, "ug" or "µg" mean microgram, "mg" means milligram, "ul" or "µl" mean microliter, "ml" means milliliter, "l" means liter.

- 5 The present invention extends to the preparation of antisense oligonucleotides and ribozymes that may be used to interfere with the expression of one or more Ema protein at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

10

- Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule. (See Weintraub, 1990; Marcus-Sekura, 1988.) In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense
- 15 nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into Ema-producing cells. Antisense methods have been used to inhibit the expression of many genes *in vitro*
- 20 (Marcus-Sekura, 1988; Hambor et al., 1988).

- Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs
- 25 have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, 1988.). Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

- 30 Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type. (Hasselhoff and Gerlach, 1988) *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to



occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

5

### *Antibodies*

This invention further provides an antibody capable of specifically recognizing or binding to the isolated Ema polypeptide of the present invention. The antibody may be  
10 a monoclonal or polyclonal antibody. Further, the antibody may be labeled with a detectable marker that is either a radioactive, calorimetric, fluorescent, or a luminescent marker. The labeled antibody may be a polyclonal or monoclonal antibody. In one embodiment, the labeled antibody is a purified labeled antibody. Methods of labeling antibodies are well known in the art.

15

In a further aspect, the present invention provides a purified antibody to a bacterial Ema polypeptide, particularly a streptococcal Ema polypeptide. In a still further aspect, the present invention provides a purified antibody to a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.

20

Antibodies against the isolated polypeptides of the present invention include naturally raised and recombinantly prepared antibodies. These may include both polyclonal and monoclonal antibodies prepared by known genetic techniques, as well as bi-specific (chimeric) antibodies, and antibodies including other functionalities suiting them for  
25 diagnostic use. Such antibodies can be used in immunoassays to diagnose infection with a particular strain or species of bacteria. The antibodies can also be used for passive immunization to treat an infection with Group B streptococcal bacteria. These antibodies may also be suitable for modulating bacterial adherence and/or invasion including but not limited to acting as competitive agents.

30

The present invention provides a monoclonal antibody to a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The invention thereby extends to an immortal cell line that produces a monoclonal antibody

to a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.

An antibody to an Ema polypeptide, particularly selected from EmaA, EmaB, EmaC,

- 5 EmaD or EmaE, labeled with a detectable label is further provided. In particular embodiments, the label may selected from the group consisting of an enzyme, a chemical which fluoresces, and a radioactive element.

- 10 The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, the term "antibody" includes polyclonal and monoclonal antibodies, and fragments thereof. Furthermore, the term "antibody" includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.

15

An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567.

20

An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

- 25 The phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule.

- 30 Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub> and F(v), which portions are preferred for use in the therapeutic methods described herein.

Fab and F(ab')<sub>2</sub> portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-known and are  
5 produced from F(ab')<sub>2</sub> portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact antibody molecules is preferred herein.

10 The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of  
15 antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.

Various procedures known in the art may be used for the production of polyclonal antibodies to polypeptide or derivatives or analogs thereof (*see, e.g., Antibodies -- A*  
20 *Laboratory Manual*, Harlow and Lane, eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1988). For the production of antibody, various host animals can be immunized by injection with the Group B streptococcal Ema polypeptide, an immunogenic fragment thereof, or a derivative (*e.g., fragment or fusion protein*) thereof, including but not limited to rabbits, mice, rats, sheep, goats,  
25 etc. In one embodiment, the polypeptide can be conjugated to an immunogenic carrier, *e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH)*. Various adjuvant may be used to increase the immunological response, depending on the host species.

30 For preparation of monoclonal antibodies, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used (*see, e.g., Antibodies -- A Laboratory Manual*, Harlow and Lane, eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor,

New York, 1988). These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human

5 monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). Human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030) or by transforming human B cells with EBV

10 virus *in vitro* (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, *J. Bacteriol.* 159-870; Neuberger *et al.*, 1984, *Nature* 312:604-608; Takeda *et al.*, 1985, *Nature* 314:452-454) by splicing the genes from a mouse antibody molecule specific for a polypeptide

15 together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human infections or diseases, since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response,

20 themselves. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse *et al.*, 1989, *Science* 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for the polypeptide, or its derivatives, or analogs.

25 Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')<sub>2</sub> fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragment, and the Fab fragments which can be

30 generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA

(enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

Antibodies can be labeled for detection *in vitro*, *e.g.*, with labels such as enzymes, fluorophores, chromophores, radioisotopes, dyes, colloidal gold, latex particles, and chemiluminescent agents. Alternatively, the antibodies can be labeled for detection *in vivo*, *e.g.*, with radioisotopes (preferably technetium or iodine); magnetic resonance shift reagents (such as gadolinium and manganese); or radio-opaque reagents.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. The polypeptide can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$ .

Enzyme labels are likewise useful, and can be detected by any of the presently utilized calorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the

like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of  
5 example for their disclosure of alternate labeling material and methods.

### Diagnostic Applications

10 The present invention also relates to a variety of diagnostic applications, including methods for identifying or monitoring streptococcal infections. The present invention also relates to a variety of diagnostic applications, including methods for identifying or monitoring Group B streptococcal infections. The present invention further relates to diagnostic applications or methods utilizing the polypeptides of the present invention,  
15 immunogenically recognized fragments thereof, or antibodies thereto. Such methods include the analysis and evaluation of agents, analogs or compounds which modulate the activity of the Ema polypeptides. The Ema polypeptides may also be utilized in diagnostic methods and assays for monitoring and determining immunological response and antibody response upon streptococcal infection or vaccination.

20

As described in detail above, antibody(ies) to the Ema polypeptides or fragments thereof can be produced and isolated by standard methods including the well known hybridoma techniques. For convenience, the antibody(ies) to the Ema polypeptides will be referred to herein as Ab<sub>1</sub> and antibody(ies) raised in another species as Ab<sub>2</sub>.

25

The presence of streptococci in cells can be ascertained by the usual immunological procedures applicable to such determinations. A number of useful procedures are known. Procedures which are especially useful utilize either the Ema polypeptides labeled with a detectable label, antibody against the Ema polypeptides labeled with a  
30 detectable label, or secondary antibody labeled with a detectable label.

The procedures and their application are all familiar to those skilled in the art and accordingly may be utilized within the scope of the present invention. The

"competitive" procedure, is described in U.S. Patent Nos. 3,654,090 and 3,850,752. The "sandwich" procedure, is described in U.S. Patent Nos. RE 31,006 and 4,016,043. Still other procedures are known such as the "double antibody," or "DASP" procedure.

5

In each instance, the Ema polypeptides forms complexes with one or more antibody(ies) or binding partners and one member of the complex is labeled with a detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

10

In a further embodiment of this invention, commercial test kits suitable for use by a medical specialist may be prepared to determine the presence or absence of streptococci, particularly of streptococci expressing one or more Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In as much as the  
15 *ema* locus, as described herein, is found in the genomic DNA of many, if not all, serotypes of Group B streptococci, it is a useful general marker for Group B streptococci. In as much as Ema homologs exist in other species of streptococci, including Group A and *S. pneumoniae*, it is a useful general marker for streptococci. Therefore, commercial test kits for determining the presence or absence of  
20 streptococci, and thereby determining whether an individual is infected with streptococci are contemplated and provided by this invention. Therefore, commercial test kits for determining the presence or absence of Group B streptococci, and thereby determining whether an individual is infected with Group B streptococci are contemplated and provided by this invention.

25

The present invention includes methods for determining and monitoring infection by streptococci by detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the streptococcal Ema polypeptide is measured by:

30

- a. contacting a sample in which the presence or activity of a Streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal

- polypeptide under conditions that allow binding of the streptococcal polypeptide to the antibody to occur; and
- b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;
- 5 wherein the detection of binding indicates the presence or activity of the streptococcal polypeptide in the sample.

- The present invention includes methods for determining and monitoring infection by
- 10 Group B streptococci by detecting the presence of a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the streptococcal Ema polypeptide is measured by:
- a. contacting a sample in which the presence or activity of a Group B Streptococcal polypeptide selected from the group of EmaA, EmaB,
- 15 EmaC, EmaD and EmaE is suspected with an antibody to the said Group B streptococcal polypeptide under conditions that allow binding of the Group B streptococcal polypeptide to the antibody to occur; and
- b. detecting whether binding has occurred between the Group B
- 20 streptococcal polypeptide from the sample and the antibody;
- wherein the detection of binding indicates the presence or activity of the a Group B streptococcal polypeptide in the sample.

- The present invention further provides a method for detecting the presence of a
- 25 bacterium having a gene encoding a Group B polypeptide selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, comprising:
- a. contacting a sample in which the presence or activity of the bacterium is suspected with an oligonucleotide which hybridizes to a Group B streptococcal polypeptide gene selected from the group of *emaA*,
- 30 *emaB*, *emaC*, *emaD* and *emaE*, under conditions that allow specific hybridization of the oligonucleotide to the gene to occur; and
- b. detecting whether hybridization has occurred between the oligonucleotide and the gene;



wherein the detection of hybridization indicates that presence or activity of the bacterium in the sample.

The invention includes an assay system for screening of potential compounds effective  
5 to modulate the activity of a bacterial Ema protein of the present invention. In one instance, the test compound, or an extract containing the compound, could be administered to a cellular sample expressing the particular Ema protein to determine the compound's effect upon the activity of the protein by comparison with a control. In a further instance the test compound, or an extract containing the compound, could  
10 be administered to a cellular sample expressing the Ema protein to determine the compound's effect upon the activity of the protein, and thereby on adherence of said cellular sample to host cells, by comparison with a control.

Accordingly, a test kit may be prepared for the demonstration of the presence of Ema  
15 polypeptide or Ema activity in cells, comprising:

- (a) a predetermined amount of at least one labeled immunochemically reactive component obtained by the direct or indirect attachment of the Ema polypeptide or a specific binding partner thereto, to a detectable label;
- (b) other reagents; and
- 20 (c) directions for use of said kit.

More specifically, the diagnostic test kit may comprise:

- (a) a known amount of the Ema polypeptide as described above (or a binding partner) generally bound to a solid phase to form an immunosorbent, or in the  
25 alternative, bound to a suitable tag, or plural such end products, etc. (or their binding partners) one of each;
- (b) if necessary, other reagents; and
- (c) directions for use of said test kit.

30 In a further variation, the test kit may be prepared and used for the purposes stated above, which operates according to a predetermined protocol (e.g. "competitive," "sandwich," "double antibody," etc.), and comprises:

- (a) a labeled component which has been obtained by coupling the Ema polypeptide to a detectable label;
- (b) one or more additional immunochemical reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of:
- (i) a ligand capable of binding with the labeled component (a);
  - (ii) a ligand capable of binding with a binding partner of the labeled component (a);
  - (iii) a ligand capable of binding with at least one of the component(s) to be determined; and
  - (iv) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined; and
- (c) directions for the performance of a protocol for the detection and/or determination of one or more components of an immunochemical reaction between the Ema polypeptide and a specific binding partner thereto.

In accordance with the above, an assay system for screening potential drugs effective to modulate the activity of the Ema polypeptide may be prepared. The Ema polypeptide may be introduced into a test system, and the prospective drug may also be introduced into the resulting cell culture, and the culture thereafter examined to observe any changes in the Ema polypeptide activity of the cells, due either to the addition of the prospective drug alone, or due to the effect of added quantities of the known Ema polypeptide.

25

### Therapeutic Applications

The therapeutic possibilities that are raised by the existence of the Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE derive from the fact that the Ema polypeptides of the present invention are found generally in various serotypes of Group B streptococci. In addition, broader therapeutic possibilities that are raised by the existence of Ema homologous polypeptides in various distinct species of streptococci, including *S. pneumoniae* and *S. pyogenes*. In addition Ema homologous polypeptides have been identified in *E. faecalis* and *C.*

*diphtheriae*. Of particular relevance to their suitability in vaccine and immunological therapy is that the Ema A, EmaB, and EmaC polypeptides possess N-terminal sequences consistent with a signal peptide, indicating secretion from the bacterial cell and at least partial extracellular localization. In addition, the EmaA, EmaB, EmaC, 5 EmaD and EmaE polypeptides demonstrate homology to distinct bacterial proteins involved in or implicated in bacterial adhesion and invasion. Thus, the Ema polypeptides are anticipated to be involved in or required for streptococcal adhesion to and/or invasion of cells, critical for bacterial survival and virulence in the human host.

10 *Modulators of Extracellular Matrix Adhesin Protein*

Thus, in instances where it is desired to reduce or inhibit the effects resulting from the extracellular matrix adhesin protein Ema of the present invention, an appropriate inhibitor of one or more of the Ema proteins, particularly EmaA, EmaB, EmaC, EmaD 15 and EmaE could be introduced to block the activity of one or more Ema protein.

The present invention contemplates screens for a modulator of an Ema polypeptide, in particular modulating adhesion or invasion facilitated by EmaA, EmaB, EmaC, EmaD or EmaE. In one such embodiment, an expression vector containing the Ema 20 polypeptide of the present invention, or a derivative or analog thereof, is placed into a cell in the presence of at least one agent suspected of exhibiting Ema polypeptide modulator activity. The cell is preferably a bacterial cell, most preferably a streptococcal cell, or a bacterial host cell. The amount of adhesion or binding activity is determined and any such agent is identified as a modulator when the amount of 25 adhesion or binding activity in the presence of such agent is different than in its absence. The vectors may be introduced by any of the methods described above. In a related embodiment the GBS Ema polypeptide is expressed in streptococci and the step of determining the amount of adhesion or binding activity is performed by determining the amount of binding to bacterial host cells *in vitro*.

30

When the amount of adhesion or binding activity in the presence of the modulator is greater than in its absence, the modulator is identified as an agonist or activator of the Ema polypeptide, whereas when the amount of adhesion binding activity in the

presence of the modulator is less than in its absence, the modulator is identified as an antagonist or inhibitor of the Ema polypeptide. As any person having skill in the art would recognize, such determinations as these and those below could require some form of statistical analysis, which is well within the skill in the art.

5

Natural effectors found in cells expressing Ema polypeptide can be fractionated and tested using standard effector assays as exemplified herein, for example. Thus an agent that is identified can be a naturally occurring adhesion or binding modulator. Alternatively, natural products libraries can be screened using the assays of the present invention for screening such agents.

10

Another approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" [Scott and Smith, 1990, *Science* 249:386-390 (1990); Cwirla, et al., *Proc. Natl. Acad. Sci.*, 87:6378-6382 (1990); Devlin et al., *Science*, 249:404-406 (1990)], very large libraries can be constructed ( $10^6$ - $10^8$  chemical entities). Yet another approach uses primarily chemical methods, of which the Geysen method [Geysen et al., *Molecular Immunology* 23:709-715 (1986); Geysen et al. *J. Immunologic Method* 102:259-274 (1987)] and the method of Fodor et al. [*Science* 251:767-773 (1991)] are examples. Furka et al. [*14th International Congress of Biochemistry, Volume 5*, Abstract FR:013 (1988); Furka, *Int. J. Peptide Protein Res.* 37:487-493 (1991)], Houghton [U.S. Patent No. 4,631,211, issued December 1986] and Rutter et al. [U.S. Patent No. 5,010,175, issued April 23, 1991] describe methods to produce a mixture of peptides that can be tested.

15

20

25

In another aspect, synthetic libraries [Needels et al., *Proc. Natl. Acad. Sci. USA* 90:10700-4 (1993); Ohlmeyer et al., *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Lam et al., International Patent Publication No. WO 92/00252; Kocis et al., International Patent Publication No. WO 9428028, each of which is incorporated herein by reference in its entirety], and the like can be used to screen for such an agent.

30

This invention provides antagonist or blocking agents which include but are not limited to: peptide fragments, mimetic, a nucleic acid molecule, a ribozyme, a polypeptide, a small molecule, a carbohydrate molecule, a monosaccharide, an oligosaccharide or an

antibody. Also, agents which competitively block or inhibit streptococcal bacterium are contemplated by this invention. This invention provides an agent which comprises an inorganic compound, a nucleic acid molecule, an oligonucleotide, an organic compound, a peptide, a peptidomimetic compound, or a protein which inhibits the  
5 polypeptide.

### *Vaccines*

10 In a further aspect, the present invention extends to vaccines based on the Ema proteins described herein. The present invention provides a vaccine comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant. The present invention provides a vaccine comprising one or more bacterial Ema polypeptide  
15 selected from the group of polypeptides comprising the amino acid sequence set out in any of SEQ ID NO: 23, 26, 29, 32 and 37, and a pharmaceutically acceptable adjuvant.

The present invention further provides a vaccine comprising one or more Group B  
20 streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more additional GBS antigen. The present invention further provides a vaccine comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more antigens selected from the group of the polypeptide  
25 Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof, Lmb or an immunogenic fragment thereof, C5a-ase or an immunogenic fragment thereof, and Group B streptococcal polysaccharides or oligosaccharides.

30

In another aspect, the invention is directed to a vaccine for protection of an animal subject from infection with streptococci comprising an immunogenic amount of one or more streptococcal Ema polypeptide, or a derivative or fragment thereof. The Ema

polypeptide may be particularly selected from the group of EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. In a further aspect, the invention is directed to a vaccine for protection of an animal subject from infection with streptococci comprising an immunogenic amount of one or more Ema polypeptide

5 EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. In a further aspect, the invention is directed to a vaccine for protection of an animal subject from infection with GBS comprising an immunogenic amount of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. Such a vaccine may contain the protein conjugated covalently to a

10 streptococcal or GBS bacterial polysaccharide or oligosaccharide or polysaccharide or oligosaccharide from one or more streptococcal or GBS serotypes.

This invention provides a vaccine which comprises a polypeptide bacterial Ema protein and a pharmaceutically acceptable adjuvant or carrier. In particular, a vaccine

15 is provided which comprises one or more Ema polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. This invention provides a vaccine which comprises a combination of at least one bacterial Ema protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and at least one other Group B streptococcal protein particularly Spb1 and/or Spb2 and/or C protein alpha antigen,

20 and a pharmaceutically acceptable adjuvant or carrier. The Ema polypeptide may comprise an amino acid sequence of a Ema protein EmaA, EmaB, EmaC, EmaD, EmaE as set forth in FIGURES 2-6 and SEQ ID NOS: 2, 4, 6, 8 and 10.

This invention further provides a vaccine comprising an isolated nucleic acid encoding

25 a bacterial Ema polypeptide and a pharmaceutically acceptable adjuvant or carrier. This invention further provides a vaccine comprising an isolated nucleic acid encoding a streptococcal Ema polypeptide and a pharmaceutically acceptable adjuvant or carrier. This invention further provides a vaccine comprising an isolated nucleic acid encoding a GBS Ema polypeptide and a pharmaceutically acceptable adjuvant or

30 carrier. This invention further provides a vaccine comprising isolated nucleic acid encoding one or more GBS Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable adjuvant

or carrier. The nucleic acid may comprise a nucleic acid sequence of a GBS Ema polypeptide as set forth in any of SEQ ID NOS:1, 3, 5, 7, or 9.

- Active immunity against streptococci can be induced by immunization (vaccination) with an immunogenic amount of the polypeptide, or peptide derivative or fragment thereof, and an adjuvant, wherein the polypeptide, or antigenic derivative or fragment thereof, is the antigenic component of the vaccine. The polypeptide, or antigenic derivative or fragment thereof, may be one antigenic component, in the presence of other antigenic components in a vaccine. For instance, the polypeptide of the present invention may be combined with other known streptococcal polypeptides or poly/oligosaccharides, or immunogenic fragments thereof, including for instance GBS capsular polysaccharide, Spb1, Spb2, C protein alpha antigen, Rib, Lmb, and C5a-ase in a multi-component vaccine. Such multi-component vaccine may be utilized to enhance immune response, even in cases where the polypeptide of the present invention elicits a response on its own. The polypeptide of the present invention may also be combined with existing vaccines, whole bacterial or capsule-based vaccines, alone or in combination with other GBS polypeptides, particularly Spb1 and/or Spb2 and/or C protein alpha antigen and/or Rib to enhance such existing vaccines.
- The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al., *Immunology, Second Ed.*, 1984, Benjamin/Cummings: Menlo Park, California, p. 384). Often, a primary challenge with an antigen alone, in the absence of an adjuvant, will fail to elicit a humoral or cellular immune response. Adjuvant include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvant such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Preferably, the adjuvant is pharmaceutically acceptable.

- The invention further provides a vaccine which comprises a non-adherent, non-virulent mutant, including but not limited to the *ema*<sup>-</sup> mutants herein described and contemplated. Medaglini et al (Madaglini *et al* (1995) *Proc Natl Acad Sci USA* 92:6868-6872) and Oggioni and Pozzi (Oggioni, M.R. and Pozzi, G. (1996) *Gene* 169:85-90) have previously described the use of *Streptococcus gordonii*, a commensal bacterium of the human oral cavity, as live vaccine delivery vehicles and for heterologous gene expression. Such *ema*<sup>-</sup> mutant can therefore be utilized as a vehicle for expression of immunogenic proteins for the purposes of eliciting an immune response to such other proteins in the context of vaccines. Active immunity against Group B streptococci, can be induced by immunization (vaccination) with an immunogenic amount of the *ema*<sup>-</sup> vehicle expressing an immunogenic protein. Also contemplated by the present invention is the use of any such *ema*<sup>-</sup> mutant in expressing a therapeutic protein in the host in the context of other forms of therapy.
- 15 The polypeptide of the present invention, or fragments thereof, can be prepared in an admixture with an adjuvant to prepare a vaccine. Preferably, the polypeptide or peptide derivative or fragment thereof, used as the antigenic component of the vaccine is an antigen common to all or many serotypes of GBS bacteria, or common to closely related species of bacteria, for instance *Streptococcus*.
- 20 Vectors containing the nucleic acid-based vaccine of the invention can be introduced into the desired host by methods known in the art, *e.g.*, transfection, electroporation, micro injection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, *e.g.*, Wu *et al.*, 1992, *J. Biol. Chem.* 267:963-967; Wu and Wu, 1988, *J. Biol. Chem.* 263:14621-14624; Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990).
- 25 The modes of administration of the vaccine or compositions of the present invention may comprise the use of any suitable means and/or methods for delivering the vaccine or composition to the host animal whereby they are immunostimulatively effective. Delivery modes may include, without limitation, parenteral administration methods, such as paracancerally, transmucosally, transdermally, intramuscularly, intravenously,
- 30



intradermally, subcutaneously, intraperitoneally, intraventricularly, intracranially and intratumorally. Preferably, since the desired result of vaccination is to elucidate an immune response to the antigen, and thereby to the pathogenic organism, administration directly, or by targeting or choice of a viral vector, indirectly, to lymphoid tissues, *e.g.*, lymph nodes or spleen, is desirable. Since immune cells are continually replicating, they are ideal target for retroviral vector-based nucleic acid vaccines, since retroviruses require replicating cells. These vaccines and compositions can be used to immunize mammals, for example, by the intramuscular or parenteral routes, or by delivery to mucosal surfaces using microparticles, capsules, liposomes and targeting molecules, such as toxins and antibodies. The vaccines and immunogenic compositions may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols and triglycerides. Oral formulations may include normally employed excipients, such as pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

These compositions may take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 1 to 95% of the immunogenic compositions of the present invention. The immunogenic compositions are administered in a manner compatible with the dosage formulation, and in such amount as to be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be immunized, including, for example, the capacity of the subject's immune system to synthesize antibodies, and if needed, to produce a cell-mediated, humoral or antibody-mediated immune response. Precise amounts of antigen and immunogenic composition to be administered depend on the judgement of the practitioner. However, suitable dosage ranges are readily determinable by those skilled in the art and may be of the order of micrograms to milligrams. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage of the vaccine may also depend on the route of administration and will vary according to the size of the host.

Passive immunity can be conferred to an animal subject suspected of suffering an infection with streptococci by administering antiserum, polyclonal antibodies, or a neutralizing monoclonal antibody against one or more Ema polypeptide of the invention to the patient. A combination of antibodies directed against one or more

5 Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, in combination with one or more of antibodies against Spb1, Spb2, Rib and C protein alpha antigen is also contemplated by the present invention. Although passive immunity does not confer long term protection, it can be a valuable tool for the treatment of a bacterial infection in a subject who has not been vaccinated. Passive

10 immunity is particularly important for the treatment of antibiotic resistant strains of bacteria, since no other therapy may be available. Preferably, the antibodies administered for passive immune therapy are autologous antibodies. For example, if the subject is a human, preferably the antibodies are of human origin or have been "humanized," in order to minimize the possibility of an immune response against the

15 antibodies. The active or passive vaccines of the invention can be used to protect an animal subject from infection by streptococcus, particularly Group B streptococcus.

Vaccines for GBS have been previously generated and tested. Preliminary vaccines used unconjugated purified polysaccharide. GBS polysaccharides and oligosaccharides

20 are poorly immunogenic and fail to elicit significant memory and booster responses. Baker et al immunized 40 pregnant women with purified serotype III capsular polysaccharide (Baker, C.J. et al. (1998) *New Engl J of Med* **319**:1180-1185). Overall, only 57% of women with low levels of specific antibody responded to the the vaccine. The poor immunogenicity of purified polysaccharide antigen was further

25 demonstrated in a study in which thirty adult volunteers were immunized with a tetravalent vaccine composed of purified polysaccharide from serotypes Ia, Ib, II, and III (Kotloff, K.L. et al. (1996) *Vaccine* **14**:446-450). Although safe, this vaccine was only modestly immunogenic, with only 13% of subjects responding to type Ib, 17% to type II, 33% responding to type Ia, and 70% responding to type III polysaccharide.

30 The poor immunogenicity of polysaccharide antigens prompted efforts to develop polysaccharide conjugate vaccines, whereby these polysaccharides or oligosaccharides are conjugated to protein carriers. Ninety percent of healthy adult women immunized with a type III polysaccharide-tetanus toxoid conjugate vaccine responded with a

4-fold rise in antibody concentration, compared to 50% immunized with plain polysaccharide (Kasper, D.L. et al (1996) *J of Clin Invest* **98**:2308-2314). A type Ia/Ib polysaccharide-tetanus toxoid conjugate vaccine was similarly more immunogenic in healthy adults than plain polysaccharide (Baker, C.J. et al (1999) *J Infect Dis* **179**:142-150).

The general method for the conjugation of polysaccharide is described in Wessels et al (Wessels, M.R. et al (1990) *J. Clin Investigation* **86**: 1428-1433). Prior to coupling with tetanus toxoid, aldehyde groups are introduced on the polysaccharide by controlled periodate oxidation, resulting in the conversion of a portion of the sialic acid residues of the polysaccharide to residues of the 8-carbon analogue of sialic acid, 5-acetamido-3,5-dideoxy-D-galactosyloctulosonic acid. Tetanus toxoid is conjugated to the polysaccharide by reductive amination using free aldehyde groups present on the partially oxidized sialic acid residues. The preparation and conjugation of oligosaccharides is described in Paoletti et al (Paoletti, L.C. et al (1990) *J. Biol Chem* **265**: 18278-18283). Purified capsular polysaccharide is depolymerized by enzymatic digestion using endo-beta-galactosidase produced by *Citrobacter freundii*. Following digestion, oligosaccharides are fractionated by gel filtration chromatography. Tetanus toxoid was covalently coupled via a synthetic spacer molecule to the reducing end of the oligosaccharide by reductive amination.

Methods and vaccines comprising GBS conjugate vaccines, comprising capsular polysaccharide and protein are provided and described in U.S. Patent 5, 993,825, 5,843,461, 5,795,580, 5,302,386 and 4,356,263, which are incorporated herein by reference in their entirety. These conjugate vaccines include polysaccharide-tetanus toxoid conjugate vaccines.

One polypeptide proposed to be utilized in a GBS vaccine is the repetitive GBS C protein alpha antigen, which contains up to nine tandemly repeated units of 82 amino acids (Michel, J.K. et al (1992) *PNAS USA* **89**: 10060-10064). The polypeptide, methods and vaccines thereof, including polysaccharide-conjugate vaccines generated therewith, are provided and described in U.S. Patent 5,968,521, 5,908,629, 5,858,362, 5,847,081, 5,843,461, 5,843,444, 5,820,860, and 5,648,241,

which are herein incorporated by reference in their entirety. Antibodies generated against C protein alpha antigen with a large numbers of repeats protect against infection, but GBS are able to change the structure of the protein by deleting one or more of the repeat regions and escape detection by these antibodies (Madoff, L.C. et al (1996) *PNAS USA* **93**: 4131-4136). This effect could theoretically be prevented by immunization with a protein with a lower number of repeat units, but the immunogenicity of the C protein alpha antigen is inversely related to the number of repeats - 65% of mice responded to immunization with the 9-repeat protein, but only 11% to a 1-repeat protein (Gravekamp, C. et al (1997) *Infect Immunity* **65**: 5216-5221). This is a disadvantage with any protein with a repetitive structure - it is common for bacteria to be able to alter or reassort these genes to alter the proteins exposed on their surface.

Typical doses for a vaccine composed of a protein antigen are in the range of 2.5-50 ug of total protein per dose. Typical doses for a polysaccharide-protein conjugate vaccine are 7.5-25 ug of polysaccharide and 1.25-250 ug of carrier protein. These types of vaccines are almost always given intramuscularly. Dosing schedules of a vaccine can be readily determined by the skilled artisan, particularly by comparison of similar vaccines, including other GBS vaccines. If used as a universal vaccine, a GBS vaccine would be integrated into the routine immunization schedule. Most similar vaccines require a primary series of immunizations (usually 2 or 3 doses at 2 month intervals beginning at 1 or 2 months of age) and a single booster at 12-18 months of age. A smaller number of doses or a single dose may be adequate in older children (over a year of age). For immunization of pregnant women, an exemplary immunization schedule would be a single dose given in the second or early third trimester. For immunization of non-pregnant adults, a single dose would probably be used. The requirement for subsequent booster doses in adults is difficult to predict - this would be based on the immunogenicity of the vaccine and ongoing surveillance of vaccine efficacy.

30

In a further aspect, the present invention provides an immunogenic composition comprising one of more bacterial Ema polypeptides. In a still further aspect, the present invention provides an immunogenic composition comprising one of more streptococcal Ema polypeptides. In a particular aspect, the present invention provides  
5 an immunogenic composition comprising one of more Group B streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD, EmaE and a fragment thereof, and a pharmaceutically acceptable adjuvant. Immunogenic compositions may comprise a combination of one or more Group B Ema polypeptide, or an immunogenic polypeptide fragment thereof, with one or more additional GBS  
10 polypeptide or GBS capsular polysaccharide or oligosaccharide.

The present invention further provides an immunogenic composition comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more antigens selected from the  
15 group of the polypeptide Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof, and Group B streptococcal polysaccharides or oligosaccharides.

## 20 *Pharmaceutical Compositions*

The invention provides pharmaceutical compositions comprising a bacterial Ema polypeptide, particularly a streptococcal Ema polypeptide, and a pharmaceutically acceptable carrier. The invention provides pharmaceutical compositions comprising a  
25 Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The present invention further provides pharmaceutical compositions comprising one or more GBS Ema polypeptide, or a fragment thereof, in combination with one or more of GBS polypeptide Spb1, Spb2, C protein alpha antigen, Rib, a Group B streptococcal  
30 polysaccharide or oligosaccharide vaccine, and an anti-streptococcal vaccine.

Such pharmaceutical composition for preventing streptococcal attachment to mucosal surface may include antibody to Ema polypeptide EmaA, EmaB, EmaC, EmaD or

EmaE or any combination of antibodies to one or more such Ema polypeptide. In addition, any such composition may further include antibody to GBS polypeptides Spb1, Spb2, C protein alpha antigen, or Rib. Blocking adherence using such antibody blocks the initial step in infection thereby reducing colonization. This in turn decreases person to person transmission and prevents development of symptomatic disease.

The present invention provides a pharmaceutical composition comprising an antibody to a Group B streptococcal protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The invention further provides a pharmaceutical composition comprising a combination of at least two antibodies to Group B streptococcal proteins and a pharmaceutically acceptable carrier, wherein at least one antibody to a protein selected from the group of EmaA, EmaB, EmaC, EmaD, EmaE, is combined with at least one antibody to a protein selected from the group of Spb1, Spb2, Rib, and C protein alpha antigen.

15

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of streptococci, so as to treat or prevent the adverse consequences of invasive, spontaneous, or idiopathic pathological states.

20

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of Group B streptococci, so as to treat or prevent the adverse consequences of invasive, spontaneous, or idiopathic pathological states.

25

The invention provides a method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

30

The invention further provides a method for preventing infection with a bacterium that expresses a Group B streptococcal Ema polypeptide comprising administering an

immunogenically effective dose of a vaccine comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

5 The present invention is directed to a method for treating infection with a bacterium that expresses a Group B streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier to a subject.

10 The invention further provides a method for treating infection with a bacterium that expresses a Group B streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier to a subject.

15

In a further aspect, the invention provides a method of inducing an immune response in a subject which has been exposed to or infected with a Group B streptococcal bacterium comprising administering to the subject an amount of the pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, 20 EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier, thereby inducing an immune response.

The invention still further provides a method for preventing infection by a streptococcal bacterium in a subject comprising administering to the subject an amount 25 of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a streptococcal bacterium.

30 The invention further provides an *ema* mutant bacteria which is non-adherent and/or non-invasive to cells and which is mutated in one or more genes selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*. Particularly, such *ema* mutant is a Group B streptococcal bacteria. Such non-adherent and/or non-invasive *ema* mutant

bacteria can further be utilized in expressing other immunogenic or therapeutic proteins for the purposes of eliciting immune responses to any such other proteins in the context of vaccines and in other forms of therapy.

- 5 This invention provides a method of inhibiting colonization of host cells in a subject which has been exposed to or infected with a streptococcal bacterium comprising administering to the subject an amount of a pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, thereby inducing an immune response. The therapeutic peptide that blocks  
10 colonization is delivered by the respiratory mucosal. The pharmaceutical composition comprises the polypeptide selected from the group of SEQ ID NO: 2, 4, 6, 8 and 10.

As used herein, "pharmaceutical composition" could mean therapeutically effective amounts of polypeptide products or antibodies of the invention together with suitable  
15 diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or carriers useful in therapy against bacterial infection or in inducing an immune response. A "therapeutically effective amount" as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. Such compositions are liquids or lyophilized or otherwise dried formulations and include  
20 diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking  
25 substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or  
30 spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the polypeptides of the present invention. The choice of compositions will depend on the physical and chemical properties of the polypeptide. Controlled or sustained release compositions include



formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and the polypeptides of the present invention coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of  
5 tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms, protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.

10 Further, as used herein "pharmaceutically acceptable carrier" are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol,  
15 vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte  
20 replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.

The phrase "pharmaceutically acceptable" refers to molecular entities and  
25 compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.

The phrase "therapeutically effective amount" is used herein to mean an amount  
30 sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant infection by streptococcal bacterium. Alternatively, in the case of a vaccine or immunogenic composition, a therapeutically effective amount is used herein to

mean an amount sufficient and suitable to elicit an immune response and antibody response in an individual, and particularly to provide a response sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant infection by

5 streptococcal bacterium.

Controlled or sustained release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the

10 compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.

15

When administered, compounds are often cleared rapidly from mucosal surfaces or the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent administrations of relatively large doses of bioactive compounds may be required to sustain therapeutic efficacy. Compounds modified by

20 the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al.,

25 1982; and Katre et al., 1987). Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-compound adducts less frequently or

30 in lower doses than with the unmodified compound.

*Dosages.* The sufficient amount may include but is not limited to from about 1 µg/kg to about 1000 mg/kg. The amount may be 10 mg/kg. The pharmaceutically acceptable form of the composition includes a pharmaceutically acceptable carrier.

- 5 As noted above, the present invention provides therapeutic compositions comprising pharmaceutical compositions comprising vectors, vaccines, polypeptides, nucleic acids and antibodies, anti-antibodies, and agents, to compete with the Group B streptococcus bacterium for pathogenic activities, such as adherence to host cells.
- 10 The preparation of therapeutic compositions which contain an active component is well understood in the art. Typically, such compositions are prepared as an aerosol of the polypeptide delivered to the nasopharynx or as injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be
- 15 emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering
- 20 agents which enhance the effectiveness of the active ingredient.

- An active component can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide
- 25 or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-
- 30 ethylamino ethanol, histidine, procaine, and the like.

A composition comprising "A" (where "A" is a single protein, DNA molecule, vector, etc.) is substantially free of "B" (where "B" comprises one or more contaminating

proteins, DNA molecules, vectors, etc.) when at least about 75% by weight of the proteins, DNA, vectors (depending on the category of species to which A and B belong) in the composition is "A". Preferably, "A" comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by weight.

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host. In the context of the present invention, a deficit in the response of the host is evidenced by continuing or spreading bacterial infection. An improvement in a clinically significant condition in the host includes a decrease in bacterial load, clearance of bacteria from colonized host cells, reduction in fever or inflammation associated with infection, or a reduction in any symptom associated with the bacterial infection.

According to the invention, the component or components of a therapeutic composition of the invention may be introduced parenterally, transmucosally, *e.g.*, orally, nasally, pulmonarailly, or rectally, or transdermally. Preferably, administration is parenteral, *e.g.*, via intravenous injection, and also including, but is not limited to, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. Oral or pulmonary delivery may be preferred to activate mucosal immunity; since Group B streptococci generally colonize the nasopharyngeal and pulmonary mucosa, particularly that of neonates, mucosal immunity may be a particularly effective preventive treatment. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; *i.e.*, carrier, or vehicle.

In another embodiment, the active compound can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-  
5 327; see generally *ibid.*).

In yet another embodiment, the therapeutic compound can be delivered in a controlled release system. For example, the polypeptide may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other  
10 modes of administration. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug*  
15 *Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic  
20 target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)). Preferably, a controlled release device is introduced into a subject in proximity of the site of inappropriate immune activation or a tumor. Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533  
25 (1990)).

A subject in whom administration of an active component as set forth above is an effective therapeutic regimen for a bacterial infection is preferably a human, but can be any animal. Thus, as can be readily appreciated by one of ordinary skill in the art, the  
30 methods and pharmaceutical compositions of the present invention are particularly suited to administration to any animal, particularly a mammal, and including, but by no means limited to, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild

animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., *i.e.*, for veterinary medical use.

In the therapeutic methods and compositions of the invention, a therapeutically effective dosage of the active component is provided. A therapeutically effective dosage can be determined by the ordinary skilled medical worker based on patient characteristics (age, weight, sex, condition, complications, other diseases, etc.), as is well known in the art. Furthermore, as further routine studies are conducted, more specific information will emerge regarding appropriate dosage levels for treatment of various conditions in various patients, and the ordinary skilled worker, considering the therapeutic context, age and general health of the recipient, is able to ascertain proper dosing. Generally, for intravenous injection or infusion, dosage may be lower than for intraperitoneal, intramuscular, or other route of administration. The dosing schedule may vary, depending on the circulation half-life, and the formulation used. The compositions are administered in a manner compatible with the dosage formulation in the therapeutically effective amount. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.

*Administration with other compounds.* For treatment of a bacterial infection, one may administer the present active component in conjunction with one or more pharmaceutical compositions used for treating bacterial infection, including but not limited to (1) antibiotics; (2) soluble carbohydrate inhibitors of bacterial adhesin; (3) other small molecule inhibitors of bacterial adhesin; (4) inhibitors of bacterial metabolism, transport, or transformation; (5) stimulators of bacterial lysis, or (6) anti-bacterial antibodies or vaccines directed at other bacterial antigens. Other potential

active components include anti-inflammatory agents, such as steroids and non-steroidal anti-inflammatory drugs. Administration may be simultaneous (for example, administration of a mixture of the present active component and an antibiotic), or may be *in seriatim*.

5

Accordingly, in specific embodiment, the therapeutic compositions may further include an effective amount of the active component, and one or more of the following active ingredients: an antibiotic, a steroid, etc.

10 Thus, in a specific instance where it is desired to reduce or inhibit the infection resulting from a bacterium mediated binding of bacteria to a host cell, or an antibody thereto, or a ligand thereof or an antibody to that ligand, the polypeptide is introduced to block the interaction of the bacteria with the host cell.

15 Also contemplated herein is pulmonary delivery of an inhibitor of the polypeptide of the present invention having which acts as adhesin inhibitory agent (or derivatives thereof). The adhesin inhibitory agent (or derivative) is delivered to the lungs of a mammal, where it can interfere with bacterial, *i.e.*, streptococcal, and preferably Group B streptococcal binding to host cells. Other reports of preparation of proteins for  
20 pulmonary delivery are found in the art [Adjei *et al.* (1990) *Pharmaceutical Research*, 7:565-569; Adjei *et al.* (1990) *International Journal of Pharmaceutics*, 63:135-144 (leuprolide acetate); Braquet *et al.* (1989), *Journal of Cardiovascular Pharmacology*, 13(suppl. 5):143-146 (endothelin-1); Hubbard *et al.* (1989) *Annals of Internal Medicine*, Vol. III, pp. 206-212 ( $\alpha$ 1-antitrypsin); Smith *et al.* (1989) *J. Clin. Invest.* 25 84:1145-1146 ( $\alpha$ -1-proteinase); Oswein *et al.*, "Aerosolization of Proteins", *Proceedings of Symposium on Respiratory Drug Delivery II*, Keystone, Colorado, March, (1990) (recombinant human growth hormone); Debs *et al.* (1988) *J. Immunol.* 140:3482-3488 (interferon- $\gamma$  and tumor necrosis factor alpha); Platz *et al.*, U.S. Patent No. 5,284,656 (granulocyte colony stimulating factor)]. A method and composition  
30 for pulmonary delivery of drugs is described in U.S. Patent No. 5,451,569, issued September 19, 1995 to Wong *et al.*

All such devices require the use of formulations suitable for the dispensing of adhesin inhibitory agent (or derivative). Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvant and/or carriers useful in therapy. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified adhesin inhibitory agent may also be prepared in different formulations depending on the type of chemical modification or the type of device employed.

- 10 Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise adhesin inhibitory agent (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active adhesin inhibitory agent per ml of solution. The formulation may also include a buffer and a simple sugar (*e.g.*, for adhesin inhibitory agent stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the adhesin inhibitory agent caused by atomization of the solution in forming the aerosol.

- Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the adhesin inhibitory agent (or derivative) suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

- The liquid aerosol formulations contain adhesin inhibitory agent and a dispersing agent in a physiologically acceptable diluent. The dry powder aerosol formulations of the present invention consist of a finely divided solid form of adhesin inhibitory agent and a dispersing agent. With either the liquid or dry powder aerosol formulation, the formulation must be aerosolized. That is, it must be broken down into liquid or solid particles in order to ensure that the aerosolized dose actually reaches the mucous



membranes of the nasal passages or the lung. The term "aerosol particle" is used herein to describe the liquid or solid particle suitable for nasal or pulmonary administration, *i.e.*, that will reach the mucous membranes. Other considerations, such as construction of the delivery device, additional components in the formulation, and particle characteristics are important. These aspects of pulmonary administration of a drug are well known in the art, and manipulation of formulations, aerosolization means and construction of a delivery device require at most routine experimentation by one of ordinary skill in the art. In a particular embodiment, the mass median dynamic diameter will be 5 micrometers or less in order to ensure that the drug particles reach the lung alveoli [Wearley, L.L. (1991) *Crit. Rev. in Ther. Drug Carrier Systems* 8:333].

Systems of aerosol delivery, such as the pressurized metered dose inhaler and the dry powder inhaler are disclosed in Newman, S.P., *Aerosols and the Lung*, Clarke, S.W. and Davia, D. editors, pp. 197-22 and can be used in connection with the present invention.

In a further embodiment, as discussed in detail *infra*, an aerosol formulation of the present invention can include other therapeutically or pharmacologically active ingredients in addition to adhesin inhibitory agent, such as but not limited to an antibiotic, a steroid, a non-steroidal anti-inflammatory drug, etc.

*Liquid Aerosol Formulations.* The present invention provides aerosol formulations and dosage forms for use in treating subjects suffering from bacterial, *e.g.*, streptococcal, in particularly streptococcal, infection. In general such dosage forms contain adhesin inhibitory agent in a pharmaceutically acceptable diluent. Pharmaceutically acceptable diluents include but are not limited to sterile water, saline, buffered saline, dextrose solution, and the like. In a specific embodiment, a diluent that may be used in the present invention or the pharmaceutical formulation of the present invention is phosphate buffered saline, or a buffered saline solution generally between the pH 7.0-8.0 range, or water.

The liquid aerosol formulation of the present invention may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, solubilizing or emulsifying agents, surfactants and excipients. The formulation may include a carrier. The carrier is a macromolecule which is soluble in the circulatory system and which is physiologically acceptable where physiological acceptance means that those of skill in the art would accept injection of said carrier into a patient as part of a therapeutic regime. The carrier preferably is relatively stable in the circulatory system with an acceptable plasma half life for clearance. Such macromolecules include but are not limited to Soya lecithin, oleic acid and sorbitan trioleate, with sorbitan trioleate preferred.

The formulations of the present embodiment may also include other agents useful for pH maintenance, solution stabilization, or for the regulation of osmotic pressure. Examples of the agents include but are not limited to salts, such as sodium chloride, or potassium chloride, and carbohydrates, such as glucose, galactose or mannose, and the like.

The present invention further contemplates liquid aerosol formulations comprising adhesin inhibitory agent and another therapeutically effective drug, such as an antibiotic, a steroid, a non-steroidal anti-inflammatory drug, etc.

*Aerosol Dry Powder Formulations.* It is also contemplated that the present aerosol formulation can be prepared as a dry powder formulation comprising a finely divided powder form of adhesin inhibitory agent and a dispersant.

Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing adhesin inhibitory agent (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation. The adhesin inhibitory agent (or derivative) should most advantageously be prepared in particulate form with an average particle size of less than 10 mm (or microns), most preferably 0.5 to 5 mm, for most effective delivery to the distal lung. In another embodiment, the dry powder formulation can comprise a finely divided dry powder containing adhesin inhibitory agent, a dispersing agent and

also a bulking agent. Bulking agents useful in conjunction with the present formulation include such agents as lactose, sorbitol, sucrose, or mannitol, in amounts that facilitate the dispersal of the powder from the device.

- 5 The present invention further contemplates dry powder formulations comprising adhesin inhibitory agent and another therapeutically effective drug, such as an antibiotic, a steroid, a non-steroidal anti-inflammatory drug, etc.

- Contemplated for use herein are oral solid dosage forms, which are described generally  
10 in *Remington's Pharmaceutical Sciences*, 18th Ed.1990 (Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent  
15 No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given by Marshall, K. In: *Modern Pharmaceutics* Edited by G.S. Banker and C.T. Rhodes Chapter 10, 1979, herein incorporated by reference. In general, the formulation will include the component or  
20 components (or chemically modified forms thereof) and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material in the intestine.

- Also specifically contemplated are oral dosage forms of the above derivatized  
25 component or components. The component or components may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in  
30 overall stability of the component or components and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski and Davis, 1981,

"Soluble Polymer-Enzyme Adducts" In: *Enzymes as Drugs*, Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, pp. 367-383; Newmark, *et al.* (1982) *J. Appl. Biochem.* 4:185-189. Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are

5 polyethylene glycol moieties.

For the component (or derivative) the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations which will not dissolve in the stomach, yet

10 will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the protein (or derivative) or by release of the biologically active material beyond the stomach environment, such as in the intestine.

15 To ensure full gastric resistance a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and

20 Shellac. These coatings may be used as mixed films.

A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow. Capsules may consist of a hard shell (such as

25 gelatin) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.

30 The peptide therapeutic can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

Colorants and flavoring agents may all be included. For example, the protein (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

5

One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol,  $\alpha$ -lactose, anhydrous lactose, cellulose, sucrose, modified dextran and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium  
10 chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include but are not limited to starch, including  
15 the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramyopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include  
20 powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants. Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and  
25 hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

An antifrictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between  
30 the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium

lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

To aid dissolution of the therapeutic into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.

Additives which potentially enhance uptake of the polypeptide (or derivative) are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

*Pulmonary Delivery.* Also contemplated herein is pulmonary delivery of the present polypeptide (or derivatives thereof). The polypeptide (or derivative) is delivered to the lungs of a mammal while inhaling and coats the mucosal surface of the alveoli. Other reports of this include Adjei *et al.* (1990) *Pharmaceutical Research* 7:565-569; Adjei *et al.* (1990) *International Journal of Pharmaceutics* 63:135-144 (leuprolide acetate); Braquet *et al.* (1989) *Journal of Cardiovascular Pharmacology*, 13(suppl. 5):143-146 (endothelin-1); Hubbard *et al.* (1989) *Annals of Internal Medicine*, Vol. III, pp. 206-212 (a1- antitrypsin); Smith *et al.* (1989) *J. Clin. Invest.* 84:1145-1146 (a-1-proteinase); Oswein *et al.* (1990) "Aerosolization of Proteins", *Proceedings of Symposium on Respiratory Drug Delivery II*, Keystone, Colorado, March, (recombinant human growth hormone); Debs *et al.* (1988) *J. Immunol.* 140:3482-3488 (interferon-g and tumor necrosis factor alpha) and Platz *et al.*, U.S.

Patent No. 5,284,656 (granulocyte colony stimulating factor). A method and composition for pulmonary delivery of drugs for systemic effect is described in U.S. Patent No. 5,451,569, issued September 19, 1995 to Wong et al.

- 5 Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
- 10 Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise polypeptide (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation may also include a buffer and a simple sugar (*e.g.*, for protein stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce
- 15 or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

- Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the polypeptide (or derivative) suspended in a
- 20 propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include
- 25 sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

- Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing polypeptide (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which
- 30 facilitate dispersal of the powder from the device, *e.g.*, 50 to 90% by weight of the formulation. The protein (or derivative) should most advantageously be prepared in particulate form with an average particle size of less than 10 mm (or microns), most preferably 0.5 to 5 mm, for most effective delivery to the distal lung.

*Nasal Delivery.* Nasal or nasopharyngeal delivery of the polypeptide (or derivative) is also contemplated. Nasal delivery allows the passage of the polypeptide directly over the upper respiratory tract mucosal after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran.

tide nomenclature, *J. Biol. Chem.*, **243**:3552-59 (1969), abbreviations for amino acid

The therapeutic polypeptide-, analog- or active fragment-containing compositions are conventionally administered intravenously, as by injection of a unit dose, for example.

The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to be administered depends on the subject to be treated, capacity of the subject's immune system to utilize the active ingredient, and degree of inhibition or neutralization of ~ binding capacity desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration.

Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.

The invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the preferred embodiments of the



invention and should in no way be construed, however, as limiting the broad scope of the invention.

### EXAMPLE 1

5

#### IDENTIFICATION OF GROUP B STREPTOCOCCUS GENES

Comparing the genetic and phenotypic composition of genetically-related groups of a bacterial species facilitates identifying virulence factors present in the most pathogenic groups. Type III GBS can be subdivided into three groups of related strains based on the analysis of restriction digest patterns (RDPs) produced by digestion of chromosomal DNA with Hind III and Sse 8387 (5, 6). Over 90% of invasive type III GBS disease in neonates in Japan and in Salt Lake City is caused by bacteria from one of three RDP types, termed RDP type III-3, while RDP type III-2 are significantly more likely to be isolated from vagina than from blood or CSF (6). These results suggest that this genetically-related cluster of type III-3 GBS are more virulent than III-2 strains and could be responsible for the majority of invasive type III disease globally. We proposed that bacterial factors that contribute to the increased virulence of III-3 strains can be identified by characterizing the differences between the genetic composition of III-3 and III-2 strains. Such genetic differences will be found in the bacterial chromosomes since these strains do not contain plasmids (6).

To identify genes present in virulent type III-3 GBS strains and not in the avirulent type III-2 strains we used a modification of the technique described by Lisitsyn et al (7). High molecular weight genomic DNA from an invasive RDP type III-3 GBS strain (strain 874391) and a colonizing ("avirulent") RDP type III-2 strain (strain 865043) was prepared by cell lysis with mutanolysin and Proteinase K digestion (5). For genetic subtraction, genomic DNA from both strains was digested with Taq I. Taq I-digested DNA from the virulent strain was mixed with two complementary oligonucleotides (TaqA (5'-CTAGGTGGATCCTTCGGCAAT-3' (SEQ ID NO: 11)) and TaqB (5'-CGATTGCCGA-3' (SEQ ID NO: 12)), heated to 50°C for 5 minutes, then allowed to cool slowly to 16°C in T4 ligase buffer. Oligonucleotides were ligated to the virulent strain DNA by incubation with 20 units of T4 ligase at 16°C for 12

hours. After ligation, 500 ng of DNA from the virulent strain, with ligated linkers, and 40 ug of DNA from the avirulent strain, without linkers, was mixed together, denatured by heating, and hybridized at 68°C for 20 hours.

- 5 Ten percent of the resulting hybridization mixture was incubated with Taq DNA polymerase and dNTPs to fill in the ends of annealed virulent strain DNA. The hybridized DNA was amplified by Taq DNA polymerase for 10 cycles using the TaqA oligonucleotide as the forward and reverse amplification primer. After amplification, single stranded products remaining after amplification were digested with mung bean
- 10 nuclease. Twenty percent of the resulting product was then reamplified for 20 cycles. This process of subtraction followed by PCR amplification results in enhanced amplification of DNA segments from the III-3 strains that do not hybridize with DNA segments from the III-2 strains.
- 15 A total of four cycles of subtraction and amplification were carried out, using successively smaller quantities of III-3 specific PCR products and alternating two sets of adaptors (TaqA/B (SEQ ID NOS: 11 and 12, respectively) and TaqE/F (TaqE (5'-AGGCAACTGTGCTAACCGAGGGAAT-3' (SEQ ID NO: 13)); and TaqF (5'-CGATTCCCTCG-3' (SEQ ID NO: 14)). The final amplification products were
- 20 ligated into pBS KS+ vectors. Thirteen clones were randomly selected for analysis. These probes were used in slot and dot blot experiments to determine whether subtraction was successful and to identify probes hybridizing with all III-3 strains. Each of the 6 unique probes hybridized with the parental III-3 virulent strain, while none of the probes hybridized with the avirulent III-2 strains. Two of the amplified
- 25 sequence tags (clones DY1-1 and DY1-11) hybridized with genomic DNA from all 62 type III isolates, but did not hybridize with DNA prepared from the III-2 and III-1 isolates (FIGURE 1). To obtain additional sequence information, we constructed a genomic GBS III-3 library. Multiple plaques hybridizing with each of the III-3 GBS-specific probes have been purified for further characterization.

30

## RESULTS

### THE *spb* LOCUS

Three overlapping genomic clones hybridizing with probe DY1-1 were identified. A 6.4 kb Sal I-Bgl II fragment present in each clone was subcloned and sequenced. This genomic DNA is present in all RDP type III-3 strains but not in serotype III-2, III-1 or other GBS serotype strains.

5

Over 90% of this genomic DNA fragment has been sequenced and found to contain 5 open reading frames (ORFs). Two ORFs appear to be candidates for virulence genes. *spb1* is a 1509 bp ORF. The predicted protein (502 amino acids and Mr 53,446) has the characteristics of a cell-wall bound protein. The nucleic acid and predicted amino acid sequences of *spb1* are provided in SEQ ID NOS: 15 and 16, respectively. The N-terminus of the predicted protein is a hydrophilic, basic stretch of 6 amino acids followed by a 23 amino acid hydrophobic, proline-rich core, consistent with a signal peptide. The hydrophilic mature protein terminates in a typical LPXTG (SEQ ID NO: 17) domain that immediately precedes a hydrophobic 20 amino acid core and a short, basic hydrophilic terminus. The nucleotide sequence is not homologous to sequences of other known bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including the fimbrial type 2 protein of *Actinomyces naeslundii* (27% identity over 350 amino acids) and the fimbrial type 1 protein of *Actinomyces viscosus* (25% homology over 420 amino acids) (16), the T6 surface protein of *S. pyogenes* (23% identity over 359 amino acids) (20), and the hsf (27% identity over 260 amino acids) and HMW1 adhesins (25% identity over 285 amino acids) of *Haemophilus influenzae* (21, 22). The function of the *S. pyogenes* T6 protein is unknown. Each of the other homologs plays a role in bacterial adhesion and/or invasion.

25

A *spb1*<sup>-</sup> isogenic deletion mutant GBS strain was created by homologous recombination (using the method as described in Example 2 below) and the ability of the *spb1*<sup>-</sup> mutant to adhere to and invade A549 respiratory epithelial cells was determined. Compared to the wild type strain, the number of *spb1*<sup>-</sup> bacteria adherent to A549 monolayers was reduced by 60.0% (p<0.01) and the number of intracellular invading bacteria was reduced by 53.6% (p<0.01). This data suggests *spb1* may contribute to the pathogenesis of GBS pneumonia and bacterial entry into the bloodstream.

30

The second ORF, *spb2*, terminates 37 bp upstream from *spb1* and is in the same transcriptional orientation. This 1692 bp ORF has a deduced amino acid sequence of 579 residues and Mr 64,492. The nucleic acid and predicted amino acid sequences of *spb2* are provided in SEQ ID NOS: 18 and 19, respectively. *spb2* shares 50.5%  
5 nucleic acid identity and 20.7% amino acid identity with *spb1*. Conservation is highest in the carboxy-terminal regions, including a shared LPSTGG (SEQ ID NO: 20) motif. In contrast to *spb1*, *spb2* does not have a obvious signal sequence. Its secretion may be mediated by carboxy-terminal recognition sequences or by accessory peptides (23). The deduced amino acid sequence of Spb2 is also homologous with *S.*  
10 *pyogenes* T6 and *Actinomyces naeslundii* proteins, and to *Listeria monocytogenes* internalin A (22% identity over 308 amino acids); again, proteins important in adhesion and invasion (24).

#### THE *ema* LOCUS

15

Two genomic clones hybridizing with probe DY1-11 were identified. A 7 kb Hind III fragment present in each clone was subcloned and sequenced. Unlike the serotype III specific *spb* sequences, this genomic DNA, which is adjacent to a region of serotype III-3 specific DNA, was found to be present in all GBS tested to date, including  
20 serotype Ia, Ib, II and V strains. This region of the GBS chromosome, which we have designated the extracellular matrix adhesin (*ema*) locus, contains 5 significant ORFs.

#### *emaA*

The first ORF, *emaA*, is 738 bp long, with a predicted protein product of 246 amino  
25 acids and Mr 26.2. The nucleic acid sequence (SEQ ID NO: 1) and predicted amino acid sequence (SEQ ID NO: 2) of *emaA* are shown in FIGURE 2. The EmaA protein is a non-repetitive protein. The 27 amino acid N-terminus of the predicted protein is consistent with a signal peptide. The mature protein has an imperfect cell wall binding domain (XPXTGG (SEQ ID NO:21)) followed by a transmembrane spanning domain  
30 encompassing residues 219 - 235 and a terminal hydrophilic tail. The *emaA* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including a collagen adhesin, Bbp, of *Staphylococcus aureus*

(37% identity over 103 aa) (15), a type 2 fimbrial structural subunit of *Actinomyces naeslandii* (39% homology over 112 aa) (16), and the FimP protein of *Actinomyces viscosus* (28% homology over 228 aa) (17). The function of the *S. pyogenes* T6 protein is unknown. The type 1 and type 2 fimbria of *Actinomyces* mediate bacterial  
5 adhesion to salivary glycoproteins and various host cells, contributing to the pathogenesis of dental caries.

### emaB

The second ORF, *emaB*, begins 94 bp 3' of *emaA* and is in the same transcriptional  
10 orientation. The nucleic acid sequence (SEQ ID NO: 3) and predicted amino acid sequence (SEQ ID NO: 4) of *emaB* are shown in FIGURE 3. It is 924 bp long, with a predicted protein product of 308 amino acids and Mr 33.9. The predicted EmaB protein is a nonrepetitive protein. The 27 amino acids N-terminus of the predicted protein is consistent with a signal peptide. The mature protein has an imperfect cell  
15 wall binding domain (XPXTG) followed by a transmembrane spanning domain encompassing residues 279-294. The *emaB* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including a type 2 fimbrial structural subunit of *Actinomyces naeslandii* (28% homology over 222 amino  
20 acids), the T6 protein of *S. pyogenes* (26% homology over 266 amino acids) (20), and a *S. epidermidis* putative cell-surface adhesin (24% identity over 197 amino acids). The first of these proteins mediates adhesion of *S. aureus* to collagen and is postulated to contribute to the pathogenesis of osteomyelitis and infectious arthritis.

### 25 emaC

The third ORF, *emaC*, begins 2 bp 3' of *emaB* and is the same transcriptional orientation. It is 918 bp long, with a predicted protein product of 305 amino acids and Mr 34.5. The nucleic acid sequence (SEQ ID NO: 5) and predicted amino acid  
30 sequence (SEQ ID NO: 6) of *emaC* are depicted in FIGURE 4. The EmaC protein is a nonrepetitive protein. The 30 amino acid N-terminus of the predicted protein is consistent with a signal peptide. The mature protein has a transmembrane spanning domain encompassing residues 265 - 281. The *emaC* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid

sequence, however, shares segmental homology with a number of characterized proteins, including proteins associated with the assembly of type 2 fimbrial structural subunit of *Actinomyces naeslandii* (38% homology over 234 amino acids) (16).

These proteins are required for the assembly of type 2 fimbria.

5

#### emaD

The fourth ORF, *emaD*, is 852 bp long, overlaps *emaC* by 47 bp, and is in the same transcriptional orientation. The predicted protein product is 284 amino acids and Mr 33.1. The nucleic acid sequence (SEQ ID NO: 7) and predicted amino acid sequence  
10 (SEQ ID NO:8) of *emaD* are shown in FIGURE 5. No indentifiable N-terminal signal sequence is present and potential transmembrane segments are present at positions 19-35 and 252-280. The mature protein is not repetative and lacks a cell wall binding domain. The *emaD* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, shares segmental homology with  
15 the same fimbria-associated proteins of *Actinomyces* as does EmaC.

#### emaE

The fifth ORF, *emaE*, begins 42 bp 3' of *emaD* and is in the same transcriptional orientation. It is 2712 bp long, with a predicted protein product of 904 aa and Mr  
20 100.9. FIGURE 6 depicts the nucleic acid sequence (SEQ ID NO: 9) and predicted amino acid sequence (SEQ ID NO: 10) of *emaE*. The predicted EmaE protein is a nonrepetitive protein. An obvious N-terminal signal peptide is not evident but a putative transmembrane region is located at residues 24-40. The mature protein has an imperfect cell wall binding domain (XPXTGG (SEQ ID NO: 21)) followed by a  
25 transmembrane spanning domain encompassing residues 880 - 896. The *emaE* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including the F1 and F2 fibronectin binding proteins of *S. pyogenes* (31% homology over 207 amino acids) (18, 19). These proteins mediate  
30 high affinity binding to fibronectin, and are important in the adhesion of *S. pyogenes* to respiratory cells.

The similarity of the protein products of the *ema* locus to physiologically important adhesins and invasins of other bacterial species suggests that the Ema proteins have a role in facilitating the adhesion of GBS to extracellular matrix components and to cell surfaces and subsequent invasion of epithelial and endothelial cells, the initial steps in the pathogenesis of infection.

Several lines of evidence suggest the members of the *ema* and the *spb* locus may have similar functions, but are likely to represent distinct classes of proteins. The *ema* and *spb* locus genes are each and all similar to physiologically important adhesions and invasions of the bacterial species, however, both Spb1 and Spb2 have prototypical gram positive cell-wall binding domains, whereas the members of the *ema* locus have an unusual motif, suggesting a distinct mechanism of cell surface anchoring. Second, the *spb* locus is restricted to virulent serotype III-3 strains of GBS, whereas the *ema* locus appears to be ubiquitous in all GBS serotypes. Third, *spb1* and *spb2* are more homologous to one another than to members of the *ema* locus and *ema* genes are more closely homologous to one another than to *spb1* and *spb2*.

## EXAMPLE 2

### **BIOLOGIC CHARACTERIZATION OF NOVEL GBS GENES**

#### Isogenic Mutant Bacterial Strains

To identify biologic activity of these novel GBS genes, isogenic mutant bacterial strains are created which are identical in all respects except for the presence or absence of a particular gene. Deletion mutants are created by allelic replacement. The relevant gene, with 100-300 bp of flanking sequences, is subcloned and modified by the deletion of an intragenic portion of the coding sequence and, in some cases, the insertion of a kanamycin resistance gene. The mutant gene is cloned into the suicide vector pHY304 (kindly provided by Dr. Craig Rubens), a broad host range plasmid containing a temperature sensitive ori, erythromycin resistance gene (*erm<sup>TS</sup>*), and a pBS multiple cloning site. The pHY304 vector is a derivative of the vector pWV01 (Framson, P.E. et al (1997) *Applied Environ Microbiology* 63:3539-3547). Plasmids

containing mutant genes are electroporated into strain 874391 and single cross-over mutants are selected by antibiotic resistance at 37°C. The resulting antibiotic resistant colonies are subjected to a temperature shift to 30°C. Integration of the plasmid is unstable at this permissive temperature because there are two functional ori's on the chromosome. Excised plasmid is eliminated by growth on nonselective media for many generations, then colonies are screened for the presence of the mutant allele by erythromycin-sensitivity. Double-crossover mutants are stable and do not require maintenance under drug selection. The mutant genotype is confirmed by Southern blotting or PCR demonstrating the appropriate deletion. The resulting mutants are screened for the presence of gene expression by Northern and Western blot analysis. The phenotype of the knockout mutants is then compared with that of the wild type strain 874391 by examining growth rate and colony morphology, and the expression of  $\beta$ -hemolysin and CAMP factor. Surface protein expression is assessed by Western blot, using polyclonal sera from rabbits immunized with whole, heat-killed type III GBS.

### *In Vitro* Models

#### A. Adherence

Adhesion of GBS to host cells is a prerequisite for invasive disease. Three different cell types have the potential to be important in this process: i) adhesion to respiratory epithelial cells is likely to facilitate most early onset neonatal infections, ii) adhesion to gastrointestinal epithelial cells has been postulated to be important in the pathogenesis of late onset neonatal infections, and iii) adhesion to endothelial cells is necessary for both endocarditis and other endovascular infections, and is likely to be the initial event in GBS meningitis. The ability of wild type and mutant strains to adhere to epithelial and endothelial cells is compared in adhesion assays.

Four different cell lines are used to investigate the role of novel GBS genes in adhesion. GBS adhere to and invade A549 human alveolar epithelial carcinoma cells and surface proteins appear to play an important role in this process (8). GBS binding to A549 cells is used as an *in vitro* model for respiratory colonization. GBS also adhere to C2BBel, a human intestinal epithelial cell line, which is used as a model for



gastrointestinal colonization, and to HeLa cervical epithelial cells, a model for genital colonization and maternal infection. For endothelial adhesion, two cell lines are studied: freshly isolated human umbilical vein endothelial (HUVE) cells; and an immortalized human brain microvascular endothelial cell line (BMEC). Adhesion assays are performed as described by Tamura et al (9). Cell lines are grown to confluence in 96-well tissue culture plates in recommended media. Monolayers are washed with PBS and fixed with 0.5% glutaraldehyde. Following blocking with 5% BSA in PBS, cells are inoculated with various inocula of GBS, centrifuged for 10 minutes at 2000 rpm and incubated for 1 hour at 4°C. Nonadherent bacteria are removed by washing three times with 5% nonfat dry milk in PBS and bound bacteria are then eluted and plated quantitatively.

#### B. Invasion

GBS adhere to and invade respiratory epithelium, endothelium and BMEC (8, 10, 11). The ability of wild type and isogenic mutant GBS strains to invade the above epithelial and endothelial cells are tested as previously described (8, 10, 11). Assays that distinguish the ability of GBS to invade eukaryotic cells versus adhere to cells capitalize on the inability of penicillin and gentamicin to enter host cells, allowing quantification of intracellular bacteria after extracellular bacteria are killed. GBS are grown to the desired growth phase in TH broth, washed twice with PBS and resuspended in tissue culture media containing 10% fetal calf serum. Tissue culture monolayers grown to confluence in 24-well plates are inoculated with varying inocula of GBS, centrifuged at 800xg and incubated at 37°C in 5% CO<sub>2</sub> for 2-6 hours. Extracellular bacteria are removed by washing four times with PBS. Cells are then incubated in fresh medium with 5 mg/ml penicillin and 100 mg/ml gentamicin for 2 hours. Media is then removed, monolayers washed, and cells lysed by treatment with 0.025% Triton X-100. Cell lysates are sonicated to disrupt bacterial chains and aliquots plated quantitatively.

#### C. Antibody to GBS Proteins

The ability of specific antibody to the novel GBS proteins to promote opsonophagocytic killing of GBS is tested (12). Rabbits are immunized with recombinant or purified GBS proteins produced by standard techniques. Rabbit

antiserum of different dilutions (ranging from 1/50 to 1/5,000) that has been exhaustively absorbed with the relevant isogenic mutant strain at 4°C will be incubated with GBS in the presence of human complement and polymorphonuclear leukocytes ( $3 \times 10^6$ ). Opsonophagocytic killing is expressed as the log number of CFU surviving following 1 hour of incubation subtracted from the log of the number of CFU at the zero time point. Killing of wild type strains is compared to that of isogenic mutants lacking novel GBS proteins.

### In Vivo Models

10

The neonatal rat has been used by numerous laboratories as a model of GBS infection because it closely mimics human neonatal infection (13). The contribution of novel genes to the pathogenesis of GBS infections is tested by comparing wild type and mutant in this system. Rat pups are inoculated by two routes. First, pups are inoculated intranasally to mimic the respiratory infection and sepsis typical of early onset GBS infection. Secondly, intraperitoneal or subcutaneous inoculation reproduces the high grade bacteremia associated with GBS sepsis and that precedes GBS meningitis (14).

20 Rat pups are inoculated with varying doses of GBS strains and mortality is determined. The level of bacteremia is determined by quantitative blood cultures. Lung, liver, spleen and meningeal tissue are preserved for histologic examination.

The ability of antiserum to the GBS proteins to protect neonatal rats from GBS infection is tested (13). Newborn rats (<18 hours old) receive an intraperitoneal injection of 0.5 ml of undiluted rabbit antiserum, followed by the intraperitoneal inoculation of the equivalent of one LD50 unit of GBS (usually about 5000 bacteria) in PBS. Mortality and morbidity are then determined.

### 30 Role of Novel GBS Proteins in Vaccines

Several surface proteins of GBS, including C and Rib are immunogenic and protective against GBS infection in infant rodent models (25, 26). None of these proteins are

present in all GBS strains (27). Furthermore, each of these proteins has a repetitive structure. The phenotypic variability of these repetitive proteins allows escape mutants expressing variant forms to evade host immune systems and may limit the effectiveness of these vaccines (28). It is notable that each of the predicted proteins of the *spb* and *ema* loci do not have a repetitive structure and would not have this disadvantage.

The novel GBS proteins we describe here may be useful antigens for a GBS vaccine. The data presented herein indicates these proteins have a role in mediating adhesion to and invasion of GBS to human epithelial cells, thus antibody against these antigens may prevent these initial steps in infection. It is highly desirable to develop a vaccine that prevents colonization of pregnant women and other individuals at increased risk of invasive GBS infection, as this would eliminate most infections. Our data suggests that antibody against *Spb1* is effective in reducing colonization or infection following colonization with highly virulent strains of serotype III, and therefore this protein is a particularly useful vaccine antigen. Members of the *ema* locus, unlike *spb1* and *spb2*, are ubiquitous in GBS and therefore have a role in the prevention of infection by multiple serotypes of GBS. An optimal vaccine formulation includes combinations of these antigens.

Two strategies are used to design GBS vaccines using these novel proteins. First, purified recombinant or affinity-purified proteins are used as vaccine antigens, singly or in combination (25). Second, these proteins are used as carrier proteins for capsular polysaccharide or oligosaccharide-based vaccines. GBS polysaccharides and oligosaccharides are generally poorly immunogenic and fail to elicit significant memory and booster responses (29). Conjugation of these polysaccharides or oligosaccharides to protein carriers increases immunogenicity. GBS polysaccharide conjugated to tetanus toxoid, for example, has been used to immunize pregnant women and results in high levels of maternal serum anti-polysaccharide antibody which may be transferred to the fetus in the third trimester of pregnancy (30). Selection of appropriate carrier proteins is important for the development of polysaccharide-protein vaccine formulations. For example, *Haemophilus influenzae* type b poly- or oligosaccharide conjugated to different protein carriers has variable immunogenicity and elicits

antibody with varying avidity (31, 32). Repeated immunization with the same carrier protein may also suppress immune responses by competition for specific B cells (epitopic suppression) or other mechanisms. This is of particular concern for the development of GBS vaccines since recently developed polyaccharide and  
5 oligosaccharide-protein conjugate vaccines against the bacteria *H. influenzae*, *S. pneumoniae*, and *N. meningitidis* all utilize a restricted number of carrier proteins (tetanus toxoid, CRM197, diphtheria toxoid), increasing the number of exposures to these carriers an individual is likely to receive. A "designer" vaccine, composed of a GBS polysaccharide or oligosaccharide coupled to a GBS-specific carrier protein,  
10 such as the novel GBS polypeptides provided herein, particularly including Spb1, EmaC and EmaE, may be a preferable strategy. The large size of certain of these novel GBS antigens may also be an advantage to traditional carrier proteins as increasing size is associated with improved immunogenicity.

15

### **EXAMPLE 3**

#### **EMA HOMOLOGS IN STREPTOCOCCI AND OTHER BACTERIA**

As noted above, the GBS Ema proteins share segmental homology with certain characterized proteins from other bacterial species, including bacterial adhesion and  
20 invasion proteins. The segmental homolog is noted as in the range of 24-39%. In addition, the Ema proteins demonstrate some homology to one another. A comparison of the *ema* genes shows that EmaA and EmaB are 47% homologous, however, due to the difference in their predicted lengths it is necessary to insert gaps in the EmaA sequence in order to line them up. The two Ema proteins which are most  
25 similar in structure, EmaC and EmaD share 48.7% amino acid homology to one another. EmaA/B, EmaC/D and EmaE are each  $\leq 20\%$  homologous to one another.

The *ema* sequences were used to search the unannotated microbial genomes (Eubacteria). The predicted Ema proteins were searched against translations in all six  
30 frames (tblast x) of finished and unfinished unannotated microbial genomes available at the web site of the National Center for Biotechnology Information (NCBI). Segmental amino acid homolog was identified.

EmaA has some segmental homolog with *S. pneumoniae*, *E. faecalis*, *B. anthracis* and *C. diphtheriae*. Ema B has some segmental homolog with *B. anthracis*. EmaE has segmental homology to *S. pyogenes* and lesser homology to *B. anthracis*.

- 5 Significant homology was identified between the GBS EmaC and EmaD and proteins in other bacterial species. EmaC has significant (55% identity over 149 amino acids) homology to a region of the *S. pneumoniae* chromosome and the *S. pyogenes* chromosome (47% identity over 150 amino acids). Lesser segmental homology was found to *E. faecalis*, *S. equi*, and *C. diphtheriae*. EmaD has strong segmental  
10 homology (66% over 184 amino acids) to a region of the *S. pneumoniae* chromosome, and lesser segmental homology to *C. diphtheriae* and *S. pyogenes*.

We have identified two Ema homologs in *S. pneumoniae*. These *S. pneumoniae* homologs show homology to EmaC and EmaD and, like EmaC and EmaD, also  
15 demonstrate homology to fimbria-associated protein of *Actinomyces*. The encoding nucleic acid and predicted amino acid sequence of the first *S. pneumoniae* EmaC/D homolog are provided in SEQ ID NOS: 24 and 23, respectively. The genome region nucleic acid including the first homolog encoding sequence is provided in SEQ ID NO: 22. The nucleic acid and predicted amino acid sequence of the second *S. pneumoniae*  
20 EmaC/D homolog are provided in SEQ ID NOS: 27 and 26 respectively. The genomic region nucleic acid of this second homolog is found in SEQ ID NO: 25. An EmaC/D homolog has been identified in *Enterococcus faecalis* by search and analysis. The *E. faecalis* EmaC/D homolog predicted amino acid sequence is provided in SEQ ID NO: 29. The nucleic acid sequence encoding this *E. faecalis* Ema homolog  
25 is provided in SEQ ID NO: 30. The nucleic acid sequence of *E. faecalis* which genomic region encodes the EmaC/D homolog is provided in SEQ ID NO: 28.

We have also identified an EmaD homolog in *Corynebacterium diphtheriae*. The predicted amino acid sequence of the *C. diphtheriae* EmaD homolog is provided in  
30 SEQ ID NO: 32. *C. diphtheriae* nucleic acid sequence which encodes the homolog is found in SEQ ID NO: 33. The corresponding genomic region sequence of *C. diphtheriae* is provided in SEQ ID NO: 31.

A predicted EmaC/D homolog has been identified in *S. pyogenes*. The predicted partial amino acid sequence of this Ema homolog provided in SEQ ID NO: 37.

A region of amino acids TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34) is  
 5 found in GBS EmaC, GBS EmaD, in both the EmaC/D homologs of *S. pneumoniae*,  
 and in the *E. faecalis* Ema homolog. A similar sequence  
 TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35) is also found in the *C. diphtheriae*  
 Ema homolog. The *S. pyogenes* predicted Ema homolog has a similar sequence  
 TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36) as well.

10

The following is a list of the references referred to in this Example section.

#### References

- 15 1 Baker CJ. Group B streptococcal infections. In Streptococcal infections.  
 Clinical aspects, microbiology, and molecular pathogenesis. (D. L. Stevens and E. L.  
 Kaplan), New York: Oxford University Press, 222-237, 2000.
- 2 Blumberg HM, Stephens DS, Modansky M, Erwin M, Elliot J, Facklam RR,  
 20 Schuchat A, Baughman W and Farley MM. Invasive group B streptococcal disease:  
 The emergence of serotype V. Journal of Infectious Diseases 173:365-373, 1996.
- 3 Kogan G, Uhrin D, Brisson J-R, Paoletti LC, Blodgett AE, Kasper DL and  
 Jennings HJ. Structural and immunochemical characterization of the type VIII group  
 25 B Streptococcus capsular polysaccharide. The Journal of Biological Chemistry  
 271:8786-8790, 1996.
- 4 Rubens CE, Raff HV, Jackson CJ, Chi EY, Bielitzki JT and Hillier SL.  
 Pathophysiology and histopathology of group B streptococcal sepsis in Macaca  
 30 nemestrina primates induced after intraamniotic inoculation: evidence for bacterial  
 cellular invasion. Journal of Infectious Diseases 164:320--330, 1991.

- 5 Nagano Y, Nagano N, Takahashi S, Murono K, Fujita K, Taguchi F and Okuwaki Y. Restriction endonuclease digest patterns of chromosomal DNA from group B b-haemolytic streptococci. *Journal of Medical Microbiology* 35:297-303, 1991.
- 5 6 Takahashi S, Adderson EE, Nagano Y, Nagano N, Briesacher MR and Bohnsack JF. Identification of a highly encapsulated, genetically related group of invasive type III group B streptococci. *The Journal of Infectious Diseases* 177:1116-1119, 1998.
- 10 7 Lisitsyn N, Lisitsyn N and Wigler M. Cloning the differences between two complex genomes. *Science* 259:946-951, 1993.
- 8 Rubens CE, Smith S, Hulse M, Chi EY and van Belle G. Respiratory epithelial  
15 cell invasion by group B streptococci. *Infection & Immunity* 60:5157-63, 1992.
- 9 Tamura GS, Kuypers JM, Smith S, Raff H and Rubens CE. Adherence of group B streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components. *Infection and Immunity* 62:2450-8, 1994.
- 20 10 Nizet V, Kim KS, Stins M, Jonas M, Chi EY, Nguyen D and Rubens CE. Invasion of brain microvascular endothelial cells by group B streptococci. *Infection and Immunity* 65:5074-5081, 1997.
- 25 11 Gibson RL, Lee MK, Soderland C, Chi EY and Rubens CE. Group B streptococci invade endothelial cells: type III capsular polysaccharide attenuates invasion. *Infection & Immunity* 61:478-85, 1993.
- 12 Gravekamp C, Kasper DL, Michel JL, Kling DE, Carey V and Madoff LC.  
30 Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats. *Infection and Immunity* 65:5216-5221, 1997.

- 13 Hill HR, Gonzales LA, Knappe WA, Fischer GW, Kelsey DK and Raff HV. Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci. *Journal of Infectious Diseases* 163:792-797, 1991.
- 5
- 14 Kim KS, Wass CA and Cross AS. Blood-brain barrier permeability during the development of experimental bacterial meningitis in the rat. *Experimental Neurology* 145:253-257, 1997.
- 10 15 Patti JM, Jonsson H, Guss B, Switalski LM, Wiberg K, Lindberg M and Hook M. Molecular characterization and expression of a gene encoding a *Staphylococcus aureus* collagen adhesin. *The Journal of Biologic Chemistry* 267:4766-4772, 1992.
- 15 16 Yeung MK and Cisar JO. Sequence homology between the subunits of two immunologically and functionally distinct types of fimbriae of *Actinomyces* spp. *The Journal of Bacteriology* 172:2462-8, 1990.
- 17 Li T, Johansson I, Hay DI and Stromberg N. Strains of *Actinomyces naeslundii* and *Actinomyces viscosus* exhibit structurally variant fimbrial subunit proteins and bind to different peptide motifs in salivary proteins. *Infection and Immunity* 20 67:2053-2059, 1999.
- 18 Jaffe J, Natanson-Yaron S, Caparon MG and Hanski E. Protein F2, a novel fibronectin-binding protein from *Streptococcus pyogenes*, possesses two binding 25 domains. *Molecular Microbiology* 21:2720-728, 1996.
- 19 Rocha CL and Fischetti VA. Identification and characterization of a novel fibronectin-binding protein on the surface of Group A streptococci. *Infection and Immunity* 66:1482-1491, 1999.
- 30
- 20 Schneewind O, Jones KF and Fischetti VA. Sequence and structural characteristics of the trypsin-resistant T6 protein of group A streptococci. *The Journal of Bacteriology* 172:3310-7, 1990.



- 21 St. Geme III JW, Cutter D and Barenkamp SJ. Characterization of the genetic locus encoding *Haemophilus influenzae* type b surface fibrils. *The Journal of Bacteriology* 178:6281-6287, 1996.
- 5 22 Barenkamp SJ and Leininger E. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable *Haemophilus influenzae* high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of *Bordetella pertussis*. *Infection and Immunity* 60:1302-1313, 1992.
- 10 23 Micheils T, Wattiau P, Brasseur R, Ruyschaert JM and Cornelis G. Secretion of Yop proteins by *Yersinia*. *Infection and Immunity* 58:2840-2849, 1990.
- 24 Gaillard JL, Berche P, Frehel C, Gouin E and Cossart P. Entry of *L. monocytogenes* into cells is mediated by internalin, a repeat protein reminiscent of  
15 surface antigens from gram-positive cocci. *Cell* 65:1127-1141, 1991.
- 25 Madoff LC, Michel JL, Gong EW, Rodewald AK and Kasper DL. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. *Infection and Immunity* 60:4989-4994, 1992.
- 20 26 Stalhammar-Carlemalm M, Stenberg L and Lindahl G. Protein Rib: A novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. *The Journal of Experimental Medicine* 177:1593-1603, 1993.
- 25 27 Ferrieri P and Flores AE. Surface protein expression in group B streptococcal invasive isolates. *Advances in Experimental Medicine* 418:635-637, 1997.
- 28 Madoff LC, Michel JT, Gong EW, Kling DE and Kasper DL. Group B  
30 streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. *Proceedings of the National Academy of Science U.S.A.* 93:4131-4136, 1996.

- 29 Baker CJ, Rench MA and Edwards MS. Immunization of pregnant women  
with a polysaccharide vaccine of group B Streptococcus. New England Journal of  
Medicine 319:1180-1185, 1988.
- 5 30 Baker CJ, Paoletti LC, Wessels MR, Guttormsen H-K, Rench MA, Hickman  
ME and Kasper DL. Safety and immunogenicity of capsular polysaccharide-tetanus  
toxoid conjugate vaccines for group B streptococcal types Ia and Ib. The Journal of  
Infectious Diseases 179:142-150, 1999.
- 10 31 Decker MD, Edwards KM, Bradley R and Palmer P. Comparative trial in  
infants of four conjugate Haemophilus influenzae type b vaccines. The Journal of  
Pediatrics 120:184-189, 1992.
- 32 Schlesinger Y, Granoff DM and Group TVS. Avidity and bactericidal activity  
15 of antibody elicited by different Haemophilus influenzae type b conjugate vaccines.  
Journal of the American Medical Association 267:1489-1494, 1992.

This invention may be embodied in other forms or carried out in other ways without  
departing from the spirit or essential characteristics thereof. The present disclosure is  
20 therefore to be considered as in all aspects illustrate and not restrictive, the scope of  
the invention being indicated by the appended Claims, and all changes which come  
within the meaning and range of equivalency are intended to be embraced therein.

Various references are cited throughout this Specification, each of which is  
25 incorporated herein by reference in its entirety.

WHAT IS CLAIMED IS:

1. An isolated streptococcal polypeptide EmaA.
2. The EmaA polypeptide of Claim 1 which comprises the amino acid sequence set out in SEQ ID NO: 2, and analogs, variants and immunogenic fragments thereof.
3. An isolated streptococcal polypeptide EmaB.
4. The EmaC polypeptide of Claim 3 which comprises the amino acid sequence set out in SEQ ID NO: 4, and analogs, variants and immunogenic fragments thereof.
5. An isolated streptococcal polypeptide EmaC.
6. The EmaC polypeptide of Claim 5 which comprises the amino acid sequence set out in SEQ ID NO: 6, and analogs, variants and immunogenic fragments thereof.
7. An isolated streptococcal polypeptide EmaD.
8. The EmaD polypeptide of Claim 7 which comprises the amino acid sequence set out in SEQ ID NO: 8, and analogs, variants and immunogenic fragments thereof.
9. An isolated streptococcal polypeptide EmaE.
10. The EmaE polypeptide of Claim 9 which comprises the amino acid sequence set out in SEQ ID NO: 10, and analogs, variants and immunogenic fragments thereof.

11. The streptococcal polypeptide of any of Claims 1, 3, 5, 7 or 9 labeled with a detectable label.
12. A vaccine comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant.
13. The vaccine of Claim 12, further comprising an antigen selected from the group consisting of:
  - a. the polypeptide Spb1 or an immunogenic fragment thereof;
  - b. the polypeptide Spb2 or an immunogenic fragment thereof;
  - c. the polypeptide C protein alpha antigen or an immunogenic fragment thereof;
  - d. the polypeptide Rib or an immunogenic fragment thereof;
  - e. the polypeptide Lmb or an immunogenic fragment thereof;
  - f. the polypeptide C5a-ase or an immunogenic fragment thereof;
  - g. Group B streptococcal polysaccharides or oligosaccharides; and
  - h. any combination of one or more of the foregoing.
14. An immunogenic composition comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant.
15. The immunogenic composition of Claim 14, further comprising an antigen selected from the group consisting of:
  - a. the polypeptide Spb1 or an immunogenic fragment thereof;
  - b. the polypeptide Spb2 or an immunogenic fragment thereof;
  - c. the polypeptide C protein alpha antigen or an immunogenic fragment thereof;
  - d. the polypeptide Rib or an immunogenic fragment thereof;
  - e. the polypeptide Lmb or an immunogenic fragment thereof;
  - f. the polypeptide C5a-ase or an immunogenic fragment thereof;
  - g. Group B streptococcal polysaccharides or oligosaccharides; and

- h. any combination of one or more of the foregoing.
- 16. A pharmaceutical composition comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier.
  - 17. The pharmaceutical composition of Claim 16, further comprising an active ingredient selected from the group consisting of:
    - a. Spb1 or Spb2 polypeptide;
    - b. C protein alpha antigen;
    - c. Rib polypeptide;
    - d. Lmb polypeptide;
    - e. C5a-ase polypeptide;
    - f. a Group B streptococcal polysaccharide or oligosaccharide; and
    - g. an anti-streptococcal vaccine.
  - 18. A purified antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.
  - 19. A monoclonal antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.
  - 20. An immortal cell line that produces a monoclonal antibody according to Claim 19.
  - 21. The antibody of any of Claims 19 or 20 labeled with a detectable label.
  - 22. The antibody of Claim 21 wherein the label is selected from the group consisting of an enzyme, a chemical which fluoresces, and a radioactive element.

23. A pharmaceutical composition comprising one or more antibodies to a streptococcal protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprising a combination of at least two antibodies to streptococcal proteins and a pharmaceutically acceptable carrier, wherein at least one antibody to a protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, is combined with at least one antibody to a protein selected from the group of Spb1 and Spb2, Rib, Lmb, C5a-ase and C protein alpha antigen.
25. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 1, or a fragment thereof.
26. The isolated nucleic acid of Claim 25, wherein the nucleic acid is selected from the group consisting of:
  - a. the DNA sequence of SEQ ID NO: 1;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - f. hybridizable fragments thereof.
27. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 3.
28. The isolated nucleic acid of Claim 27, wherein the nucleic acid is selected from the group consisting of:
  - a. the DNA sequence of SEQ ID NO: 3;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;

- c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - f. hybridizable fragments thereof
29. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 5.
30. The isolated nucleic acid of Claim 29, wherein the nucleic acid is selected from the group consisting of:
- a. the DNA sequence of SEQ ID NO: 5;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - f. hybridizable fragments thereof
31. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 7.
32. The isolated nucleic acid of Claim 31, wherein the nucleic acid is selected from the group consisting of:
- a. the DNA sequence of SEQ ID NO: 7;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - f. hybridizable fragments thereof

33. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 9.
34. The isolated nucleic acid of Claim 33, wherein the nucleic acid is selected from the group consisting of:
  - a. the DNA sequence of SEQ ID NO: 9;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - f. hybridizable fragments thereof
35. A vector which comprises the nucleic acid of any of Claims 25, 27, 29, 31 or 33 and a promoter.
36. The vector of Claim 35, wherein the promoter comprises a bacterial, yeast, insect or mammalian promoter.
37. The vector of Claim 35, wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA.
38. A host vector system for the production of a polypeptide which comprises the vector of Claim 35 in a suitable host cell.
39. The host vector system of Claim 38, wherein the suitable host cell comprises a prokaryotic or eukaryotic cell.
40. The nucleic acid of any of Claims 25, 27, 29, 31 or 33 which is a recombinant DNA molecule.




41. The recombinant DNA molecule of Claim 40, wherein the DNA molecule is operatively linked to an expression control sequence.
42. A unicellular host transformed with a recombinant DNA molecule of Claim 40.
43. A nucleic acid vaccine comprising the recombinant DNA molecule of Claim 40.
44. A method for detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, wherein the streptococcal polypeptide is measured by:
  - a. contacting a sample in which the presence or activity of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal polypeptide under conditions that allow binding of the streptococcal polypeptide to antibody to occur; and
  - b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;wherein the detection of binding indicates the presence or activity of the streptococcal polypeptide in the sample.
45. A method for detecting the presence of a bacterium having a gene encoding a streptococcal polypeptide selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, comprising:
  - a. contacting a sample in which the presence or activity of the bacterium is suspected with an oligonucleotide which hybridizes to a streptococcal polypeptide gene selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, under conditions that allow specific hybridization of the oligonucleotide to the gene to occur; and
  - b. detecting whether hybridization has occurred between the oligonucleotide and the gene;wherein the detection of hybridization indicates that presence or activity of the bacterium in the sample.

46. A method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine of Claim 12 to a subject.
47. A method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of the immunogenic composition of Claim 14 to a subject.
48. A method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition of Claim 16 to a subject.
49. A method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition of Claim 23 to a subject.
50. A method of inducing an immune response in a subject which has been exposed to or infected with a streptococcal bacterium comprising administering to the subject an amount of the pharmaceutical composition of Claim 16, thereby inducing an immune response.
51. A method for preventing infection by a streptococcal bacterium in a subject comprising administering to the subject an amount of a pharmaceutical composition of Claim 23 and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a streptococcal bacterium.
52. An isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:23.
53. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 52.

- 5    54.    The isolated nucleic acid of Claim 53, wherein the nucleic acid is selected from the group consisting of:
- a.    the DNA sequence of SEQ ID NO: 24;
  - b.    DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - 10    c.    DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d.    degenerate variants thereof;
  - e.    alleles thereof; and
  - f.    hybridizable fragments thereof.
- 15    55.    An isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:26.
56.    An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 55.
- 20    57.    The isolated nucleic acid of Claim 56, wherein the nucleic acid is selected from the group consisting of:
- a.    the DNA sequence of SEQ ID NO: 27;
  - b.    DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - 25    c.    DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d.    degenerate variants thereof;
  - e.    alleles thereof; and
  - f.    hybridizable fragments thereof.
- 30    58.    An isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:37.
59.    An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 58.

60. An enterococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:29.
- 35 61. An isolated nucleic acid which encodes the enterococcal polypeptide of Claim 60.
62. The isolated nucleic acid of Claim 61, wherein the nucleic acid is selected from the group consisting of:
- a. the DNA sequence of SEQ ID NO: 30;
  - 40 b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - 45 e. alleles thereof; and
  - f. hybridizable fragments thereof.
63. An isolated *Corynebacterium* Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO: 32.
64. An isolated nucleic acid which encodes the *Corynebacterium* polypeptide of Claim 63.
- 50 65. The isolated nucleic acid of Claim 64, wherein the nucleic acid is selected from the group consisting of:
- a. the DNA sequence of SEQ ID NO: 33;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - 55 c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - 60 f. hybridizable fragments thereof.

66. An isolated bacterial polypeptide comprising the amino acid sequence  
TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), wherein the polypeptide  
is not isolated from *Actinomyces*.
67. An isolated streptococcal polypeptide comprising the amino acid sequence  
TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34).
68. An isolated bacterial polypeptide comprising the amino acid sequence  
TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35).
69. An isolated bacterial polypeptide comprising the amino acid sequence  
TLVTCTPYGVNTKRLVVRG (SEQ ID NO: 36).
70. An isolated streptococcal polypeptide comprising the amino acid sequence  
TLVTCTPYGVNTKRLVVRG (SEQ ID NO: 36).
71. An isolated polypeptide having the amino acid sequence selected from the  
group of  
TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), TLVTCTPYGINTHRLLVTA  
(SEQ ID NO: 35), and TLVTCTPYGVNTKRLVVRG (SEQ ID NO: 36).



**Figure 1. RDP type III-3 specific probes.** Dot blot hybridization of probe DY1-1 with genomic DNA isolated from type III GBS. 10 ug of genomic DNA from each of 62 type III GBS strains was transferred to nylon membrane. Radiolabeled probe 1 hybridized with DNA from all III-3 strains (rows A-D) including the original type III-3 strain (well E-1). The probe failed to hybridize with DNA from III-2 strains (F1- F10, G1-7) including the original strain used in the subtraction hybridization (well E 10) and III-1 strains (wells H1-3; cf. Figure 3). The same pattern of hybridization was observed using probe DY1-11.

## FIGURE 1

**EmaA**

atg acc ctt gtt aaa aat caa gat gct ctt gat aaa gct act gca aat	48
Met Thr Leu Val Lys Asn Gln Asp Ala Leu Asp Lys Ala Thr Ala Asn	
1 5 10 15	
aca gat gat gcg gca ttt ttg gaa att cca gtt gca tca act att aat	96
Thr Asp Asp Ala Ala Phe Leu Glu Ile Pro Val Ala Ser Thr Ile Asn	
20 25 30	
gaa aaa gca gtt tta gga aaa gca att gaa aat act ttt gaa ctt caa	144
Glu Lys Ala Val Leu Gly Lys Ala Ile Glu Asn Thr Phe Glu Leu Gln	
35 40 45	
tat gac cat act cct gat aaa gct gac aat cca aaa cca tct aat cct	192
Tyr Asp His Thr Pro Asp Lys Ala Asp Asn Pro Lys Pro Ser Asn Pro	
50 55 60	
cca aga aaa cca gaa gtt cat act ggt ggg aaa cga ttt gta aag aaa	240
Pro Arg Lys Pro Glu Val His Thr Gly Gly Lys Arg Phe Val Lys Lys	
65 70 75 80	
gac tca aca gaa aca caa aca cta ggt ggt gct gag ttt gat ttg ttg	288
Asp Ser Thr Glu Thr Gln Thr Leu Gly Ala Glu Phe Asp Leu Leu	
85 90 95	
gct tct gat ggg aca gca gta aaa tgg aca gat gct ctt att aaa gcg	336
Ala Ser Asp Gly Thr Ala Val Lys Trp Thr Asp Ala Leu Ile Lys Ala	
100 105 110	
aat act aat aaa aac tat att gct gga gaa gct gtt act ggg caa cca	384
Asn Thr Asn Lys Asn Tyr Ile Ala Gly Glu Ala Val Thr Gly Gln Pro	
115 120 125	
atc aaa ttg aaa tca cat aca gac ggt acg ttt gag att aaa ggt ttg	432
Ile Lys Leu Lys Ser His Thr Asp Gly Thr Phe Glu Ile Lys Gly Leu	
130 135 140	
gct tat gca gtt gat gcg aat gca gag ggt aca gca gta act tac aaa	480
Ala Tyr Ala Val Asp Ala Asn Ala Glu Gly Thr Ala Val Thr Tyr Lys	
145 150 155 160	
tta aaa gaa aca aaa gca cca gaa ggt tat gta atc cct gat aaa gaa	528
Leu Lys Glu Thr Lys Ala Pro Glu Gly Tyr Val Ile Pro Asp Lys Glu	
165 170 175	
atc gag ttt aca gta tca caa aca tct tat aat aca aaa cca act gac	576
Ile Glu Phe Thr Val Ser Gln Thr Ser Tyr Asn Thr Lys Pro Thr Asp	
180 185 190	
atc acg gtt gat agt gct gat gca aca cct gat aca att aaa aac aac	624
Ile Thr Val Asp Ser Ala Asp Ala Thr Pro Asp Thr Ile Lys Asn Asn	
195 200 205	
aaa cgt cct tca atc cct aat act ggt ggt att ggt acg gct atc ttt	672
Lys Arg Pro Ser Ile Pro Asn Thr Gly Gly Ile Gly Thr Ala Ile Phe	
210 215 220	
gtc gct atc ggt gct gcg gtg atg gct ttt gct gtt aag ggg atg aag	720
Val Ala Ile Gly Ala Ala Val Met Ala Phe Ala Val Lys Gly Met Lys	
225 230 235 240	
cgt cgt aca aaa gat aac taa	738
Arg Arg Thr Lys Asp Asn	
245	

**FIGURE 2**

EmaB																	
atg	aaa	caa	aca	tta	aaa	ctt	atg	ttt	tct	ttt	ctg	ttg	atg	tta	ggg		48
Met	Lys	Gln	Thr	Leu	Lys	Leu	Met	Phe	Ser	Phe	Leu	Leu	Met	Leu	Gly		
1				5				10						15			
act	atg	ttt	gga	att	agc	caa	act	gtt	tta	gcg	caa	gaa	act	cat	cag		96
Thr	Met	Phe	Gly	Ile	Ser	Gln	Thr	Val	Leu	Ala	Gln	Glu	Thr	His	Gln		
			20					25						30			
ttg	acg	att	gtt	cat	ctt	gaa	gca	agg	gat	att	gat	cgt	cca	aat	cca		144
Leu	Thr	Ile	Val	His	Leu	Glu	Ala	Arg	Asp	Ile	Asp	Arg	Pro	Asn	Pro		
			35					40						45			
cag	ttg	gag	att	gcc	cct	aaa	gaa	ggg	act	cca	att	gaa	gga	gta	ctc		192
Gln	Leu	Glu	Ile	Ala	Pro	Lys	Glu	Gly	Thr	Pro	Ile	Glu	Gly	Val	Leu		
			50					55						60			
tat	cag	ttg	tac	caa	tta	aaa	tca	act	gaa	gat	ggc	gat	ttg	ttg	gca		240
Tyr	Gln	Leu	Tyr	Gln	Leu	Lys	Ser	Thr	Glu	Asp	Gly	Asp	Leu	Leu	Ala		
								70							80		
cat	tgg	aat	tcc	cta	act	atc	aca	gaa	ttg	aaa	aaa	cag	gcg	cag	cag		288
His	Trp	Asn	Ser	Leu	Thr	Ile	Thr	Glu	Leu	Lys	Lys	Gln	Ala	Gln	Gln		
															95		
gtt	ttt	gaa	gcc	act	act	aat	caa	caa	gga	gag	gct	aca	ttt	aac	caa		336
Val	Phe	Glu	Ala	Thr	Thr	Asn	Gln	Gln	Gly	Lys	Ala	Thr	Phe	Asn	Gln		
															110		
cta	cca	gat	gga	att	tat	tat	ggt	ctg	gcg	gtt	aaa	gcc	ggt	gaa	aaa		384
Leu	Pro	Asp	Gly	Ile	Tyr	Tyr	Gly	Leu	Ala	Val	Lys	Ala	Gly	Glu	Lys		
aat	cgt	aat	gtc	tca	gct	ttc	ttg	gtt	gac	ttg	tct	gag	gat	aaa	gtg		432
Asn	Arg	Asn	Val	Ser	Ala	Phe	Leu	Val	Asp	Leu	Ser	Glu	Asp	Lys	Val		
att	tat	cct	aaa	atc	atc	tgg	tcc	aca	ggt	gag	ttg	gac	ttg	ctt	aaa		480
Ile	Tyr	Pro	Lys	Ile	Ile	Trp	Ser	Thr	Gly	Glu	Leu	Asp	Leu	Leu	Lys		
gtt	ggt	gtg	gat	ggt	gat	acc	aaa	aaa	cca	cta	gca	ggc	gtt	gtc	ttt		528
Val	Gly	Val	Asp	Gly	Asp	Thr	Lys	Lys	Pro	Leu	Ala	Gly	Val	Val	Phe		
gaa	ctt	tat	gaa	aag	aat	ggt	agg	act	cct	att	cgt	gtg	aaa	aat	ggg		576
Glu	Leu	Tyr	Glu	Lys	Asn	Gly	Arg	Thr	Pro	Ile	Arg	Val	Lys	Asn	Gly		
gtg	cat	tct	caa	gat	att	gac	gct	gca	aaa	cat	tta	gaa	aca	gat	tca		624
Val	His	Ser	Gln	Asp	Ile	Asp	Ala	Ala	Lys	His	Leu	Glu	Thr	Asp	Ser		
tca	ggg	cat	atc	aga	att	tcc	ggg	ctc	atc	cat	ggg	gac	tat	gtc	tta		672
Ser	Gly	His	Ile	Arg	Ile	Ser	Gly	Leu	Ile	His	Gly	Asp	Tyr	Val	Leu		
aaa	gaa	atc	gag	aca	cag	tca	gga	tat	cag	atc	gga	cag	gca	gag	act		720
Lys	Glu	Ile	Glu	Thr	Gln	Ser	Gly	Tyr	Gln	Ile	Gly	Gln	Ala	Glu	Thr		
gct	gtg	act	att	gaa	aaa	tca	aaa	aca	gta	aca	gta	acg	att	gaa	aat		768
Ala	Val	Thr	Ile	Glu	Lys	Ser	Lys	Thr	Val	Thr	Val	Thr	Ile	Glu	Asn		
aaa	aaa	gtt	ccg	aca	cct	aaa	gtg	cca	tct	cga	gga	ggt	ctt	att	ccc		816
Lys	Lys	Val	Pro	Thr	Pro	Lys	Val	Pro	Ser	Arg	Gly	Gly	Leu	Ile	Pro		

FIGURE 3A



```
aaa aca ggt gag caa cag gca atg gca ctt gta att att ggt ggt att 864
Lys Thr Gly Glu Gln Gln Ala Met Ala Leu Val Ile Ile Gly Gly Ile
      275                280                285

tta att gct tta gcc tta cga tta cta tca aaa cat cgg aaa cat caa 912
Leu Ile Ala Leu Ala Leu Arg Leu Leu Ser Lys His Arg Lys His Gln
      290                295                300

aat aag gat tag 924
Asn Lys Asp
305
```

**FIGURE 3B**

EmaC																	
atg gga caa aaa tca aaa ata tct cta gct acg aat att cgt ata tgg																	48
Met Gly Gln Lys Ser Lys Ile Ser Leu Ala Thr Asn Ile Arg Ile Trp																	
1 5 10 15																	
att ttt cgt tta att ttc tta gcg ggt ttc ctt gtt ttg gca ttt ccc																	96
Ile Phe Arg Leu Ile Phe Leu Ala Gly Phe Leu Val Leu Ala Phe Pro																	
20 25 30																	
atc gtt agt cag gtc atg tac ttt caa gcc tct cac gcc aat att aat																	144
Ile Val Ser Gln Val Met Tyr Phe Gln Ala Ser His Ala Asn Ile Asn																	
35 40 45																	
gct ttt aaa gaa gct gtt acc aag att gac cgg gtg gag att aat cgg																	192
Ala Phe Lys Lys Glu Ala Val Thr Lys Ile Asp Arg Val Glu Ile Asn Arg																	
50 55 60																	
cgt tta gaa ctt gct tat gct tat aac gcc agt ata gca ggt gcc aaa																	240
Arg Leu Glu Leu Ala Tyr Ala Tyr Asn Ala Ser Ile Ala Gly Ala Lys																	
65 70 75 80																	
act aat ggc gaa tat cca gcg ctt aaa gac ccc tac tct gct gaa caa																	288
Thr Asn Gly Glu Tyr Pro Ala Leu Lys Asp Pro Tyr Ser Ala Glu Gln																	
85 90 95																	
aag cag gca ggg gtc gtt gag tac gcc cgc atg ctt gaa gtc aaa gaa																	336
Lys Gln Ala Gly Val Val Glu Tyr Ala Arg Met Leu Glu Val Lys Glu																	
100 105 110																	
caa ata ggt cat gtg att att cca aga att aat cag gat atc cct att																	384
Gln Ile Gly His Val Ile Ile Pro Arg Ile Asn Gln Asp Ile Pro Ile																	
115 120 125																	
tac gct ggc tct gct gaa gaa aat ctt cag agg ggc gtt gga cat tta																	432
Tyr Ala Gly Ser Ala Glu Glu Asn Leu Gln Arg Gly Val Gly His Leu																	
130 135 140																	
gag ggg acc agt ctt cca gtc ggt ggt gag tca act cat gcc gtt cta																	480
Glu Gly Thr Ser Leu Pro Val Gly Gly Glu Ser Thr His Ala Val Leu																	
145 150 155 160																	
act gcc cat cga ggg cta cca acg gcc aag cta ttt acc aat tta gac																	528
Thr Ala His Arg Gly Leu Pro Thr Ala Lys Leu Phe Thr Asn Leu Asp																	
165 170 175																	
aag gta aca gta ggt gac cgt ttt tac att gaa cac atc ggc gga aag																	576
Lys Val Thr Val Gly Asp Arg Phe Tyr Ile Glu His Ile Gly Gly Lys																	
180 185 190																	
att gct tat cag gta gac caa atc aaa gtt atc gcc cct gat cag tta																	624
Ile Ala Tyr Gln Val Asp Gln Ile Lys Val Ile Ala Pro Asp Gln Leu																	
195 200 205																	
gag gat ttg tac gtg att caa gga gaa gat cac gtc acc cta tta act																	672
Glu Asp Leu Tyr Val Ile Gln Gly Glu Asp His Val Thr Leu Leu Thr																	
210 215 220																	
tcg aca cct tat atg ata aat agt cat cgc ctc ctc gtt cga ggc aag																	720
Cys Thr Pro Tyr Met Ile Asn Ser His Arg Leu Leu Val Arg Gly Lys																	
225 230 235 240																	
cga att cct tat gtg gaa aaa aca gtg cag aaa gat tca aag acc ttc																	768
Arg Ile Pro Tyr Val Glu Lys Thr Val Gln Lys Asp Ser Lys Thr Phe																	
245 250 255																	
agg caa caa caa tac cta acc tat gct atg tgg gta gtc gtt gga ctt																	816
Arg Gln Gln Gln Tyr Leu Thr Tyr Ala Met Trp Val Val Val Gly Leu																	
260 265 270																	
atc ttg ctg tcg ctt ctc att tgg ttt aaa aag acg aaa cag aaa aag																	864
Ile Leu Leu Ser Leu Leu Ile Trp Phe Lys Lys Thr Lys Gln Lys Lys																	
275 280 285																	
cgg aga aag aat gaa aaa gcg gct agt caa aat agt cac aat aat tcg																	912
Arg Arg Lys Asn Glu Lys Ala Ala Ser Gln Asn Ser His Asn Asn Ser																	
290 295 300																	
aaa taa																	918
Lys																	
305																	

FIGURE 4

**EmaD**

atg aaa aag cgg cta gtc aaa ata gtc aca ata att cga aat aat aaa 48  
 Met Lys Lys Arg Leu Val Lys Ile Val Thr Ile Ile Arg Asn Asn Lys  
 1 5 10 15

atc aga acc ctc att ttt gtg atg gga agt ctg att ctc tta ttt ccg 96  
 Ile Arg Thr Leu Ile Phe Val Met Gly Ser Leu Ile Leu Leu Phe Pro  
 20 25 30

att gtg agc cag gta agt tac tac ctt gct tgc cat caa aat att aat 144  
 Ile Val Ser Gln Val Ser Tyr Tyr Leu Ala Ser His Gln Asn Ile Asn  
 35 40 45

caa ttt aag cgg gaa gtc gct aag att gat act aat acg gtt gaa cga 192  
 Gln Phe Lys Arg Glu Val Ala Lys Ile Asp Thr Asn Thr Val Glu Arg  
 50 55 60

cgc atc gct tta gct aat gct tac aat gag acg tta tca agg aat ccc 240  
 Arg Ile Ala Leu Ala Asn Ala Tyr Asn Glu Thr Leu Ser Arg Asn Pro  
 65 70 75 80

ttg ctt ata gac cct ttt acc agt aag caa aaa gaa ggt ttg aga gag 288  
 Leu Leu Ile Asp Pro Phe Thr Ser Lys Gln Lys Glu Gly Leu Arg Glu  
 85 90 95

tat gct cgt atg ctt gaa gtt cat gag caa ata ggt cat gtg gca atc 336  
 Tyr Ala Arg Met Leu Glu Val His Glu Gln Ile Gly His Val Ala Ile  
 100 105 110

cca agt att ggg gtt gat att cca att tat gct gga aca tcc gaa act 384  
 Pro Ser Ile Gly Val Asp Ile Pro Ile Tyr Ala Gly Thr Ser Glu Thr  
 115 120 125

gtg ctt cag aaa ggt agt ggg cat ttg gag gga acc agt ctt cca gtg 432  
 Val Leu Gln Lys Gly Ser Gly His Leu Glu Gly Thr Ser Leu Pro Val  
 130 135 140

gga ggt ttg tca acc cat tca gta cta act gcc cac cgt ggc ttg cca 480  
 Gly Gly Leu Ser Thr His Ser Val Leu Thr Ala His Arg Gly Leu Pro  
 145 150 155 160

aca gct agg cta ttt acc gac tta aat aaa gtt aaa aaa ggc cag att 528  
 Thr Ala Arg Leu Phe Thr Asp Leu Asn Lys Val Lys Lys Gly Gln Ile  
 165 170 175

ttc tat gtg acg aac atc aag gaa aca ctt gcc tac aaa gtc gtg tct 576  
 Phe Tyr Val Thr Asn Ile Lys Glu Thr Leu Ala Tyr Lys Val Val Ser  
 180 185 190

atc aaa gtt gtg gat cca aca gct tta agt gag gtt aag att gtc aat 624  
 Ile Lys Val Val Asp Pro Thr Ala Leu Ser Glu Val Lys Ile Val Asn  
 195 200 205

ggt aag gat tat ata acc ttg ctg act tgc aca cct tac atg atc aat 672  
 Gly Lys Asp Tyr Ile Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn  
 210 215 220

agt cat cgt ctc ttg gta aaa gga gag cgt att cct tat gat tct acc 720  
 Ser His Arg Leu Leu Val Lys Gly Glu Arg Ile Pro Tyr Asp Ser Thr  
 225 230 235 240

gag gcg gaa aag cac aaa gaa caa acc gta caa gat tat cgt ttg tca 768  
 Glu Ala Glu Lys His Lys Glu Gln Thr Val Gln Asp Tyr Arg Leu Ser  
 245 250 255

cta gtg ttg aag ata cta cta gta tta tta att gga ctc ttc atc gtg 816  
 Leu Val Leu Lys Ile Leu Leu Val Leu Leu Ile Gly Leu Phe Ile Val  
 260 265 270

ata atg atg aga aga tgg atg caa cat cgt caa taa 852  
 Ile Met Met Arg Arg Trp Met Gln His Arg Gln

275

280



275	280	285	
att ttt gat ggt act gaa gcg acc gta tca aag gga gtt gcc gat caa Ile Phe Asp Gly Thr Glu Ala Thr Val Ser Lys Gly Val Ala Asp Gln 290 295 300			912
aat ggt aaa gcg ctg aat gat agt gta tca tgg gat tat cat aaa act Asn Gly Lys Ala Leu Asn Asp Ser Val Ser Trp Asp Tyr His Lys Thr 305 310 315 320			960
act ttt aca gca act aca cat aat tac agt tat tta aat tta aca aat Thr Phe Thr Ala Thr Thr His Asn Tyr Ser Tyr Leu Asn Leu Thr Asn 325 330 335			1008
gat gct aac gaa gtt aat att cta aag tca aga att cca aag gaa gcg Asp Ala Asn Glu Val Asn Ile Leu Lys Ser Arg Ile Pro Lys Glu Ala 340 345 350			1056
gag cat ata aat ggg gat cgc acg ctc tat caa ttt ggt gcg aca ttt Glu His Ile Asn Gly Asp Arg Thr Leu Tyr Gln Phe Gly Ala Thr Phe 355 360 365			1104
act caa aaa gct cta atg aaa gca aat gaa att tta gag aca caa agt Thr Gln Lys Ala Leu Met Lys Ala Asn Glu Ile Leu Glu Thr Gln Ser 370 375 380			1152
tct aat gct aga aaa aaa ctt att ttt cac gta act gat ggt gtc cct Ser Asn Ala Arg Lys Lys Leu Ile Phe His Val Thr Asp Gly Val Pro 385 390 395 400			1200
acg atg tct tat gcc ata aat ttt aat cct tat ata tca aca tct tac Thr Met Ser Tyr Ala Ile Asn Phe Asn Pro Tyr Ile Ser Thr Ser Tyr 405 410 415			1248
caa aac cag ttt aat tct ttt tta aat aaa ata cca gat aga agt ggt Gln Asn Gln Phe Asn Ser Phe Leu Asn Lys Ile Pro Asp Arg Ser Gly 420 425 430			1296
att ctc caa gag gat ttt ata atc aat ggt gat gat tat caa ata gta Ile Leu Gln Glu Asp Phe Ile Ile Asn Gly Asp Asp Tyr Gln Ile Val 435 440 445			1344
aaa gga gat gga gag agt ttt aaa ctg ttt tcg gat aga aaa gtt cct Lys Gly Asp Gly Glu Ser Phe Lys Leu Phe Ser Asp Arg Lys Val Pro 450 455 460			1392
gtt act gga gga acg aca caa gca gct tat cga gta ccg caa aat caa Val Thr Gly Gly Thr Thr Gln Ala Ala Tyr Arg Val Pro Gln Asn Gln 465 470 475 480			1440
ctc tct gta atg agt aat gag gga tat gca att aat agt gga tat att Leu Ser Val Met Ser Asn Glu Gly Tyr Ala Ile Asn Ser Gly Tyr Ile 485 490 495			1488
tat ctc tat tgg aga gat tac aac tgg gtc tat cca ttt gat cct aag Tyr Leu Tyr Trp Arg Asp Tyr Asn Trp Val Tyr Pro Phe Asp Pro Lys 500 505 510			1536
aca aag aaa gtt tct gca acg aaa caa atc aaa act cat ggt gag cca Thr Lys Lys Val Ser Ala Thr Lys Gln Ile Lys Thr His Gly Glu Pro 515 520 525			1584
aca aca tta tac ttt aat gga aat ata aga cct aaa ggt tat gac att Thr Thr Leu Tyr Phe Asn Gly Asn Ile Arg Pro Lys Gly Tyr Asp Ile 530 535 540			1632
ttt act gtt ggg att ggt gta aac gga gat cct ggt gca act cct ctt Phe Thr Val Gly Ile Gly Val Asn Gly Asp Pro Gly Ala Thr Pro Leu 545 550 555 560			1680
gaa gct gag aaa ttt atg caa tca ata tca agt aaa aca gaa aat tat			1728

FIGURE 6B

Glu	Ala	Glu	Lys	Phe	Met	Gln	Ser	Ile	Ser	Ser	Lys	Thr	Glu	Asn	Tyr	
				565					570					575		
act	aat	gtt	gat	gat	aca	aat	aaa	att	tat	gat	gag	cta	aat	aaa	tac	1776
Thr	Asn	Val	Asp	Asp	Thr	Asn	Lys	Ile	Tyr	Asp	Glu	Leu	Asn	Lys	Tyr	
			580					585					590			
ttt	aaa	aca	att	gtt	gag	gaa	aaa	cat	tct	att	gtt	gat	gga	aat	gtg	1824
Phe	Lys	Thr	Ile	Val	Glu	Glu	Lys	His	Ser	Ile	Val	Asp	Gly	Asn	Val	
			595				600					605				
act	gat	cct	atg	gga	gag	atg	att	gaa	ttc	caa	tta	aaa	aat	ggg	caa	1872
Thr	Asp	Pro	Met	Gly	Glu	Met	Ile	Glu	Phe	Gln	Leu	Lys	Asn	Gly	Gln	
	610					615					620					
agt	ttt	aca	cat	gat	gat	tac	gtt	ttg	gtt	gga	aat	gat	ggc	agt	caa	1920
Ser	Phe	Thr	His	Asp	Asp	Tyr	Val	Leu	Val	Gly	Asn	Asp	Gly	Ser	Gln	
	625					630				635					640	
tta	aaa	aat	ggg	gtg	gct	ctt	ggg	gga	cca	aac	agt	gat	ggg	gga	att	1968
Leu	Lys	Asn	Gly	Val	Ala	Leu	Gly	Gly	Pro	Asn	Ser	Asp	Gly	Gly	Ile	
				645				650						655		
tta	aaa	gat	gtt	aca	gtg	act	tat	gat	aag	aca	tct	caa	acc	atc	aaa	2016
Leu	Lys	Asp	Val	Thr	Val	Thr	Tyr	Asp	Lys	Thr	Ser	Gln	Thr	Ile	Lys	
			660					665					670			
atc	aat	cat	ttg	aac	tta	gga	agt	gga	caa	aaa	gta	gtt	ctt	acc	tat	2064
Ile	Asn	His	Leu	Asn	Leu	Gly	Ser	Gly	Gln	Lys	Val	Val	Leu	Thr	Tyr	
		675				680						685				
gat	gta	cgt	tta	aaa	gat	aac	tat	ata	agt	aac	aaa	ttt	tac	aat	aca	2112
Asp	Val	Arg	Leu	Lys	Asp	Asn	Tyr	Ile	Ser	Asn	Lys	Phe	Tyr	Asn	Thr	
		690				695					700					
aat	aat	cgt	aca	acg	cta	agt	ccg	aag	agt	gaa	aaa	gaa	cca	aat	act	2160
Asn	Asn	Arg	Thr	Thr	Leu	Ser	Pro	Lys	Ser	Glu	Lys	Glu	Pro	Asn	Thr	
		705			710					715					720	
att	cgt	gat	ttc	cca	att	ccc	aaa	att	cgt	gat	gtt	cgt	gag	ttt	ccg	2208
Ile	Arg	Asp	Phe	Pro	Ile	Pro	Lys	Ile	Arg	Asp	Val	Arg	Glu	Phe	Pro	
			725						730					735		
gta	cta	acc	atc	agt	aat	cag	aag	aaa	atg	ggg	gag	gtt	gaa	ttt	att	2256
Val	Leu	Thr	Ile	Ser	Asn	Gln	Lys	Lys	Met	Gly	Glu	Val	Glu	Phe	Ile	
			740					745					750			
aaa	gtt	aat	aaa	gac	aaa	cat	tca	gaa	tcg	ctt	ttg	gga	gct	aag	ttt	2304
Lys	Val	Asn	Lys	Asp	Lys	His	Ser	Glu	Ser	Leu	Leu	Gly	Ala	Lys	Phe	
		755					760					765				
caa	ctt	cag	ata	gaa	aaa	gat	ttt	tct	ggg	tat	aag	caa	ttt	gtt	cca	2352
Gln	Leu	Gln	Ile	Glu	Lys	Asp	Phe	Ser	Gly	Tyr	Lys	Gln	Phe	Val	Pro	
			770			775					780					
gag	gga	agt	gat	gtt	aca	aca	aag	aat	gat	ggg	aaa	att	tat	ttt	aaa	2400
Glu	Gly	Ser	Asp	Val	Thr	Thr	Lys	Asn	Asp	Gly	Lys	Ile	Tyr	Phe	Lys	
	785				790					795					800	
gca	ctt	caa	gat	ggg	aac	tat	aaa	tta	tat	gaa	att	tca	agt	cca	gat	2448
Ala	Leu	Gln	Asp	Gly	Asn	Tyr	Lys	Leu	Tyr	Glu	Ile	Ser	Ser	Pro	Asp	
				805				810						815		
ggc	tat	ata	gag	gtt	aaa	acg	aaa	cct	gtt	gtg	aca	ttt	aca	att	caa	2496
Gly	Tyr	Ile	Glu	Val	Lys	Thr	Lys	Pro	Val	Val	Thr	Phe	Thr	Ile	Gln	
			820					825					830			
aat	gga	gaa	gtt	acg	aac	ctg	aaa	gca	gat	cca	aat	gct	aat	aaa	aat	2544
Asn	Gly	Glu	Val	Thr	Asn	Leu	Lys	Ala	Asp	Pro	Asn	Ala	Asn	Lys	Asn	
			835				840					845				

FIGURE 6C

caa atc ggg tat ctt gaa gga aat ggt aaa cat ctt att acc aac act	2592
Gln Ile Gly Tyr Leu Glu Gly Asn Gly Lys His Leu Ile Thr Asn Thr	
850 855 860	
ccc aaa cgc cca cca ggt gtt ttt cct aaa aca ggg gga att ggt aca	2640
Pro Lys Arg Pro Pro Gly Val Phe Pro Lys Thr Gly Gly Ile Gly Thr	
865 870 875 880	
att gtc tat ata tta gtt ggt tct act ttt atg ata ctt acc att tgt	2688
Ile Val Tyr Ile Leu Val Gly Ser Thr Phe Met Ile Leu Thr Ile Cys	
885 890 895	
tct ttc cgt cgt aaa caa ttg taa	2712
Ser Phe Arg Arg Lys Gln Leu	
900	

FIGURE 6D

## SEQUENCE LISTING

<110> Adderson, Elisabeth  
Bohnsack, John

<120> GROUP B STREPTOCOCCUS POYPEPTIDES NUCLEIC ACIDS AND  
THERAPEUTIC COMPOSITIONS AND VACCINES THEREOF

<130> 2511-1-001

<140> UNKNOWN

<141> 2000-08-08

<160> 37

<170> PatentIn Ver. 2.0

<210> 1

<211> 737

<212> DNA

<213> Streptococcus agalactiae

<400> 1

atgacccttg ttaaaaatca agatgctctt gataaagcta ctgcaaatac agatgatgcg 60  
gcatttttgg aaattccagt tgcattcaact attaatgaaa aagcagtttt aggaaaagca 120  
attgaaaata cttttgaact tcaatatgac catactcctg ataaagctga caatccaaaa 180  
ccatctaatac ctccaagaaa accagaagtt catactggtg ggaaacgatt tgtaaagaaa 240  
gactcaacag aaacacaaac actaggtggt gctgagtttg atttgttggc ttctgatggg 300  
acagcagtaa aatggacaga tgctcttatt aaagcgaata ctaataaaaa ctatattgct 360  
ggagaagctg ttactgggca accaatcaaa ttgaaatcac atacagacgg tacgtttgag 420  
attaaagggtt tggcttatgc agttgatgcg aatgcagagg gtacagcagt aacttacaaa 480  
ttaaagaaaa caaaagcacc agaagggttat gtaatccctg ataaagaaat cgagtttaca 540  
gtatcacaaa catcttataa tacaaaacca actgacatca cggttgatag tgctgatgca 600  
acacctgata caattaaaaa caacaaacgt ccttcaatcc ctaatactgg tggatttggg 660  
acggctatct ttgtcgctat cggtgctgcg gtgatggctt ttgctgttaa ggggatgaag 720  
cgctgtacaa aagataa 737



&lt;210&gt; 2

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Streptococcus agalactiae

&lt;400&gt; 2

```

Met Thr Leu Val Lys Asn Gln Asp Ala Leu Asp Lys Ala Thr Ala Asn
  1              5              10              15

Thr Asp Asp Ala Ala Phe Leu Glu Ile Pro Val Ala Ser Thr Ile Asn
      20              25              30

Glu Lys Ala Val Leu Gly Lys Ala Ile Glu Asn Thr Phe Glu Leu Gln
      35              40              45

Tyr Asp His Thr Pro Asp Lys Ala Asp Asn Pro Lys Pro Ser Asn Pro
      50              55              60

Pro Arg Lys Pro Glu Val His Thr Gly Gly Lys Arg Phe Val Lys Lys
      65              70              75              80

Asp Ser Thr Glu Thr Gln Thr Leu Gly Gly Ala Glu Phe Asp Leu Leu
      85              90              95

Ala Ser Asp Gly Thr Ala Val Lys Trp Thr Asp Ala Leu Ile Lys Ala
      100             105             110

Asn Thr Asn Lys Asn Tyr Ile Ala Gly Glu Ala Val Thr Gly Gln Pro
      115             120             125

Ile Lys Leu Lys Ser His Thr Asp Gly Thr Phe Glu Ile Lys Gly Leu
      130             135             140

Ala Tyr Ala Val Asp Ala Asn Ala Glu Gly Thr Ala Val Thr Tyr Lys
      145             150             155             160

Leu Lys Glu Thr Lys Ala Pro Glu Gly Tyr Val Ile Pro Asp Lys Glu
      165             170             175

Ile Glu Phe Thr Val Ser Gln Thr Ser Tyr Asn Thr Lys Pro Thr Asp
      180             185             190

Ile Thr Val Asp Ser Ala Asp Ala Thr Pro Asp Thr Ile Lys Asn Asn
      195             200             205

Lys Arg Pro Ser Ile Pro Asn Thr Gly Gly Ile Gly Thr Ala Ile Phe

```

210	215	220
Val Ala Ile Gly Ala Ala Val Met Ala Phe Ala Val Lys Gly Met Lys		
225	230	235 240
Arg Arg Thr Lys Asp		
245		

<210> 3  
 <211> 924  
 <212> DNA  
 <213> Streptococcus agalactiae

<400> 3  
 atgaaacaaa cattaaaact tatgttttct tttctgttga tgttagggac tatgttttga 60  
 attagccaaa ctgttttagc gcaagaaact catcagttga cgattgttca tcttgaagca 120  
 agggatattg atcgtccaaa tccacagttg gagattgccc ctaaagaagg gactccaatt 180  
 gaaggagtac tctatcagtt gtaccaatta aaatcaactg aagatggcga tttgttggca 240  
 cattggaatt ccctaactat cacagaattg aaaaaacagg cgcagcaggt ttttgaagcc 300  
 actactaatc aacaaggaaa ggctacattt aaccaactac cagatggaat ttattatggg 360  
 ctggcgggta aagccgggtga aaaaaatcgt aatgtctcag ctttcttggt tgacttgtct 420  
 gaggataaag tgatttatcc taaaatcatc tgggtccacag gtgagttgga cttgcttaaa 480  
 gttgggtgtg atggtgatac caaaaaacca ctagcaggcg ttgtctttga actttatgaa 540  
 aagaatggta ggactcctat tcgtgtgaaa aatgggggtgc attctcaaga tattgacgct 600  
 gcaaaacatt tagaaacaga ttcattcagg catatcagaa tttccgggct catccatggg 660  
 gactatgtct taaaagaaat cgagacacag tcaggatatc agatcggaca ggcagagact 720  
 gctgtgacta ttgaaaaatc aaaaacagta acagtaacga ttgaaaataa aaaagttccg 780  
 acacctaaag tgccatctcg aggaggtctt attcccaaaa caggtgagca acaggcaatg 840  
 gcacttgtaa ttattggtgg tattttaatt gctttagcct tacgattact atcaaaacat 900  
 cggaacatc aaaataagga ttag 924

&lt;210&gt; 4

&lt;211&gt; 307

&lt;212&gt; PRT

&lt;213&gt; Streptococcus agalactiae

&lt;400&gt; 4

Met Lys Gln Thr Leu Lys Leu Met Phe Ser Phe Leu Leu Met Leu Gly  
 1 5 10 15

Thr Met Phe Gly Ile Ser Gln Thr Val Leu Ala Gln Glu Thr His Gln  
 20 25 30

Leu Thr Ile Val His Leu Glu Ala Arg Asp Ile Asp Arg Pro Asn Pro  
 35 40 45

Gln Leu Glu Ile Ala Pro Lys Glu Gly Thr Pro Ile Glu Gly Val Leu  
 50 55 60

Tyr Gln Leu Tyr Gln Leu Lys Ser Thr Glu Asp Gly Asp Leu Leu Ala  
 65 70 75 80

His Trp Asn Ser Leu Thr Ile Thr Glu Leu Lys Lys Gln Ala Gln Gln  
 85 90 95

Val Phe Glu Ala Thr Thr Asn Gln Gln Gly Lys Ala Thr Phe Asn Gln  
 100 105 110

Leu Pro Asp Gly Ile Tyr Tyr Gly Leu Ala Val Lys Ala Gly Glu Lys  
 115 120 125

Asn Arg Asn Val Ser Ala Phe Leu Val Asp Leu Ser Glu Asp Lys Val  
 130 135 140

Ile Tyr Pro Lys Ile Ile Trp Ser Thr Gly Glu Leu Asp Leu Leu Lys  
 145 150 155 160

Val Gly Val Asp Gly Asp Thr Lys Lys Pro Leu Ala Gly Val Val Phe  
 165 170 175

Glu Leu Tyr Glu Lys Asn Gly Arg Thr Pro Ile Arg Val Lys Asn Gly  
 180 185 190

Val His Ser Gln Asp Ile Asp Ala Ala Lys His Leu Glu Thr Asp Ser  
 195 200 205

Ser Gly His Ile Arg Ile Ser Gly Leu Ile His Gly Asp Tyr Val Leu  
 210 215 220

Lys Glu Ile Glu Thr Gln Ser Gly Tyr Gln Ile Gly Gln Ala Glu Thr  
 225 230 235 240

Ala Val Thr Ile Glu Lys Ser Lys Thr Val Thr Val Thr Ile Glu Asn  
 245 250 255

Lys Lys Val Pro Thr Pro Lys Val Pro Ser Arg Gly Gly Leu Ile Pro  
 260 265 270

Lys Thr Gly Glu Gln Gln Ala Met Ala Leu Val Ile Ile Gly Gly Ile  
 275 280 285

Leu Ile Ala Leu Ala Leu Arg Leu Leu Ser Lys His Arg Lys His Gln  
 290 295 300

Asn Lys Asp  
 305

<210> 5

<211> 918

<212> DNA

<213> Streptococcus agalactiae

<400> 5

atgggacaaa aatcaaaaat atctctagct acgaatatc gtatatggat ttttcgttta 60  
 attttcttag cgggtttcct tgttttggca tttcccatcg ttagtcaggt catgtacttt 120  
 caagcctctc acgccaatat taatgctttt aaagaagctg ttaccaagat tgaccgggtg 180  
 gagattaatc ggcgtttaga acttgcttat gcttataacg ccagtatagc aggtgccaaa 240  
 actaatggcg aatatccagc gcttaaagac cctactctg ctgaacaaaa gcaggcaggg 300  
 gtcgttgagt acgcccgc at gcttgaagtc aaagaacaaa taggtcatgt gattattcca 360  
 agaattaatc aggatatccc tatttacgct ggctctgctg aagaaaatct tcagaggggc 420  
 gttggacatt tagaggggac cagtcttcca gtcggtgggtg agtcaactca tgccgtttcta 480  
 actgcccatac gagggctacc aacggccaag ctatttacca atttagacaa ggtaacagta 540  
 ggtgaccgtt tttacattga acacatcggc ggaaagattg cttatcaggt agaccaaatac 600  
 aaagttatcg cccctgatca gtttagaggat ttgtacgtga ttcaaggaga agatcacgtc 660  
 accctattaa cttgcacacc ttatatgata aatagtcac gcctcctcgt tcgaggcaag 720

cgaattcctt atgtggaaaa aacagtgcag aaagattcaa agaccttcag gcaacaacaa 780  
 tacctaacct atgctatgtg ggtagtcgtt ggacttatct tgctgtcgct tctcatttgg 840  
 tttaaaaaga cgaaacagaa aaagcggaga aagaatgaaa aagcggctag tcaaaatagt 900  
 cacaataatt cgaaataa 918

<210> 6

<211> 305

<212> PRT

<213> Streptococcus agalactiae

<400> 6

Met Gly Gln Lys Ser Lys Ile Ser Leu Ala Thr Asn Ile Arg Ile Trp  
 1 5 10 15

Ile Phe Arg Leu Ile Phe Leu Ala Gly Phe Leu Val Leu Ala Phe Pro  
 20 25 30

Ile Val Ser Gln Val Met Tyr Phe Gln Ala Ser His Ala Asn Ile Asn  
 35 40 45

Ala Phe Lys Glu Ala Val Thr Lys Ile Asp Arg Val Glu Ile Asn Arg  
 50 55 60

Arg Leu Glu Leu Ala Tyr Ala Tyr Asn Ala Ser Ile Ala Gly Ala Lys  
 65 70 75 80

Thr Asn Gly Glu Tyr Pro Ala Leu Lys Asp Pro Tyr Ser Ala Glu Gln  
 85 90 95

Lys Gln Ala Gly Val Val Glu Tyr Ala Arg Met Leu Glu Val Lys Glu  
 100 105 110

Gln Ile Gly His Val Ile Ile Pro Arg Ile Asn Gln Asp Ile Pro Ile  
 115 120 125

Tyr Ala Gly Ser Ala Glu Glu Asn Leu Gln Arg Gly Val Gly His Leu  
 130 135 140

Glu Gly Thr Ser Leu Pro Val Gly Gly Glu Ser Thr His Ala Val Leu  
 145 150 155 160

Thr Ala His Arg Gly Leu Pro Thr Ala Lys Leu Phe Thr Asn Leu Asp  
 165 170 175

Lys Val Thr Val Gly Asp Arg Phe Tyr Ile Glu His Ile Gly Gly Lys  
 180 185 190

Ile Ala Tyr Gln Val Asp Gln Ile Lys Val Ile Ala Pro Asp Gln Leu  
 195 200 205

Glu Asp Leu Tyr Val Ile Gln Gly Glu Asp His Val Thr Leu Leu Thr  
 210 215 220

Cys Thr Pro Tyr Met Ile Asn Ser His Arg Leu Leu Val Arg Gly Lys  
 225 230 235 240

Arg Ile Pro Tyr Val Glu Lys Thr Val Gln Lys Asp Ser Lys Thr Phe  
 245 250 255

Arg Gln Gln Gln Tyr Leu Thr Tyr Ala Met Trp Val Val Val Gly Leu  
 260 265 270

Ile Leu Leu Ser Leu Leu Ile Trp Phe Lys Lys Thr Lys Gln Lys Lys  
 275 280 285

Arg Arg Lys Asn Glu Lys Ala Ala Ser Gln Asn Ser His Asn Asn Ser  
 290 295 300

Lys  
 305

<210> 7  
 <211> 852  
 <212> DNA  
 <213> Streptococcus agalactiae

<400> 7  
 atgaaaaagc ggctagtcaa aatagtcaca ataattcgaa ataataaaat cagaaccctc 60  
 atttttgtga tgggaagtct gattctctta tttccgattg tgagccaggt aagttactac 120  
 cttgettgcg atcaaaatat taatcaattt aagcgggaag tcgctaagat tgataactaat 180  
 acggttgaac gacgcacgcg tttagctaag gcttacaatg agacgttatc aaggaatccc 240  
 ttgcttatag acccttttac cagtaagcaa aaagaagggt tgagagagta tgctcgtatg 300  
 cttgaagttc atgagcaaat aggtcatgtg gcaatcccaa gtattggggg tgatattcca 360  
 atttatgctg gaacatccga aactgtgctt cagaaaggta gtgggcattt ggagggaacc 420

agtcttccag tgggaggttt gtcaacccat tcagtactaa ctgcccaccg tggcttgcca 480  
 acagctaggc tatttaccga cttaaataaa gttaaaaaag gccagatttt ctatgtgacg 540  
 aacatcaagg aaacacttgc ctacaaagtc gtgtctatca aagttgtgga tccaacagct 600  
 ttaagtgagg ttaagattgt caatggtaag gattatataa ccttgctgac ttgcacacct 660  
 tacatgatca atagtcacgc tctcttggtg aaaggagagc gtattcctta tgattctacc 720  
 gaggcggaaa agcacaaaga acaaaccgta caagattatc gtttgtcact agtggtgaag 780  
 atactactag tattattaat tggactcttc atcgtgataa tgatgagaag atggatgcaa 840  
 catcgtcaat aa 852

<210> 8

<211> 283

<212> PRT

<213> Streptococcus agalactiae

<400> 8

Met	Lys	Lys	Arg	Leu	Val	Lys	Ile	Val	Thr	Ile	Ile	Arg	Asn	Asn	Lys
1				5					10					15	
Ile	Arg	Thr	Leu	Ile	Phe	Val	Met	Gly	Ser	Leu	Ile	Leu	Leu	Phe	Pro
			20					25						30	
Ile	Val	Ser	Gln	Val	Ser	Tyr	Tyr	Leu	Ala	Ser	His	Gln	Asn	Ile	Asn
		35					40					45			
Gln	Phe	Lys	Arg	Glu	Val	Ala	Lys	Ile	Asp	Thr	Asn	Thr	Val	Glu	Arg
		50				55					60				
Arg	Ile	Ala	Leu	Ala	Asn	Ala	Tyr	Asn	Glu	Thr	Leu	Ser	Arg	Asn	Pro
	65				70					75				80	
Leu	Leu	Ile	Asp	Pro	Phe	Thr	Ser	Lys	Gln	Lys	Glu	Gly	Leu	Arg	Glu
				85					90					95	
Tyr	Ala	Arg	Met	Leu	Glu	Val	His	Glu	Gln	Ile	Gly	His	Val	Ala	Ile
			100					105					110		
Pro	Ser	Ile	Gly	Val	Asp	Ile	Pro	Ile	Tyr	Ala	Gly	Thr	Ser	Glu	Thr
		115					120					125			

Val Leu Gln Lys Gly Ser Gly His Leu Glu Gly Thr Ser Leu Pro Val  
 130 135 140  
 Gly Gly Leu Ser Thr His Ser Val Leu Thr Ala His Arg Gly Leu Pro  
 145 150 155 160  
 Thr Ala Arg Leu Phe Thr Asp Leu Asn Lys Val Lys Lys Gly Gln Ile  
 165 170 175  
 Phe Tyr Val Thr Asn Ile Lys Glu Thr Leu Ala Tyr Lys Val Val Ser  
 180 185 190  
 Ile Lys Val Val Asp Pro Thr Ala Leu Ser Glu Val Lys Ile Val Asn  
 195 200 205  
 Gly Lys Asp Tyr Ile Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn  
 210 215 220  
 Ser His Arg Leu Leu Val Lys Gly Glu Arg Ile Pro Tyr Asp Ser Thr  
 225 230 235 240  
 Glu Ala Glu Lys His Lys Glu Gln Thr Val Gln Asp Tyr Arg Leu Ser  
 245 250 255  
 Leu Val Leu Lys Ile Leu Leu Val Leu Leu Ile Gly Leu Phe Ile Val  
 260 265 270  
 Ile Met Met Arg Arg Trp Met Gln His Arg Gln  
 275 280

&lt;210&gt; 9

&lt;211&gt; 2712

&lt;212&gt; DNA

&lt;213&gt; Streptococcus agalactiae

&lt;400&gt; 9

atgatgattg tgaataatgg ttatctagaa gggagaaaaa tgaaaaagag acaaaaaata 60  
 tggagagggt tatcagttac ttactaatac ctgtcccaaa ttccatttgg tatattggta 120  
 caagggtgaaa cccaagatac caatcaagca cttggaaaag taattgttaa aaaaacggga 180  
 gacaatgcta caccattagg caaagcgact tttgtgttaa aaaatgacaa tgataagtca 240  
 gaaacaagtc acgaaacggt agagggttct ggagaagcaa ctttgaaaa cataaaacct 300  
 ggagactaca cattaagaga agaaacagca ccaattgggt ataaaaaac tgataaaacc 360



tggaaagtta aagttgcaga taacggagca acaataatcg agggatatgga tgcagataaa 420  
gcagagaaac gaaaagaagt tttgaatgcc caatatccaa aatcagctat ttatgaggat 480  
acaaaagaaa attaccatt agttaatgta gagggttcca aagttggtga acaatacaaa 540  
gcattgaatc caataaatgg aaaagatggt cgaagagaga ttgctgaagg ttggttatca 600  
aaaaaaaata caggggtcaa tgatctcgat aagaataaat ataaaattga attaactggt 660  
gagggtaaaa ccactgttga aacgaaagaa cttaatcaac cactagatgt cgttggtgcta 720  
ttagataatt caaatagtat gaataatgaa agagccaata attctcaaag agcattaaaa 780  
gctggggaag cagttgaaaa gctgattgat aaaattacat caataaaga caatagagta 840  
gctcttgtga catatgcctc aaccattttt gatgggtactg aagcgaccgt atcaaaggga 900  
gttgccgatac aaaatggtaa agcgctgaat gatagtgtat catgggatta tcataaaaact 960  
acttttacag caactacaca taattacagt tatttaaatt taacaaatga tgctaacgaa 1020  
gttaatatc taaagtcaag aattccaaag gaagcggagc atataaatgg ggatcgcacg 1080  
ctctatcaat ttggtgagc atttactcaa aaagctctaa tgaaagcaaa tgaaatttta 1140  
gagacacaaa gttctaagc tagaaaaaaa cttatttttc acgtaactga tgggtgtccct 1200  
acgatgtctt atgccataaa ttttaattcct tatatatcaa catcttacca aaaccagttt 1260  
aattcttttt taaataaaat accagataga agtgggtattc tccaagagga ttttataatc 1320  
aatggtgatg attatcaaat agtaaaagga gatggagaga gttttaaact gttttcggat 1380  
agaaaagttc ctgttactgg aggaacgaca caagcagctt atcgagtacc gcaaaatcaa 1440  
ctctctgtaa tgagtaatga gggatatgca attaatagtg gatatattta tctctattgg 1500  
agagattaca actgggtcta tccatttgat cctaagacaa agaaagtttc tgcaacgaaa 1560  
caaatcaaaa ctcatggtga gccacaaca ttatacttta atggaaatat aagacctaaa 1620  
ggttatgaca tttttactgt tgggattggt gtaaacggag atcctggtgc aactcctctt 1680  
gaagctgaga aatttatgca atcaatatca agtaaacag aaaattatac taatgttgat 1740  
gatacaata aaatttatga tgagctaaat aaatacttta aaacaattgt tgaggaaaaa 1800

cattctattg ttgatggaaa tgtgactgat cctatgggag agatgattga attccaatta 1860  
aaaaatggtc aaagttttac acatgatgat tacgttttgg ttggaaatga tggcagtcaa 1920  
ttaaaaaatg gtgtggctct tgggtggacca aacagtgatg ggggaatttt aaaagatggt 1980  
acagtgactt atgataagac atctcaaacc atcaaatca atcatttgaa cttaggaagt 2040  
ggacaaaaag tagttcttac ctatgatgta cgtttaaaag ataactatat aagtaacaaa 2100  
ttttacaata caaataatcg tacaacgcta agtccgaaga gtgaaaaaga accaaatact 2160  
attcgtgatt tccaattcc caaaattcgt gatgttcgtg agtttccggt actaaccatc 2220  
agtaatcaga agaaaatggg tgagggtgaa ttatttaaag ttaataaaga caaacattca 2280  
gaatcgcttt tgggagctaa gtttcaactt cagatagaaa aagatttttc tgggtataag 2340  
caatttgttc cagaggggaag tgatgttaca acaaagaatg atggtaaaat ttattttaaa 2400  
gcacttcaag atggtaacta taaattatat gaaatttcaa gtccagatgg ctatatagag 2460  
gttaaaacga aacctgttgt gacatttaca attcaaatg gagaagttac gaacctgaaa 2520  
gcagatccaa atgctaataa aaatcaaac cgggtatcttg aaggaaatgg taaacatctt 2580  
attaccaaca ctcccaaacg cccaccaggt gtttttccta aaacaggggg aattggtaca 2640  
attgtctata tattagttgg ttctactttt atgatactta ccatttggtc tttccgtcgt 2700  
aaacaattgt aa 2712

<210> 10

<211> 903

<212> PRT

<213> Streptococcus agalactiae

<400> 10

Met	Met	Ile	Val	Asn	Asn	Gly	Tyr	Leu	Glu	Gly	Arg	Lys	Met	Lys	Lys
1				5					10					15	

Arg	Gln	Lys	Ile	Trp	Arg	Gly	Leu	Ser	Val	Thr	Leu	Leu	Ile	Leu	Ser
			20					25						30	

Gln	Ile	Pro	Phe	Gly	Ile	Leu	Val	Gln	Gly	Glu	Thr	Gln	Asp	Thr	Asn
		35					40						45		

Gln Ala Leu Gly Lys Val Ile Val Lys Lys Thr Gly Asp Asn Ala Thr  
 50 55 60

Pro Leu Gly Lys Ala Thr Phe Val Leu Lys Asn Asp Asn Asp Lys Ser  
 65 70 75 80

Glu Thr Ser His Glu Thr Val Glu Gly Ser Gly Glu Ala Thr Phe Glu  
 85 90 95

Asn Ile Lys Pro Gly Asp Tyr Thr Leu Arg Glu Glu Thr Ala Pro Ile  
 100 105 110

Gly Tyr Lys Lys Thr Asp Lys Thr Trp Lys Val Lys Val Ala Asp Asn  
 115 120 125

Gly Ala Thr Ile Ile Glu Gly Met Asp Ala Asp Lys Ala Glu Lys Arg  
 130 135 140

Lys Glu Val Leu Asn Ala Gln Tyr Pro Lys Ser Ala Ile Tyr Glu Asp  
 145 150 155 160

Thr Lys Glu Asn Tyr Pro Leu Val Asn Val Glu Gly Ser Lys Val Gly  
 165 170 175

Glu Gln Tyr Lys Ala Leu Asn Pro Ile Asn Gly Lys Asp Gly Arg Arg  
 180 185 190

Glu Ile Ala Glu Gly Trp Leu Ser Lys Lys Asn Thr Gly Val Asn Asp  
 195 200 205

Leu Asp Lys Asn Lys Tyr Lys Ile Glu Leu Thr Val Glu Gly Lys Thr  
 210 215 220

Thr Val Glu Thr Lys Glu Leu Asn Gln Pro Leu Asp Val Val Val Leu  
 225 230 235 240

Leu Asp Asn Ser Asn Ser Met Asn Asn Glu Arg Ala Asn Asn Ser Gln  
 245 250 255

Arg Ala Leu Lys Ala Gly Glu Ala Val Glu Lys Leu Ile Asp Lys Ile  
 260 265 270

Thr Ser Asn Lys Asp Asn Arg Val Ala Leu Val Thr Tyr Ala Ser Thr  
 275 280 285

Ile Phe Asp Gly Thr Glu Ala Thr Val Ser Lys Gly Val Ala Asp Gln  
 290 295 300

Asn Gly Lys Ala Leu Asn Asp Ser Val Ser Trp Asp Tyr His Lys Thr  
 305 310 315 320  
 Thr Phe Thr Ala Thr Thr His Asn Tyr Ser Tyr Leu Asn Leu Thr Asn  
 325 330 335  
 Asp Ala Asn Glu Val Asn Ile Leu Lys Ser Arg Ile Pro Lys Glu Ala  
 340 345 350  
 Glu His Ile Asn Gly Asp Arg Thr Leu Tyr Gln Phe Gly Ala Thr Phe  
 355 360 365  
 Thr Gln Lys Ala Leu Met Lys Ala Asn Glu Ile Leu Glu Thr Gln Ser  
 370 375 380  
 Ser Asn Ala Arg Lys Lys Leu Ile Phe His Val Thr Asp Gly Val Pro  
 385 390 395 400  
 Thr Met Ser Tyr Ala Ile Asn Phe Asn Pro Tyr Ile Ser Thr Ser Tyr  
 405 410 415  
 Gln Asn Gln Phe Asn Ser Phe Leu Asn Lys Ile Pro Asp Arg Ser Gly  
 420 425 430  
 Ile Leu Gln Glu Asp Phe Ile Ile Asn Gly Asp Asp Tyr Gln Ile Val  
 435 440 445  
 Lys Gly Asp Gly Glu Ser Phe Lys Leu Phe Ser Asp Arg Lys Val Pro  
 450 455 460  
 Val Thr Gly Gly Thr Thr Gln Ala Ala Tyr Arg Val Pro Gln Asn Gln  
 465 470 475 480  
 Leu Ser Val Met Ser Asn Glu Gly Tyr Ala Ile Asn Ser Gly Tyr Ile  
 485 490 495  
 Tyr Leu Tyr Trp Arg Asp Tyr Asn Trp Val Tyr Pro Phe Asp Pro Lys  
 500 505 510  
 Thr Lys Lys Val Ser Ala Thr Lys Gln Ile Lys Thr His Gly Glu Pro  
 515 520 525  
 Thr Thr Leu Tyr Phe Asn Gly Asn Ile Arg Pro Lys Gly Tyr Asp Ile  
 530 535 540  
 Phe Thr Val Gly Ile Gly Val Asn Gly Asp Pro Gly Ala Thr Pro Leu  
 545 550 555 560

Glu Ala Glu Lys Phe Met Gln Ser Ile Ser Ser Lys Thr Glu Asn Tyr  
 565 570 575  
 Thr Asn Val Asp Asp Thr Asn Lys Ile Tyr Asp Glu Leu Asn Lys Tyr  
 580 585 590  
 Phe Lys Thr Ile Val Glu Glu Lys His Ser Ile Val Asp Gly Asn Val  
 595 600 605  
 Thr Asp Pro Met Gly Glu Met Ile Glu Phe Gln Leu Lys Asn Gly Gln  
 610 615 620  
 Ser Phe Thr His Asp Asp Tyr Val Leu Val Gly Asn Asp Gly Ser Gln  
 625 630 635 640  
 Leu Lys Asn Gly Val Ala Leu Gly Gly Pro Asn Ser Asp Gly Gly Ile  
 645 650 655  
 Leu Lys Asp Val Thr Val Thr Tyr Asp Lys Thr Ser Gln Thr Ile Lys  
 660 665 670  
 Ile Asn His Leu Asn Leu Gly Ser Gly Gln Lys Val Val Leu Thr Tyr  
 675 680 685  
 Asp Val Arg Leu Lys Asp Asn Tyr Ile Ser Asn Lys Phe Tyr Asn Thr  
 690 695 700  
 Asn Asn Arg Thr Thr Leu Ser Pro Lys Ser Glu Lys Glu Pro Asn Thr  
 705 710 715 720  
 Ile Arg Asp Phe Pro Ile Pro Lys Ile Arg Asp Val Arg Glu Phe Pro  
 725 730 735  
 Val Leu Thr Ile Ser Asn Gln Lys Lys Met Gly Glu Val Glu Phe Ile  
 740 745 750  
 Lys Val Asn Lys Asp Lys His Ser Glu Ser Leu Leu Gly Ala Lys Phe  
 755 760 765  
 Gln Leu Gln Ile Glu Lys Asp Phe Ser Gly Tyr Lys Gln Phe Val Pro  
 770 775 780  
 Glu Gly Ser Asp Val Thr Thr Lys Asn Asp Gly Lys Ile Tyr Phe Lys  
 785 790 795 800  
 Ala Leu Gln Asp Gly Asn Tyr Lys Leu Tyr Glu Ile Ser Ser Pro Asp  
 805 810 815

Gly Tyr Ile Glu Val Lys Thr Lys Pro Val Val Thr Phe Thr Ile Gln  
                   820                                  825                                  830

Asn Gly Glu Val Thr Asn Leu Lys Ala Asp Pro Asn Ala Asn Lys Asn  
                   835                                  840                                  845

Gln Ile Gly Tyr Leu Glu Gly Asn Gly Lys His Leu Ile Thr Asn Thr  
                   850                                  855                                  860

Pro Lys Arg Pro Pro Gly Val Phe Pro Lys Thr Gly Gly Ile Gly Thr  
                   865                                  870                                  875                                  880

Ile Val Tyr Ile Leu Val Gly Ser Thr Phe Met Ile Leu Thr Ile Cys  
                                   885                                  890                                  895

Ser Phe Arg Arg Lys Gln Leu  
                   900

<210> 11

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
           oligonucleotide

<400> 11

ctaggtggat ccttcggcaa t

21

<210> 12

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
           oligonucleotide

<400> 12

cgattgccga

10

<210> 13

<211> 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
oligonucleotide

&lt;400&gt; 13

aggcaactgt gctaaccgag ggaat

25

&lt;210&gt; 14

&lt;211&gt; 11

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
oligonucleotide

&lt;400&gt; 14

cgattccctc g

11

&lt;210&gt; 15

&lt;211&gt; 1509

&lt;212&gt; DNA

&lt;213&gt; Streptococcus agalactiae

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1509)

&lt;400&gt; 15

atg	aaa	aag	aaa	atg	att	caa	tcg	ctg	tta	gtg	gcg	agt	tta	gca	ttt	48
Met	Lys	Lys	Lys	Met	Ile	Gln	Ser	Leu	Leu	Val	Ala	Ser	Leu	Ala	Phe	
1				5				10						15		

ggt	atg	gct	gta	tca	cca	gtt	acg	ccg	ata	gct	ttt	gcc	gct	gag	aca	96
Gly	Met	Ala	Val	Ser	Pro	Val	Thr	Pro	Ile	Ala	Phe	Ala	Ala	Glu	Thr	
		20					25					30				

ggg	aca	att	aca	gtt	caa	gat	act	caa	aaa	ggc	gca	acc	tat	aaa	gca	144
Gly	Thr	Ile	Thr	Val	Gln	Asp	Thr	Gln	Lys	Gly	Ala	Thr	Tyr	Lys	Ala	
		35					40					45				

tat	aaa	gtt	ttt	gat	gca	gaa	ata	gat	aat	gca	aat	gta	tct	gat	tcg	192
Tyr	Lys	Val	Phe	Asp	Ala	Glu	Ile	Asp	Asn	Ala	Asn	Val	Ser	Asp	Ser	

50	55	60	
aat aaa gat gga gct tct tat tta att cct caa ggt aaa gaa gct gag			240
Asn Lys Asp Gly Ala Ser Tyr Leu Ile Pro Gln Gly Lys Glu Ala Glu			
65	70	75	80
tat aaa gct tca act gat ttt aat tct ctt ttt acg aca act act aat			288
Tyr Lys Ala Ser Thr Asp Phe Asn Ser Leu Phe Thr Thr Thr Thr Asn			
	85	90	95
gga ggg aga aca tat gta act aaa aaa gat act gcg tca gca aat gag			336
Gly Gly Arg Thr Tyr Val Thr Lys Lys Asp Thr Ala Ser Ala Asn Glu			
	100	105	110
att gcg aca tgg gct aaa tct ata tca gct aat act aca cca gtt tcc			384
Ile Ala Thr Trp Ala Lys Ser Ile Ser Ala Asn Thr Thr Pro Val Ser			
	115	120	125
act gtt act gag tca aat aat gat ggt act gag gtt att aat gtt tcc			432
Thr Val Thr Glu Ser Asn Asn Asp Gly Thr Glu Val Ile Asn Val Ser			
	130	135	140
caa tat gga tat tat tat gtt tct agc act gtt aat aat gga gct gta			480
Gln Tyr Gly Tyr Tyr Tyr Val Ser Ser Thr Val Asn Asn Gly Ala Val			
145	150	155	160
att atg gtt aca tct gta act cca aat gct act att cat gaa aag aat			528
Ile Met Val Thr Ser Val Thr Pro Asn Ala Thr Ile His Glu Lys Asn			
	165	170	175
act gat gcg aca tgg gga gat ggt ggt gga aaa act gta gat caa aaa			576
Thr Asp Ala Thr Trp Gly Asp Gly Gly Gly Lys Thr Val Asp Gln Lys			
	180	185	190
acg tac tcg gtt ggt gat aca gtc aaa tat act att act tat aag aat			624
Thr Tyr Ser Val Gly Asp Thr Val Lys Tyr Thr Ile Thr Tyr Lys Asn			
	195	200	205
gca gtc aat tat cat ggt aca gaa aaa gtg tat caa tat gtt ata aag			672
Ala Val Asn Tyr His Gly Thr Glu Lys Val Tyr Gln Tyr Val Ile Lys			
	210	215	220
gat act atg cca tct gct tct gta gtt gat ttg aac gaa ggg tct tat			720
Asp Thr Met Pro Ser Ala Ser Val Val Asp Leu Asn Glu Gly Ser Tyr			
225	230	235	240
gaa gta act att act gat gga tca ggg aat att aca act cta act caa			768
Glu Val Thr Ile Thr Asp Gly Ser Gly Asn Ile Thr Thr Leu Thr Gln			



245	250	255	
ggt tcg gaa aaa gca act ggg aag tat aac ctg tta gag gaa aat aat			816
Gly Ser Glu Lys Ala Thr Gly Lys Tyr Asn Leu Leu Glu Glu Asn Asn			
260	265	270	
aat ttc acg att act att ccg tgg gca gct acc aat act cca acc gga			864
Asn Phe Thr Ile Thr Ile Pro Trp Ala Ala Thr Asn Thr Pro Thr Gly			
275	280	285	
aat act caa aat gga gct aat gat gac ttt ttt tat aag gga ata aat			912
Asn Thr Gln Asn Gly Ala Asn Asp Asp Phe Phe Tyr Lys Gly Ile Asn			
290	295	300	
aca atc aca gtc act tat aca gga gta tta aag agt gga gct aaa cca			960
Thr Ile Thr Val Thr Tyr Thr Gly Val Leu Lys Ser Gly Ala Lys Pro			
305	310	315	320
ggt tca gct gat tta cca gaa aat aca aac att gcg acc atc aac ccc			1008
Gly Ser Ala Asp Leu Pro Glu Asn Thr Asn Ile Ala Thr Ile Asn Pro			
325	330	335	
aat act agc aat gat gac cca ggt caa aaa gta aca gtg agg gat ggt			1056
Asn Thr Ser Asn Asp Asp Pro Gly Gln Lys Val Thr Val Arg Asp Gly			
340	345	350	
caa att act ata aaa aaa att gat ggt tcc aca aaa gct tca tta caa			1104
Gln Ile Thr Ile Lys Lys Ile Asp Gly Ser Thr Lys Ala Ser Leu Gln			
355	360	365	
ggt gct ata ttt gtt tta aag aat gct acg ggt caa ttt cta aac ttt			1152
Gly Ala Ile Phe Val Leu Lys Asn Ala Thr Gly Gln Phe Leu Asn Phe			
370	375	380	
aac gat aca aat aac gtt gaa tgg ggc aca gaa gct aat gca aca gaa			1200
Asn Asp Thr Asn Asn Val Glu Trp Gly Thr Glu Ala Asn Ala Thr Glu			
385	390	395	400
tat aca aca gga gca gat ggt ata att acc att aca ggc ttg aaa gaa			1248
Tyr Thr Thr Gly Ala Asp Gly Ile Ile Thr Ile Thr Gly Leu Lys Glu			
405	410	415	
ggt aca tac tat cta gtt gag aaa aag gct ccc tta ggt tac aat ttg			1296
Gly Thr Tyr Tyr Leu Val Glu Lys Lys Ala Pro Leu Gly Tyr Asn Leu			
420	425	430	
tta gat aac tct cag aag gtt att tta gga gat gga gcc act gat acg			1344
Leu Asp Asn Ser Gln Lys Val Ile Leu Gly Asp Gly Ala Thr Asp Thr			

435	440	445	
act aat tca gat aac ctt tta gtt aac cca act gtt gaa aat aac aaa			1392
Thr Asn Ser Asp Asn Leu Leu Val Asn Pro Thr Val Glu Asn Asn Lys			
450	455	460	
ggg act gag ttg cct tca aca ggt ggt att ggt aca aca att ttc tac			1440
Gly Thr Glu Leu Pro Ser Thr Gly Gly Ile Gly Thr Thr Ile Phe Tyr			
465	470	475	480
att ata ggt gca att tta gta ata gga gca ggt atc gtg ctt gtt gct			1488
Ile Ile Gly Ala Ile Leu Val Ile Gly Ala Gly Ile Val Leu Val Ala			
485	490	495	
cgt cgt cgt tta cgt tct taa			1509
Arg Arg Arg Leu Arg Ser			
500			

&lt;210&gt; 16

&lt;211&gt; 502

&lt;212&gt; PRT

&lt;213&gt; Streptococcus agalactiae

&lt;400&gt; 16

Met Lys Lys Lys Met Ile Gln Ser Leu Leu Val Ala Ser Leu Ala Phe
1 5 10 15

Gly Met Ala Val Ser Pro Val Thr Pro Ile Ala Phe Ala Ala Glu Thr
20 25 30

Gly Thr Ile Thr Val Gln Asp Thr Gln Lys Gly Ala Thr Tyr Lys Ala
35 40 45

Tyr Lys Val Phe Asp Ala Glu Ile Asp Asn Ala Asn Val Ser Asp Ser
50 55 60

Asn Lys Asp Gly Ala Ser Tyr Leu Ile Pro Gln Gly Lys Glu Ala Glu
65 70 75 80

Tyr Lys Ala Ser Thr Asp Phe Asn Ser Leu Phe Thr Thr Thr Thr Asn
85 90 95

Gly Gly Arg Thr Tyr Val Thr Lys Lys Asp Thr Ala Ser Ala Asn Glu
100 105 110

Ile Ala Thr Trp Ala Lys Ser Ile Ser Ala Asn Thr Thr Pro Val Ser
115 120 125

Thr Val Thr Glu Ser Asn Asn Asp Gly Thr Glu Val Ile Asn Val Ser  
 130 135 140

Gln Tyr Gly Tyr Tyr Tyr Val Ser Ser Thr Val Asn Asn Gly Ala Val  
 145 150 155 160

Ile Met Val Thr Ser Val Thr Pro Asn Ala Thr Ile His Glu Lys Asn  
 165 170 175

Thr Asp Ala Thr Trp Gly Asp Gly Gly Gly Lys Thr Val Asp Gln Lys  
 180 185 190

Thr Tyr Ser Val Gly Asp Thr Val Lys Tyr Thr Ile Thr Tyr Lys Asn  
 195 200 205

Ala Val Asn Tyr His Gly Thr Glu Lys Val Tyr Gln Tyr Val Ile Lys  
 210 215 220

Asp Thr Met Pro Ser Ala Ser Val Val Asp Leu Asn Glu Gly Ser Tyr  
 225 230 235 240

Glu Val Thr Ile Thr Asp Gly Ser Gly Asn Ile Thr Thr Leu Thr Gln  
 245 250 255

Gly Ser Glu Lys Ala Thr Gly Lys Tyr Asn Leu Leu Glu Glu Asn Asn  
 260 265 270

Asn Phe Thr Ile Thr Ile Pro Trp Ala Ala Thr Asn Thr Pro Thr Gly  
 275 280 285

Asn Thr Gln Asn Gly Ala Asn Asp Asp Phe Phe Tyr Lys Gly Ile Asn  
 290 295 300

Thr Ile Thr Val Thr Tyr Thr Gly Val Leu Lys Ser Gly Ala Lys Pro  
 305 310 315 320

Gly Ser Ala Asp Leu Pro Glu Asn Thr Asn Ile Ala Thr Ile Asn Pro  
 325 330 335

Asn Thr Ser Asn Asp Asp Pro Gly Gln Lys Val Thr Val Arg Asp Gly  
 340 345 350

Gln Ile Thr Ile Lys Lys Ile Asp Gly Ser Thr Lys Ala Ser Leu Gln  
 355 360 365

Gly Ala Ile Phe Val Leu Lys Asn Ala Thr Gly Gln Phe Leu Asn Phe  
 370 375 380

Asn Asp Thr Asn Asn Val Glu Trp Gly Thr Glu Ala Asn Ala Thr Glu  
 385 390 395 400  
 Tyr Thr Thr Gly Ala Asp Gly Ile Ile Thr Ile Thr Gly Leu Lys Glu  
 405 410 415  
 Gly Thr Tyr Tyr Leu Val Glu Lys Lys Ala Pro Leu Gly Tyr Asn Leu  
 420 425 430  
 Leu Asp Asn Ser Gln Lys Val Ile Leu Gly Asp Gly Ala Thr Asp Thr  
 435 440 445  
 Thr Asn Ser Asp Asn Leu Leu Val Asn Pro Thr Val Glu Asn Asn Lys  
 450 455 460  
 Gly Thr Glu Leu Pro Ser Thr Gly Gly Ile Gly Thr Thr Ile Phe Tyr  
 465 470 475 480  
 Ile Ile Gly Ala Ile Leu Val Ile Gly Ala Gly Ile Val Leu Val Ala  
 485 490 495  
 Arg Arg Arg Leu Arg Ser  
 500

<210> 17

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: consensus

<220>

<223> X can be any amino acid

<400> 17

Leu Pro Xaa Thr Gly  
 1 5

<210> 18

<211> 1683

<212> DNA

<213> Streptococcus agalactiae

<220>

&lt;221&gt; CDS

&lt;222&gt; (1)..(1683)

&lt;400&gt; 18

```

atg gtg atc gta ttc cgg att ata cag ata tta caa ggg att ata tcc 48
Met Val Ile Val Phe Arg Ile Ile Gln Ile Leu Gln Gly Ile Ile Ser
  1             5             10             15

aag atc ctt cag gta cat att att ata agt atg att cac gag ata aag 96
Lys Ile Leu Gln Val His Ile Ile Ile Ser Met Ile His Glu Ile Lys
          20             25             30

atc ccg act caa cta aag atg cct att ata cga cag ata cta gtc tca 144
Ile Pro Thr Gln Leu Lys Met Pro Ile Ile Arg Gln Ile Leu Val Ser
          35             40             45

tca aat gtt gat aca aca act aag tac aag tac gta aaa gac gct tac 192
Ser Asn Val Asp Thr Thr Thr Lys Tyr Lys Tyr Val Lys Asp Ala Tyr
      50             55             60

aaa tta gtc ggt tgg tat tat gtt aat cca tat ggt agt att aga cct 240
Lys Leu Val Gly Trp Tyr Tyr Val Asn Pro Tyr Gly Ser Ile Arg Pro
      65             70             75             80

tat aac ttt tca ggt gct gta act caa gat atc aat tta aga gct att 288
Tyr Asn Phe Ser Gly Ala Val Thr Gln Asp Ile Asn Leu Arg Ala Ile
          85             90             95

tgg cga aag gct gga gat tat cat att ata tac agc aat gat gct gtt 336
Trp Arg Lys Ala Gly Asp Tyr His Ile Ile Tyr Ser Asn Asp Ala Val
          100             105             110

ggt aca gat gga aag cca gca ttg gat gct tct ggt cag caa tta caa 384
Gly Thr Asp Gly Lys Pro Ala Leu Asp Ala Ser Gly Gln Gln Leu Gln
          115             120             125

aca agt aat gag cct act gac cct gat tcc tat gac gat ggc tcc cat 432
Thr Ser Asn Glu Pro Thr Asp Pro Asp Ser Tyr Asp Asp Gly Ser His
          130             135             140

tca gcc tta ctg aga cgt ccg aca atg cca gat ggc tat cgt ttc cgt 480
Ser Ala Leu Leu Arg Arg Pro Thr Met Pro Asp Gly Tyr Arg Phe Arg
          145             150             155             160

ggc tgg tgg tac aat ggt aaa att tat aac cca tat gat tcc att gat 528
Gly Trp Trp Tyr Asn Gly Lys Ile Tyr Asn Pro Tyr Asp Ser Ile Asp
          165             170             175

```

att gac gcc cat tta gca gat gct aat aaa aat atc acc ata aaa cct 576  
 Ile Asp Ala His Leu Ala Asp Ala Asn Lys Asn Ile Thr Ile Lys Pro  
 180 185 190

gtc att att cca gta gga gat atc aaa tta gaa gat acc tcc atc aaa 624  
 Val Ile Ile Pro Val Gly Asp Ile Lys Leu Glu Asp Thr Ser Ile Lys  
 195 200 205

tac aat ggt aac ggt ggt act aga gta gaa aat ggt aat gtg gta aca 672  
 Tyr Asn Gly Asn Gly Gly Thr Arg Val Glu Asn Gly Asn Val Val Thr  
 210 215 220

caa gtg gag aca ccg cgt atg gag ttg aat agc aca act aca att cct 720  
 Gln Val Glu Thr Pro Arg Met Glu Leu Asn Ser Thr Thr Thr Ile Pro  
 225 230 235 240

gaa aac caa tac ttt aca agg aca ggt tac aac ctt att ggt tgg cat 768  
 Glu Asn Gln Tyr Phe Thr Arg Thr Gly Tyr Asn Leu Ile Gly Trp His  
 245 250 255

cat gat aag gat tta gct gat aca gga cgt gtg gaa ttt aca gca ggt 816  
 His Asp Lys Asp Leu Ala Asp Thr Gly Arg Val Glu Phe Thr Ala Gly  
 260 265 270

caa tca ata ggt att gat aac aac ctt gat gca aca aat acc tta tat 864  
 Gln Ser Ile Gly Ile Asp Asn Asn Leu Asp Ala Thr Asn Thr Leu Tyr  
 275 280 285

gct gtt tgg caa cct aaa gaa tac acc gtc gga gta agt aaa act gtc 912  
 Ala Val Trp Gln Pro Lys Glu Tyr Thr Val Gly Val Ser Lys Thr Val  
 290 295 300

gtt gga cta gat gaa gat aag acg aaa gac ttc ttg ttt aat cca agt 960  
 Val Gly Leu Asp Glu Asp Lys Thr Lys Asp Phe Leu Phe Asn Pro Ser  
 305 310 315 320

gaa acg ttg caa caa gag aat ttt ccg ctg aga gat ggt cag act aag 1008  
 Glu Thr Leu Gln Gln Glu Asn Phe Pro Leu Arg Asp Gly Gln Thr Lys  
 325 330 335

gaa ttt aaa gta cct tat gga act tct ata tca ata gat gaa caa gcc 1056  
 Glu Phe Lys Val Pro Tyr Gly Thr Ser Ile Ser Ile Asp Glu Gln Ala  
 340 345 350

tac gat gaa ttt aaa gta tct gag tca att aca gaa aaa aat cta gca 1104  
 Tyr Asp Glu Phe Lys Val Ser Glu Ser Ile Thr Glu Lys Asn Leu Ala  
 355 360 365

act ggt gaa gct gat aaa act tat gat gct acc ggc tta caa tcc ctg	1152
Thr Gly Glu Ala Asp Lys Thr Tyr Asp Ala Thr Gly Leu Gln Ser Leu	
370 375 380	
aca gtt tca gga gac gta gat att agc ttt acc aat aca cgt atc aag	1200
Thr Val Ser Gly Asp Val Asp Ile Ser Phe Thr Asn Thr Arg Ile Lys	
385 390 395 400	
caa aaa gta cga cta cag aaa gtt aat gtc gaa aat gat aat aat ttt	1248
Gln Lys Val Arg Leu Gln Lys Val Asn Val Glu Asn Asp Asn Asn Phe	
405 410 415	
tta gca ggt gca gtt ttt gat att tat gaa tca gat gct aat ggg aat	1296
Leu Ala Gly Ala Val Phe Asp Ile Tyr Glu Ser Asp Ala Asn Gly Asn	
420 425 430	
aaa gct tca cat cct atg tat tca ggg ctg gtg aca aac gat aaa ggc	1344
Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly	
435 440 445	
ttg tta tta gtg gat gct aat aac tac ctc agt ttg cca gta gga aaa	1392
Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys	
450 455 460	
tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440
Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys	
465 470 475 480	
aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488
Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu	
485 490 495	
caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536
Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly	
500 505 510	
agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584
Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu	
515 520 525	
cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632
Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu	
530 535 540	
gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680
Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile	
545 550 555 560	

tga

1683

&lt;210&gt; 19

&lt;211&gt; 560

&lt;212&gt; PRT

&lt;213&gt; Streptococcus agalactiae

&lt;400&gt; 19

Met Val Ile Val Phe Arg Ile Ile Gln Ile Leu Gln Gly Ile Ile Ser  
1 5 10 15

Lys Ile Leu Gln Val His Ile Ile Ile Ser Met Ile His Glu Ile Lys  
20 25 30

Ile Pro Thr Gln Leu Lys Met Pro Ile Ile Arg Gln Ile Leu Val Ser  
35 40 45

Ser Asn Val Asp Thr Thr Thr Lys Tyr Lys Tyr Val Lys Asp Ala Tyr  
50 55 60

Lys Leu Val Gly Trp Tyr Tyr Val Asn Pro Tyr Gly Ser Ile Arg Pro  
65 70 75 80

Tyr Asn Phe Ser Gly Ala Val Thr Gln Asp Ile Asn Leu Arg Ala Ile  
85 90 95

Trp Arg Lys Ala Gly Asp Tyr His Ile Ile Tyr Ser Asn Asp Ala Val  
100 105 110

Gly Thr Asp Gly Lys Pro Ala Leu Asp Ala Ser Gly Gln Gln Leu Gln  
115 120 125

Thr Ser Asn Glu Pro Thr Asp Pro Asp Ser Tyr Asp Asp Gly Ser His  
130 135 140

Ser Ala Leu Leu Arg Arg Pro Thr Met Pro Asp Gly Tyr Arg Phe Arg  
145 150 155 160

Gly Trp Trp Tyr Asn Gly Lys Ile Tyr Asn Pro Tyr Asp Ser Ile Asp  
165 170 175

Ile Asp Ala His Leu Ala Asp Ala Asn Lys Asn Ile Thr Ile Lys Pro  
180 185 190

Val Ile Ile Pro Val Gly Asp Ile Lys Leu Glu Asp Thr Ser Ile Lys  
195 200 205



Tyr Asn Gly Asn Gly Gly Thr Arg Val Glu Asn Gly Asn Val Val Thr  
 210 215 220  
 Gln Val Glu Thr Pro Arg Met Glu Leu Asn Ser Thr Thr Thr Ile Pro  
 225 230 235 240  
 Glu Asn Gln Tyr Phe Thr Arg Thr Gly Tyr Asn Leu Ile Gly Trp His  
 245 250 255  
 His Asp Lys Asp Leu Ala Asp Thr Gly Arg Val Glu Phe Thr Ala Gly  
 260 265 270  
 Gln Ser Ile Gly Ile Asp Asn Asn Leu Asp Ala Thr Asn Thr Leu Tyr  
 275 280 285  
 Ala Val Trp Gln Pro Lys Glu Tyr Thr Val Gly Val Ser Lys Thr Val  
 290 295 300  
 Val Gly Leu Asp Glu Asp Lys Thr Lys Asp Phe Leu Phe Asn Pro Ser  
 305 310 315 320  
 Glu Thr Leu Gln Gln Glu Asn Phe Pro Leu Arg Asp Gly Gln Thr Lys  
 325 330 335  
 Glu Phe Lys Val Pro Tyr Gly Thr Ser Ile Ser Ile Asp Glu Gln Ala  
 340 345 350  
 Tyr Asp Glu Phe Lys Val Ser Glu Ser Ile Thr Glu Lys Asn Leu Ala  
 355 360 365  
 Thr Gly Glu Ala Asp Lys Thr Tyr Asp Ala Thr Gly Leu Gln Ser Leu  
 370 375 380  
 Thr Val Ser Gly Asp Val Asp Ile Ser Phe Thr Asn Thr Arg Ile Lys  
 385 390 395 400  
 Gln Lys Val Arg Leu Gln Lys Val Asn Val Glu Asn Asp Asn Asn Phe  
 405 410 415  
 Leu Ala Gly Ala Val Phe Asp Ile Tyr Glu Ser Asp Ala Asn Gly Asn  
 420 425 430  
 Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly  
 435 440 445  
 Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys  
 450 455 460

Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys  
 465 470 475 480

Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu  
 485 490 495

Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly  
 500 505 510

Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu  
 515 520 525

Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu  
 530 535 540

Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile  
 545 550 555 560

<210> 20

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: consensus

<400> 20

Leu Pro Ser Thr Gly Gly  
 1 5

<210> 21

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: consensus

<220>

<223> X can be any amino acid.

<400> 21

Xaa Pro Xaa Thr Gly Gly  
 1 5

&lt;210&gt; 22

&lt;211&gt; 2714

&lt;212&gt; DNA

<213> *Streptococcus pneumoniae*

&lt;400&gt; 22

caatcagaaa ttaccacgtg gcaatgttga ctttatgaag gtggatggtc ggaccaatac 60  
ctctcttcaa ggggcaatgt tcaaagtcac gaaagaagaa agcggacact atactcctgt 120  
tcttcaaaat ggtaaggaag tagttgtaac atcagggaaa gatggtcgtt tccgagtggg 180  
aggtctagag tatgggacat actatztatg ggagctccaa gctccaactg gttatgttca 240  
attaacatcg cctgtttcct ttacaatcgg gaaagatact cgtaaggaac tggtaacagt 300  
ggttaaaaat aacaagcgac cacggattga tgtgccagat acaggggaag aaaccttgta 360  
tatcttgatg cttgttgcca tttgttggt tggtagtggg tattatctta cgaaaaa'cc 420  
aaataactga tattcaatgt acatcattat gaaaaagata gcaggctgaa gggaagacca 480  
gagtactctg aggtgatgtt aatcaggaat catggtgatg tggcatgaat cacaataacg 540  
gatatgaggc tgggcagatt gtgccagcct cattgtgggt tattgtttgt aaaacgatag 600  
gactggtctg gtaatcattt taggaatgga caggactggg attctgattt aaaatggatg 660  
gtgaatcaga aagaaatgag attttctcgt ttctcttagc agataggatt gtctgttagg 720  
aaaagcgata aaatgatgag tttgaagata aagggatgct gataaaaatg gtaaaaacaa 780  
aaaagcaaaa acgaaataat ctctattag gagtggatt tttcattgga atggcggtaa 840  
tggcgtatcc gctggtgtct cgcttgatt atcgagtga atcaaatcaa caaattgctg 900  
actttgataa ggaaaaagca acgttgatg aggctgacat tgatgaacga atgaaattgg 960  
cacaagcctt caatgactct ttgaataatg tagtgagtgg cgatccttgg tcggaagaaa 1020  
tgaagaaaaa agggcgagca gagtatgcac gtatgttaga aatccatgag cggatggggc 1080  
atgtggaaat ccccgttatt gacgtggatt tgccggttta tgctgggtact gctgaagagg 1140  
tattgcagca aggggctggg catctagagg gaacttctct gccgatcgga ggcaattcga 1200  
cccatgcggt gattacggca catacaggtt tgccaacagc taagatgttt acggatttga 1260

ccaaaacttaa agttggggat aagttttatg tgcacaatat caaggaagtg atggcctatc 1320  
aagtggatca agtaaaggtg attgagccga cgaactttga tgatttattg attgtaccag 1380  
gtcatgatta tgtgaccttg ctgacttgta cgccatacat gatcaatacc catcgtctat 1440  
tggttcgggg gcatcgata ccgtacgtag cagagggtga ggaagaattt attgcagcaa 1500  
acaaaactcag tcatctctat cgctacctgt tttatgtggc agttggtttg attgtgattc 1560  
ttttatggat tattcgacgc ttgcgcaaga agaaaaaaca accggaaaag gctttgaagg 1620  
cgctgaaagc agcaaggaag gaagtgaagg tggaggatgg acaacagtag acgttcacga 1680  
aaaaaaggca caaaaaagaa gaaacatccg ctgacccctc ttctgatttt cttagtagga 1740  
ttcgccgttg cgatatatcc attggtgtct cgttattatt atcgtattga gtcaaacgag 1800  
gttattaaag agtttgatga gacggtttcc cagatggata aggcagaact tgaggagcgt 1860  
tggcgcttgg ctcaagcctt caatgcgacc ttgaaacat ctgaaattct tgatcccttt 1920  
acagagcaag agaaaaagaa aggcgtctca gaatatgcca atatgctaaa ggtccatgag 1980  
cggattggct atgtggaaat tctgcgatt gatcaggaaa ttccgatgta tgcggaacg 2040  
agtgaggaca ttcttcagaa aggggcaggg ctgttagaag gggcttcgct gcctgttgga 2100  
ggtgaaaata ccatacagt gatcactgct cacagaggat tgccaacggc agaattgttc 2160  
agtcaattgg ataagatgaa aaaaggggat atcttttatc ttcacgtttt agatcaggtg 2220  
ttggcctacc aagtggatca gatagtgaag gtggagccga atgactttga gcctgtcttg 2280  
attcaacatg gggaagatta tgcgacottg ttgacttgta caccgtatat gattaacagt 2340  
catcgtctgt tggtagctgg gaagcggatt ccgtatacgg caccaattgc agagcggaa 2400  
cgagcggatga gagagcgtgg gcaattctgg ttgtggttat tactaggagc gatggcggtc 2460  
atccttctct tgctgtatcg cgtgtatcgt aatcgacgga ttgtcaaagg actagaaaag 2520  
caattggagg ggcgtcatgt caaggactaa actacgagcc ttattgggat acttggtgat 2580  
gttggttagcc tgtttgattc ctatttattg ttttgacag atggtgttgc agtctcttgg 2640  
acagggtgaaa ggtcatgcta catttgtgaa atccatgaca actgaaatgt accaagaaca 2700

acagaaccat tctc

2714

&lt;210&gt; 23

&lt;211&gt; 297

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 23

Met	Asp	Asn	Ser	Arg	Arg	Ser	Arg	Lys	Lys	Gly	Thr	Lys	Lys	Lys	Lys
1				5				10					15		

His	Pro	Leu	Ile	Leu	Leu	Leu	Ile	Phe	Leu	Val	Gly	Phe	Ala	Val	Ala
			20					25					30		

Ile	Tyr	Pro	Leu	Val	Ser	Arg	Tyr	Tyr	Tyr	Arg	Ile	Glu	Ser	Asn	Glu
		35					40					45			

Val	Ile	Lys	Glu	Phe	Asp	Glu	Thr	Val	Ser	Gln	Met	Asp	Lys	Ala	Glu
	50					55					60				

Leu	Glu	Glu	Arg	Trp	Arg	Leu	Ala	Gln	Ala	Phe	Asn	Ala	Thr	Leu	Lys
65					70					75					80

Pro	Ser	Glu	Ile	Leu	Asp	Pro	Phe	Thr	Glu	Gln	Glu	Lys	Lys	Lys	Gly
				85					90					95	

Val	Ser	Glu	Tyr	Ala	Asn	Met	Leu	Lys	Val	His	Glu	Arg	Ile	Gly	Tyr
			100					105						110	

Val	Glu	Ile	Pro	Ala	Ile	Asp	Gln	Glu	Ile	Pro	Met	Tyr	Val	Gly	Thr
		115					120					125			

Ser	Glu	Asp	Ile	Leu	Gln	Lys	Gly	Ala	Gly	Leu	Leu	Glu	Gly	Ala	Ser
	130					135					140				

Leu	Pro	Val	Gly	Gly	Glu	Asn	Thr	His	Thr	Val	Ile	Thr	Ala	His	Arg
145					150					155					160

Gly	Leu	Pro	Thr	Ala	Glu	Leu	Phe	Ser	Gln	Leu	Asp	Lys	Met	Lys	Lys
				165					170					175	

Gly	Asp	Ile	Phe	Tyr	Leu	His	Val	Leu	Asp	Gln	Val	Leu	Ala	Tyr	Gln
			180						185					190	

Val	Asp	Gln	Ile	Val	Thr	Val	Glu	Pro	Asn	Asp	Phe	Glu	Pro	Val	Leu
		195					200					205			

Ile Gln His Gly Glu Asp Tyr Ala Thr Leu Leu Thr Cys Thr Pro Tyr  
 210 215 220

Met Ile Asn Ser His Arg Leu Leu Val Arg Gly Lys Arg Ile Pro Tyr  
 225 230 235 240

Thr Ala Pro Ile Ala Glu Arg Asn Arg Ala Val Arg Glu Arg Gly Gln  
 245 250 255

Phe Trp Leu Trp Leu Leu Leu Gly Ala Met Ala Val Ile Leu Leu Leu  
 260 265 270

Leu Tyr Arg Val Tyr Arg Asn Arg Arg Ile Val Lys Gly Leu Glu Lys  
 275 280 285

Gln Leu Glu Gly Arg His Val Lys Asp  
 290 295

<210> 24

<211> 894

<212> DNA

<213> Streptococcus pneumoniae

<400> 24

atggacaaca gtagacgttc acgaaaaaaaa ggcacaaaaa agaagaaaca tccgctgata 60  
 cttcttctga ttttcttagt aggattcgcc gttgcgatat atccattggt gtctcggttat 120  
 tattatcgta ttgagtcaaa cgaggttatt aaagagtttg atgagacggt ttcccagatg 180  
 gataaggcag aacttgagga gcgttggcgc ttggctcaag ccttcaatgc gaccttgaaa 240  
 ccatctgaaa ttcttgatcc ttttacagag caagagaaaa agaaaggcgt ctcagaatat 300  
 gccaatatgc taaaggcca tgagcggatt ggctatgtgg aaattcctgc gattgatcag 360  
 gaaattccga tgtatgtcgg aacgagttag gacattcttc agaaaggggc agggctgtta 420  
 gaaggggctt cgctgcctgt tggaggtgaa aatacccata cagtgatcac tgctcacaga 480  
 ggattgccaa cggcagaatt gttcagtcaa ttggataaga tgaaaaaagg ggatatcttt 540  
 tatcttcacg ttttagatca ggtgttggcc taccaagtgg atcagatagt gacggtggag 600  
 ccgaatgact ttgagcctgt cttgattcaa catggggaag attatgcgac cttgttgact 660

tgtacaccgt atatgattaa cagtcacgt ctgttggtac gtgggaagcg gattccgtat 720  
 acggcaccaa ttgcagagcg gaatcgagcg gtgagagagc gtgggcaatt ctggttgtgg 780  
 ttattactag gagcgatggc ggtcatcctt ctcttgctgt atcgogtgta tcgtaatcga 840  
 cggattgtca aaggactaga aaagcaattg gaggggcgtc atgtcaagga ctaa 894

<210> 25

<211> 3010

<212> DNA

<213> Streptococcus pneumoniae

<400> 25

tgtaggaaa agcgataaaa tgatgagttt gaagataaag ggatgctgat aaaaatggta 60  
 aaaacaaaa agcaaaaacg aaataatctc ctattaggag tggatatttt cattggaatg 120  
 gcgtaaatgg cgtatccgct ggtgtctcgc ttgtattatc gagtggaaac aaatcaadaa 180  
 attgctgact ttgataagga aaaagcaacg ttggatgagg ctgacattga tgaacgaatg 240  
 aaattggcac aagccttcaa tgactctttg aataatgtag tgagtggcga tccttggctg 300  
 gaagaaatga agaaaaaagg gcgagcagag tatgcacgta tgtagaaat ccatgagcgg 360  
 atggggcatg tggaaatccc cgttattgac gtggatttgc cggtttatgc tggtagtct 420  
 gaagaggtat tgcagcaagg ggctgggcat ctagaggga cttctctgcc gatcggaggc 480  
 aattcgaccc atgcggtgat tacggcacat acaggtttgc caacagctaa gatgtttacg 540  
 gatttgacca aacttaaagt tggggataag ttttatgtgc acaatatcaa ggaagtgatg 600  
 gcctatcaag tggatcaagt aaaggtgatt gagccgacga actttgatga tttattgatt 660  
 gtaccaggtc atgattatgt gaccttgctg acttgtagc catacatgat caatacccat 720  
 cgtctattgg ttcgggggca tcggataccg tacgtagcag aggttgagga agaatttatt 780  
 gcagcaaaca aactcagtca tctctatcgc tacctgtttt atgtggcagt tggtttgatt 840  
 gtgattcttt tatggattat tcgacgcttg cgcaagaaga aaaaacaacc ggaaaaggct 900  
 ttgaaggcgc tgaaagcagc aaggaaggaa gtgaaggtgg aggatggaca acagtagacg 960  
 ttcacgaaaa aaaggcacia aaaagaagaa acatccgctg atccttcttc tgattttctt 1020

agtaggattc gccgttgcca tatatccatt ggtgtctcgt tattattatc gtattgagtc 1080  
aaacgaggtt attaaagagt ttgatgagac ggtttcccag atggataagg cagaacttga 1140  
ggagcgttgg cgcttggttc aagccttcaa tgcgaccttg aaaccatctg aaattcttga 1200  
tcctttttaca gagcaagaga aaaagaaagg cgtctcagaa tatgccaata tgctaaagggt 1260  
ccatgagcgg attggctatg tggaaattcc tgcgattgat caggaaattc cgatgtatgt 1320  
cggaacgagt gaggacattc ttcagaaagg ggcagggctg ttagaagggg cttcgctgcc 1380  
tgttggaggt gaaaataccc atacagtgat cactgctcac agaggattgc caacggcaga 1440  
attgttcagt caattggata agatgaaaaa aggggatatc ttttatcttc acgtttttaga 1500  
tcaggtgttg gcctaccaag tggatcagat agtgacggtg gagccgaatg actttgagcc 1560  
tgtcttgatt caacatgggg aagattatgc gaccttgttg acttgtagac cgtatatgat 1620  
taacagtcatt cgtctgttgg tacgtgggaa gcggattccg tatacggcac caattgcaga 1680  
gcggaatcga gcggtgagag agcgtgggca attctggttg tggttattac taggagcgat 1740  
ggcggtcatt cttctcttgc tgtatcgcgt gtatcgtaat cgacggattg tcaaaggact 1800  
agaaaagcaa ttggaggggc gtcattgtcaa ggactaaact acgagcctta ttgggatact 1860  
tgttgatgtt ggtagcctgt ttgattccta tttattgttt tggacagatg gtgttgagtc 1920  
ctcttggaaca ggtgaaagggt catgctacat ttgtgaaatc catgacaact gaaatgtacc 1980  
aagaacaaca gaaccattct ctgcctaca atcaacgctt ggcttcgcaa aatcgcatgt 2040  
tagatccttt tttggcggag ggatatgagg tcaattacca agtgtctgac gaccctgatg 2100  
cagtctatgg ttacttgtct attccaagtt tggaaatcat ggagccggtt tatttgggag 2160  
cagattatca tcatttaggg atgggcttgg ctcatgtgga tggtagaccg ctgcctctgg 2220  
atggtacagg gattcgctca gtgattgctg ggcaccgtgc agagccaagc catgtctttt 2280  
tccgccattt ggatcagcta aaagttggag atgctcttta ttatgataat ggccaggaaa 2340  
ttgtagaata tcagatgatg gacacagaga ttattttacc gtcggaatgg gaaaaattag 2400  
aatcggttag ctctaaaaat atcatgacct tgataacctg cgatccgatt cctaccttta 2460



ataaacgctt attagtgaat tttgaacgag tcgctgttta tcaaaaatca gatccacaaa 2520  
 cagctgcagt tgcgagggtt gcttttacga aagaaggaca atctgtatcg cgtgttgcaa 2580  
 cctctcaatg gttgtaccgt gggctagtgg tactggcatt tctgggaatc ctgtttgttt 2640  
 tgtggaagct agcacgttta ctacgaggga aataaaaaga aatgaaagga aagctaaggc 2700  
 tgttcctttt tccggctctt tgtcaactgt agtgggttga aaaaaagcta agctcgagaa 2760  
 aggacaaatt ttgtcctttc ttttttgata ttcagagcga taaaaatccg ttttttgaag 2820  
 ttttcaaagt ttcgaaaacc aaaggcattg cgcttgataa gtttgatgag attattggtc 2880  
 gcttccagtt tggcattaga atagtgtagt tgaagggcgt tgataacctt ttctttatct 2940  
 ttgaggaagg ttttaaagac agtctgaaaa ataggatgaa cctgcttaag attgtcctcg 3000  
 ataagttcga 3010

<210> 26

<211> 304

<212> PRT

<213> Streptococcus pneumoniae

<400> 26

Met	Leu	Ile	Lys	Met	Val	Lys	Thr	Lys	Lys	Gln	Lys	Arg	Asn	Asn	Leu
1				5					10					15	

Leu	Leu	Gly	Val	Val	Phe	Phe	Ile	Gly	Met	Ala	Val	Met	Ala	Tyr	Pro
			20					25					30		

Leu	Val	Ser	Arg	Leu	Tyr	Tyr	Arg	Val	Glu	Ser	Asn	Gln	Gln	Ile	Ala
		35					40					45			

Asp	Phe	Asp	Lys	Glu	Lys	Ala	Thr	Leu	Asp	Glu	Ala	Asp	Ile	Asp	Glu
	50					55					60				

Arg	Met	Lys	Leu	Ala	Gln	Ala	Phe	Asn	Asp	Ser	Leu	Asn	Asn	Val	Val
65					70					75				80	

Ser	Gly	Asp	Pro	Trp	Ser	Glu	Glu	Met	Lys	Lys	Lys	Gly	Arg	Ala	Glu
			85						90				95		

Tyr	Ala	Arg	Met	Leu	Glu	Ile	His	Glu	Arg	Met	Gly	His	Val	Glu	Ile
			100					105					110		

Pro Val Ile Asp Val Asp Leu Pro Val Tyr Ala Gly Thr Ala Glu Glu  
 115 120 125  
 Val Leu Gln Gln Gly Ala Gly His Leu Glu Gly Thr Ser Leu Pro Ile  
 130 135 140  
 Gly Gly Asn Ser Thr His Ala Val Ile Thr Ala His Thr Gly Leu Pro  
 145 150 155 160  
 Thr Ala Lys Met Phe Thr Asp Leu Thr Lys Leu Lys Val Gly Asp Lys  
 165 170 175  
 Phe Tyr Val His Asn Ile Lys Glu Val Met Ala Tyr Gln Val Asp Gln  
 180 185 190  
 Val Lys Val Ile Glu Pro Thr Asn Phe Asp Asp Leu Leu Ile Val Pro  
 195 200 205  
 Gly His Asp Tyr Val Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn  
 210 215 220  
 Thr His Arg Leu Leu Val Arg Gly His Arg Ile Pro Tyr Val Ala Glu  
 225 230 235 240  
 Val Glu Glu Glu Phe Ile Ala Ala Asn Lys Leu Ser His Leu Tyr Arg  
 245 250 255  
 Tyr Leu Phe Tyr Val Ala Val Gly Leu Ile Val Ile Leu Leu Trp Ile  
 260 265 270  
 Ile Arg Arg Leu Arg Lys Lys Lys Lys Gln Pro Glu Lys Ala Leu Lys  
 275 280 285  
 Ala Leu Lys Ala Ala Arg Lys Glu Val Lys Val Glu Asp Gly Gln Gln  
 290 295 300

&lt;210&gt; 27

&lt;211&gt; 915

&lt;212&gt; DNA

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 27

atgctgataa aaatggtaaa aacaaaaaag caaaaacgaa ataatctcct attaggagtg 60

gtatTTTTca ttggaatggc ggtaatggcg tatccgctgg tgtctcgctt gtattatcga 120  
 gtggaatcaa atcaacaaat tgctgacttt gataaggaaa aagcaacgtt ggatgaggct 180  
 gacattgatg aacgaatgaa attggcacia gccttcaatg actctttgaa taatgtagtg 240  
 agtggcgatc cttggtcgga agaaatgaag aaaaaagggc gagcagagta tgcacgtatg 300  
 ttagaaatcc atgagcggat ggggcatgtg gaaatccccg ttattgacgt ggatttgccg 360  
 gtttatgctg gtactgctga agaggtattg cagcaagggg ctgggcatct agagggaact 420  
 tctctgccga tcggaggcaa ttcgacccat gcggtgatta cggcacatac aggtttgcca 480  
 acagctaaga tgtttacgga ttgaccaaaa cttaaagttg gggataagtt ttatgtgcac 540  
 aatatcaagg aagtgatggc ctatcaagtg gatcaagtaa aggtgattga gccgacgaac 600  
 tttgatgatt tattgattgt accaggtcat gattatgtga ccttgctgac ttgtacgcea 660  
 tacatgatca atacccatcg tctattgggt cgggggcacg ggataccgta cgtagcagag 720  
 gttgaggaag aattttattgc agcaaacaaa ctcaatcacc tctatcgcta cctgttttat 780  
 gtggcagttg gtttgattgt gattctttta tggattatc gacgcttgcg caagaagaaa 840  
 aaacaaccgg aaaaggcttt gaaggcgctg aaagcagcaa ggaaggaagt gaaggtggag 900  
 gatggacaac agtag 915

<210> 28

<211> 2199

<212> DNA

<213> *Enterococcus faecalis*

<400> 28

actaaaattc gtttacttta tgcatttaaa tgaaaaagca gacacctaga aaggcttta 60  
 aatgagggcg aatgttgata acggtcctac cgacgaccaa acaccaccaa ctgttgaa 120  
 tgtgacaggt gggaaacgtt tcattaaagt cgatggcgat gtgacagcga cacaagcctt 180  
 ggcgggagct tcctttgtcg tccgtgatca aaacagcgac acagcaaatt atttgaaaat 240  
 cgatgaaaca acgaaagcag caacttgggt gaaaacaaaa gctgaagcaa ctacttttac 300

aacaacggct gatggattag ttgatatcac agggcttaaa tacggtacct attatttaga 360  
agaaactgta gctcctgatg attatgtctt gttaacaaat cggattgaat ttgtgggtcaa 420  
tgaacaatca tatggcacia cagaaaacct agtttcacca gaaaaagtac caaacaaca 480  
caaagggtacc ttaccttcaa cagggtggcaa aggaatctac gtttacttag gaagtggcgc 540  
agtcttgcta cttattgcag gagtctactt tgctagacgt agaaaagaaa atgcttaatt 600  
tctagcatca ccgaagaaat ttttagaaaa acaaagagcc tgggccaatc actgtcccag 660  
gctctcatgc tttattttta aggaggaagc aatgaagtca aaaaagaaac gtcgtatcat 720  
tgatgggttt atgattcttt taotgattat tggaataggt gcatttgctg atccttttgt 780  
tagcgatgca ttaaataact atctggatca acaaattatc gtcattatc aagcaaaagc 840  
aagccaagaa aacaccaaag aaatggctga acttcaagaa aaaatggaaa agaaaaacca 900  
agaattagcg aaaaaaggca gcaatcctgg attagatcct ttttctgaaa cgcaaaaaac 960  
aacgaaaaaa ccagacaaat cctattttga aagtcatacg attggtgttt taaccattcc 1020  
aaaaataaat gtccgtttac caatttttga taaaacgaat gcattgctat tggaaaaagg 1080  
aagctccttg ttagaaggaa cctcctatcc tacagggtgg acgaatacac atgcggtcat 1140  
ttcaggccat cgtggctctc ctcaagccaa attatttaca gatttgccag aattaaaaaa 1200  
aggcgatgaa ttttatatcg aagtcaatgg gaagacgctt gcttatcaag tagatcaaat 1260  
aaaaacggtt gaaccaactg atacaaaaga tttacacatt gagtctggcc aagatctcgt 1320  
cactttatta acttgacac cgtatatgat aaacagtcac cggttattag ttcgaggaca 1380  
tcgtatccca tatcaaccag aaaaagcagc agcgggggatg aaaaagtgg cacaacaaca 1440  
aaatttacta ttatggacat tacttttaat tgctgtgctg ttaattatta gcggcttcat 1500  
tatctggtac aagcgacgga aaaagacgac cagaaaacca aagtagtatg acgaaaaggc 1560  
taaacatact aaaaaaaaga gtaaaaaaat agcttttcaa tttttaatcc tccttatcgt 1620  
gcataattga accagagaaa cagaagtatt aacgaaataa ctaaaagagc aagccctgaa 1680  
taaaaagcga caaagggcca atcaatcgac tgtttaaat cctgccaagt ttggattttt 1740

ctgttttttt tcgcgctatc ctcaagcgtg agtaaataat tcaatagtaa gaggagtagc 1800  
 aacaccgtga aatcatttgt ggtaaaaagc acatgtaaaa atagaatgac aaagacaaca 1860  
 cgggataaca ctcgattccg caaaattaaa aataacttag cacgcataat aaaccacccat 1920  
 ttcttatcag agataatgaa tctgtttttg tctactcttt agttatatca taaaattctt 1980  
 aataatgaaa aaatgactcg agaaaataat tgaaaaaagt tttttttcct gaatcattat 2040  
 tttcgtaaat aaagaataaa cgtgttactc ttggcttatac aaatttggaa ggagtgttaa 2100  
 aaatgaaata tctggatatt attgcttttaa ttttattgat tgtcggagggt ttaaactggt 2160  
 tattagttgg tgcatttaat tttgatttag ttgcaacaa 2199

<210> 29

<211> 284

<212> PRT

<213> Enterococcus faecalis

<400> 29

Met Lys Ser Lys Lys Lys Arg Arg Ile Ile Asp Gly Phe Met Ile Leu  
 1 5 10 15

Leu Leu Ile Ile Gly Ile Gly Ala Phe Ala Tyr Pro Phe Val Ser Asp  
 20 25 30

Ala Leu Asn Asn Tyr Leu Asp Gln Gln Ile Ile Ala His Tyr Gln Ala  
 35 40 45

Lys Ala Ser Gln Glu Asn Thr Lys Glu Met Ala Glu Leu Gln Glu Lys  
 50 55 60

Met Glu Lys Lys Asn Gln Glu Leu Ala Lys Lys Gly Ser Asn Pro Gly  
 65 70 75 80

Leu Asp Pro Phe Ser Glu Thr Gln Lys Thr Thr Lys Lys Pro Asp Lys  
 85 90 95

Ser Tyr Phe Glu Ser His Thr Ile Gly Val Leu Thr Ile Pro Lys Ile  
 100 105 110

Asn Val Arg Leu Pro Ile Phe Asp Lys Thr Asn Ala Leu Leu Leu Glu  
 115 120 125

Lys Gly Ser Ser Leu Leu Glu Gly Thr Ser Tyr Pro Thr Gly Gly Thr

130	135	140
Asn Thr His Ala Val Ile Ser Gly His Arg Gly Leu Pro Gln Ala Lys		
145	150	155 160
Leu Phe Thr Asp Leu Pro Glu Leu Lys Lys Gly Asp Glu Phe Tyr Ile		
	165	170 175
Glu Val Asn Gly Lys Thr Leu Ala Tyr Gln Val Asp Gln Ile Lys Thr		
	180	185 190
Val Glu Pro Thr Asp Thr Lys Asp Leu His Ile Glu Ser Gly Gln Asp		
	195	200 205
Leu Val Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn Ser His Arg		
	210	215 220
Leu Leu Val Arg Gly His Arg Ile Pro Tyr Gln Pro Glu Lys Ala Ala		
	225	230 235 240
Ala Gly Met Lys Lys Val Ala Gln Gln Gln Asn Leu Leu Leu Trp Thr		
	245	250 255
Leu Leu Leu Ile Ala Cys Ala Leu Ile Ile Ser Gly Phe Ile Ile Trp		
	260	265 270
Tyr Lys Arg Arg Lys Lys Thr Thr Arg Lys Pro Lys		
	275	280

&lt;210&gt; 30

&lt;211&gt; 855

&lt;212&gt; DNA

&lt;213&gt; Enterococcus faecalis

&lt;400&gt; 30

atgaagtcaa aaaagaaacg tcgtatcatt gatgggtttta tgattctttt actgattatt 60

ggaataggtg catttgcgta tccttttgtt agcgatgcat taaataacta tctggatcaa 120

caaattatcg ct cattatca agcaaaagca agccaagaaa acaccaaaga aatggctgaa 180

cttcaagaaa aaatggaaaa gaaaaaccaa gaattagcga aaaaaggcag caatcctgga 240

ttagatcctt tttctgaaac gcaaaaaaca acgaaaaaac cagacaaatc ctattttgaa 300

agtcatacga ttggtgtttt aaccattcca aaaataaatg tccgtttacc aatttttgat 360

aaaacgaatg cattgctatt ggaaaaagga agtccttgt tagaaggaac ctcctatcct 420  
 acaggtggta cgaatacaca tgcggtcatt tcaggccatc gtggtctccc tcaagccaaa 480  
 ttattttacag atttgccaga attaaaaaaa ggcatgaat ttatatcga agtcaatggg 540  
 aagacgcttg cttatcaagt agatcaaata aaaaccgttg aaccaactga taaaaagat 600  
 ttacacattg agtctggcca agatctcgtc actttattaa cttgcacacc gtatatgata 660  
 aacagtcatc ggttattagt tcgaggacat cgtatcccat atcaaccaga aaaagcagca 720  
 gcggggatga aaaaagtggc acaacaaca aatttactat tatggacatt acttttaatt 780  
 gcctgtgcgt taattattag cggcttcatt atctggtaca agcgacggaa aaagacgacc 840  
 agaaaaccaaa agtag 855

<210> 31

<211> 2687

<212> DNA

<213> *Corynebacterium diphtheriae*

<400> 31

gtggtccgga gtatgacaag aacgctccgg ttcaggtaaa cggcactggg aacggtaacg 60  
 atctcgtggg cacctctgac aagaacggca acgtccactt cgagggcctg ttcgtctccg 120  
 acgaccagaa tgatccggga aagtcagctg cgcagcgtg ctacgtctc gtcgagaccg 180  
 aggcccgac gggcttcgtt actccgaaag atgggacggg cttcccagtt gctgtaaaga 240  
 ttggacagac tgctaccact acctacgacg caaaggtcga gaacgtcaag cgcgataccc 300  
 ctgacctgcc gctgaccggg ggcaagggtg tgctgttcct gatgattgcc ggtggtctgt 360  
 tgctgctggg tgctgttggg gctggtttcg tctttgtacg ccgtatcaac gagtaattga 420  
 tttgtcgcgt gattaaataa tcgcgttgcg ccgccaatg cagggcatca aatgccccgc 480  
 cggcgggcat aaacgcgggc ggggtgcggg ggctttccac cgcaccccca cattctttgt 540  
 cagagatttg ctgtttggcc tgtgccaccc ggcaccccc tatatgagaa acggacgtac 600  
 ctgtcatggg taccacgcg tcaccgcgct ctaccggacc ggataacca gacgcgcaac 660  
 caaagcgtcg ttgggtcttt tccggactcg cattgtttgc gtgtataacg gcgctagccg 720

gcctcatggt ggggttgat ccatctactg cagcgtggtt taacgcccgc gaacaggcca 780  
aactggtaga tctctatgat tccaaaattg aaaatgcaac ccctcttagc gcggaacaat 840  
tacttgaact cgcgcaccgt tataacgacc gcctgaccgt aggcgctgct ctcgatccct 900  
gggctaacgt cccccgcgga gcgggcaaag aagacggcga cggtatggcc tataaagacc 960  
agttgcgtgt tgaccgtacg gatgtcatgg ctcgatatac tatccctct atcaaggtagg 1020  
atctaccgat ctatcacggc acgagcgata acactctaaa gaagggcgct ggccatttgg 1080  
aaggtaacct gttaccgggt ggaggaccac gcacccattc cgttatcaact gcacaccgtg 1140  
gcttagctga ggccaccatg ttcactaatc tcaacaaggt tggggtaggg gatagattca 1200  
ccattgaggt gatggggcga gtccttacgt atgaagtgcg tgaaactcgt gtggtcagcc 1260  
cagaggacac taggttcctg caaactcaag acgatcgtga ccttgtcaca ctcgttactt 1320  
gtactccgtt gggcatcaat acacatcgca ttctggtgac agctgagcgc attactccca 1380  
ccccgcaatc cgatatcgat gcagcacgtc aagcttccca aatcggcttc ccttgggtggg 1440  
cggtcatttt cgcagtggga tttagcttta tcgccttggt cttctggcgt tcgggttaca 1500  
tgattcctcc aaagaagaag gaagaagaca tcgaaagcga agctgatggc gatgaactct 1560  
gaaacggcgg ggaaggaacc caacgtggtc agtaccgacg ctaaactc caccggtacc 1620  
agttccaatg cgggtaccgg tgagagctca gcgaaaaaga aagcgcagac ggcaattgct 1680  
gcgatagtca tgcttttgtg cggactgtta gggctggtga ttctgttcta tccagtcgtg 1740  
tccactcaac ttaacaatta tgaacagtct aaactcgccc gacagtttgg tgcagacgct 1800  
goccaaagctg accctgccgt agttgctgct gctcttgatg ctgcccatgc ctacaacgat 1860  
tcgctagaaa atggaccct gcaggatccg tggaccgggt gagatagcac taaggatcct 1920  
gcctatcagg catacgagaa actcttaggg gaatatccgg cgatggctca gatctctatc 1980  
ccggtatatt ccgtgaacct tcccatttac cacgggacaa gcgacgccac actcctcaaa 2040  
gggtgttgggc acctttacgg tactgcgcta cccgttgggt gactggggac gcgttcggtt 2100  
ctaacagcgc attcaggtat ccaaaaatcg accttctttg acaatttaga aaaggtcaaa 2160



aagggtgacg ccatttatgt acgcaatatt ggtgagaccc tgaaatacca agtacgacgac 2220  
atcgaaatca tccgtccagc ggagattgac cgtatccagc caatcccaga ccgagactta 2280  
attaccctcg tgacctgtac accctatgga atcaataccc ataggctttt ggttactgcc 2340  
gaacgtgtcc ctatggaacc cggtagggcg gaccgtgcat ttgccggtga cgggaattgtc 2400  
tggcagtggg ggatgaagct agctatcggg gtgttggtgg tcatccttct cctaactggg 2460  
tggctcatta tccgtatttt gcgagctagg aaattcgca agaaaacagc tggagcagac 2520  
gctgctaaat ctgttgaacc tggatgatatt gaggcgtcgc taagcgcttc agcggccgag 2580  
gagtcccagt aatatgcaga aaccaatttc cccaacacat gcaaacaccc aagcagtcgc 2640  
ccattcctga aaggacgccc tactatgaag aagactcact tgttccg 2687

<210> 32

<211> 348

<212> PRT

<213> *Corynebacterium diphtheriae*

<400> 32

Met	Ala	Met	Asn	Ser	Glu	Thr	Ala	Gly	Lys	Glu	Pro	Asn	Val	Val	Ser
1				5					10					15	

Thr	Asp	Ala	Lys	His	Ser	Thr	Gly	Thr	Ser	Ser	Asn	Ala	Gly	Thr	Gly
			20					25					30		

Glu	Ser	Ser	Ala	Lys	Lys	Lys	Ala	Gln	Thr	Ala	Ile	Ala	Ala	Ile	Val
			35				40					45			

Met	Leu	Leu	Cys	Gly	Leu	Leu	Gly	Leu	Val	Ile	Leu	Phe	Tyr	Pro	Val
	50					55					60				

Val	Ser	Thr	Gln	Leu	Asn	Asn	Tyr	Glu	Gln	Ser	Lys	Leu	Ala	Arg	Gln
65					70					75				80	

Phe	Gly	Ala	Asp	Ala	Ala	Gln	Ala	Asp	Pro	Ala	Val	Val	Ala	Ala	Ala
				85					90					95	

Leu	Asp	Ala	Ala	His	Ala	Tyr	Asn	Asp	Ser	Leu	Glu	Asn	Gly	Pro	Leu
		100						105					110		

Gln	Asp	Pro	Trp	Thr	Gly	Gly	Asp	Ser	Thr	Lys	Asp	Pro	Ala	Tyr	Gln
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

115					120					125					
Ala	Tyr	Glu	Lys	Leu	Leu	Gly	Glu	Tyr	Pro	Ala	Met	Ala	Gln	Ile	Ser
130					135					140					
Ile	Pro	Ala	Ile	Ser	Val	Asn	Leu	Pro	Ile	Tyr	His	Gly	Thr	Ser	Asp
145					150					155					160
Ala	Thr	Leu	Leu	Lys	Gly	Val	Gly	His	Leu	Tyr	Gly	Thr	Ala	Leu	Pro
					165					170					175
Val	Gly	Gly	Leu	Gly	Thr	Arg	Ser	Val	Leu	Thr	Ala	His	Ser	Gly	Ile
					180					185					190
Gln	Lys	Ser	Thr	Phe	Phe	Asp	Asn	Leu	Glu	Lys	Val	Lys	Lys	Gly	Asp
195					200					205					
Ala	Ile	Tyr	Val	Arg	Asn	Ile	Gly	Glu	Thr	Leu	Lys	Tyr	Gln	Val	Arg
210					215					220					
Asp	Ile	Glu	Ile	Ile	Arg	Pro	Ala	Glu	Ile	Asp	Arg	Ile	Gln	Pro	Ile
225					230					235					240
Pro	Asp	Arg	Asp	Leu	Ile	Thr	Leu	Val	Thr	Cys	Thr	Pro	Tyr	Gly	Ile
					245					250					255
Asn	Thr	His	Arg	Leu	Leu	Val	Thr	Ala	Glu	Arg	Val	Pro	Met	Glu	Pro
					260					265					270
Gly	Glu	Ala	Asp	Arg	Ala	Phe	Ala	Gly	Asp	Gly	Ile	Val	Trp	Gln	Trp
275					280					285					
Trp	Met	Lys	Leu	Ala	Ile	Gly	Val	Leu	Val	Val	Ile	Leu	Leu	Leu	Thr
290					295					300					
Gly	Trp	Leu	Ile	Ile	Arg	Ile	Leu	Arg	Ala	Arg	Lys	Phe	Ala	Lys	Lys
305					310					315					320
Thr	Ala	Gly	Ala	Asp	Ala	Ala	Lys	Ser	Val	Glu	Pro	Gly	Asp	Ile	Glu
					325					330					335
Ala	Ser	Leu	Ser	Ala	Ser	Ala	Ala	Glu	Glu	Ser	Gln				
340					345										

&lt;210&gt; 33

&lt;211&gt; 1047

&lt;212&gt; DNA

<213> *Corynebacterium diphtheriae*

<400> 33

atggcgatga actctgaaac ggcggggaag gaaccaacg tggtcagtac cgacgctaaa 60  
cactccaccg gtaccagttc caatgcgggt accggtgaga gctcagcgaa aaagaaagcg 120  
cagacggcaa ttgctgcgat agtcatgctt ttgtgcggac tgtagggct ggtgattctg 180  
ttctatccag tcgtgtccac tcaacttaac aattatgaac agtctaaact cgcccgacag 240  
tttggtgcag acgctgccc aagctgacct gccgtagttg ctgctgctct tgatgctgcc 300  
catgcctaca acgattcgct agaaaatgga cccctgcagg atccgtggac cgggtggagat 360  
agcactaagg atcctgccta tcaggcatac gagaaactct taggggaata tccggcgatg 420  
gctcagatct ctatcccggc tatttcogtg aaccttccca ttaccacgg gacaagcgac 480  
gccacactcc tcaaaggtgt tgggcacctt tacggtactg cgctaccctg tgggtggactg 540  
gggacgcgtt cggttctaac agcgcattoa ggtatccaaa aatcgacctt ctttgacaat 600  
ttagaaaagg tcaaaaaggg tgacgccatt tatgtacgca atattggtga gaccctgaaa 660  
taccaagtac gcgacatcga aatcatccgt ccagcggaga ttgaccgtat ccagccaatc 720  
ccagaccgag acttaattac cctcgtgacc tgtacaccct atggaatcaa taccatagg 780  
cttttggtta ctgccgaacg tgtccctatg gaaccgggtg aggcggaccg tgcatttgcc 840  
ggtgacggaa ttgtctggca gtggtggatg aagctagcta tcggtgtgtt ggtggtcatc 900  
cttctcctaa ctgggtggct cattatccgt attttgcgag ctaggaaatt cgcaagaaa 960  
acagctggag cagacgtgc taaatctgtt gaacctggtg atattgaggc gtcgctaagc 1020  
gcttcagcgg ccgaggagtc ccagtaa 1047

<210> 34

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Consensus/*Streptococcus pyogenes*

&lt;220&gt;

&lt;223&gt; X in position 12 can either be a S/T.

&lt;220&gt;

&lt;223&gt; X in position 18 can either be a R/K.

&lt;400&gt; 34

Thr	Leu	Leu	Thr	Cys	Thr	Pro	Tyr	Met	Ile	Asn	Xaa	His	Arg	Leu	Leu
1				5					10					15	

Val Xaa Gly

&lt;210&gt; 35

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Corynebacterium diphtheriae

&lt;400&gt; 35

Thr	Leu	Val	Thr	Cys	Thr	Pro	Tyr	Gly	Ile	Asn	Thr	His	Arg	Leu	Leu
1				5					10					15	

Val Thr Ala

&lt;210&gt; 36

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pyogenes

&lt;400&gt; 36

Thr	Leu	Val	Thr	Cys	Thr	Pro	Tyr	Gly	Val	Asn	Thr	Lys	Arg	Leu	Leu
1				5					10					15	

Val Arg Gly

&lt;210&gt; 37

&lt;211&gt; 150

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pyogenes

&lt;400&gt; 37

Ile Glu Asn Asn Asp Ile Met Gly Tyr Val Glu Val Pro Ser Ile Lys

1	5	10	15
Val Thr Leu Pro Ile Tyr His Tyr Thr Thr Asp Glu Val Leu Thr Lys	20	25	30
Gly Ala Gly His Leu Phe Gly Ser Ala Leu Pro Val Gly Gly Asp Gly	35	40	45
Thr His Thr Val Ile Ser Ala His Arg Gly Leu Pro Ser Ala Glu Met	50	55	60
Phe Thr Asn Leu Asn Leu Val Lys Lys Gly Asp Thr Phe Tyr Phe Arg	65	70	75
Val Leu Asn Lys Val Leu Ala Tyr Lys Val Asp Gln Ile Leu Thr Val	85	90	95
Glu Pro Asp Gln Val Thr Ser Leu Ser Gly Val Met Gly Lys Asp Tyr	100	105	110
Ala Thr Leu Val Thr Cys Thr Pro Tyr Gly Val Asn Thr Lys Arg Leu	115	120	125
Leu Val Arg Gly His Arg Ile Ala Tyr His Tyr Lys Lys Tyr Gln Gln	130	135	140
Ala Lys Lys Ala Met Lys	145	150	

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
**WO 02/012294 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/315**,  
A61K 39/09, C07K 16/12, C12N 5/12, A61K 39/40,  
C12N 15/12, 15/63, A61K 48/00, C12Q 1/68, G01N  
33/53, C07K 14/34

TN 38120 (US). **BOHNSACK, John** [US/US]; 760 South  
1200 East, Salt Lake City, UT 84102 (US).

(21) International Application Number: PCT/US01/24795

(74) Agent: **LICATA, Jane, Massey**; Licata & Tyrrell P.C., 66  
E. Main Street, Marlton, NJ 08053 (US).

(22) International Filing Date: 8 August 2001 (08.08.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/634,341 8 August 2000 (08.08.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/634,341 (CON)  
Filed on 8 August 2000 (08.08.2000)

(71) Applicants (*for all designated States except US*): **ST.  
JUDE CHILDREN'S RESEARCH HOSPITAL**  
[US/US]; 332 North Lauderdale Street, Memphis, TN  
38105-2794 (US). **UNIVERSITY OF UTAH RE-  
SEARCH FOUNDATION** [US/US]; 615 Arapen Drive,  
Suite 10, Salt Lake City, UT 84108 (US).

Published:  
— with international search report

(88) Date of publication of the international search report:  
10 April 2003

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ADDERSON,  
Elisabeth** [CA/US]; 1041 Murray Hill Lane S., Memphis,

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: GROUP B STREPTOCOCCUS POLYPEPTIDES NUCLEIC ACIDS AND THERAPEUTIC COMPOSITIONS AND VACCINES THEREOF

(57) Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including *S. pneumoniae*, *S. pyogenes*, *E. faecalis* and *C. diphtheriae* are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.



WO 02/012294 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/24795

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/315 A61K39/09 C07K16/12 C12N5/12 A61K39/40  
 C12N15/12 C12N15/63 A61K48/00 C12Q1/68 G01N33/53  
 C07K14/34

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K C12N C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RICARDO MANGANELLI ET AL.:            "Characterization of emb, a gene encoding the major adhesin of Streptococcus defectivus"            INFECTION AND IMMUNITY,            vol. 67, no. 1, January 1999 (1999-01),            pages 50-56, XP002211581            abstract            page 50, left-hand column, paragraph 3            -right-hand column, paragraph 2            page 51, right-hand column, paragraph 4 -            paragraph 6            page 52, left-hand column, paragraph 3            -page 56, left-hand column, paragraph 3            ---            -/--</p>	1,11-25, 35-51

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 "&" document member of the same patent family

Date of the actual completion of the international search

29 August 2002

Date of mailing of the international search report

09. 12. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/24795

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SPELLERBERG B ET AL: "LMB, A PROTEIN WITH SIMILARITIES TO THE LRAI ADHESIN FAMILY, MEDIATES ATTACHMENT OF STREPTOCOCCUS AGALACTIAE TO HUMAN LAMININ" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 2, February 1999 (1999-02), pages 871-878, XP000973065 ISSN: 0019-9567 abstract page 871, left-hand column, paragraph 1 -right-hand column, paragraph 3 page 874, left-hand column, paragraph 2 -right-hand column, paragraph 1 page 875, right-hand column, paragraph 2 page 876, left-hand column, paragraph 2 -page 877, right-hand column, paragraph 3 ---</p>	1,11-25, 35-51
X	<p>VERED OZERI ET AL.: "A two-domain mechanism for group A streptococcal adherence through protein F to the extracellular matrix" THE EMBO JOURNAL, vol. 15, no. 5, 1996, pages 989-998, XP002211582 abstract page 993, left-hand column, paragraph 3 -right-hand column, paragraph 2 page 996, right-hand column, paragraph 3 -page 997, left-hand column, paragraph 1 ---</p>	1,11-25, 35-51
A	<p>PATTI J M ET AL: "MSCRAMM-MEDIATED ADHERENCE OF MICROORGANISMS TO HOST TISSUES" ANNUAL REVIEW OF MICROBIOLOGY, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 48, 1994, pages 585-617, XP001037269 ISSN: 0066-4227 the whole document ---</p>	1,2, 11-26, 35-51
A	<p>WO 00 12132 A (TRINITY COLLEGE DUBLIN ;TEXAS A &amp; M UNIVERSITY SYST (US); INHIBITE) 9 March 2000 (2000-03-09) page 2, line 25 -page 3, line 13 page 9, line 19 -page 10, line 4 page 13, line 28 -page 14, line 20 page 19, line 3 -page 21, line 3 page 23, line 21 -page 39, line 19 page 40, line 7 -page 41, line 15 page 48, line 6 -page 59, line 28 --- -/--</p>	1,2, 11-26, 35-51



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/24795

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>RICH R L ET AL: "ACE IS A COLLAGEN-BINDING MSCRAMM FROM ENTEROCOCCUS FAECALIS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 38, 17 September 1999 (1999-09-17), pages 26939-26945, XP002930358 ISSN: 0021-9258 the whole document</p> <p>---</p>	1,2, 11-26, 35-51
A	<p>WO 98 38312 A (UNIV WASHINGTON) 3 September 1998 (1998-09-03)  the whole document</p> <p>---</p>	1,2, 11-26, 35-51
A	<p>PATTI J M ET AL: "CRITICAL RESIDUES IN THE LIGAND-BINDING SITE OF THE STAPHYLOCOCCUS AUREUS COLLAGEN-BINDING ADHESIN (MSCRAMM)" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12005-12011, XP002044191 ISSN: 0021-9258 the whole document</p> <p>-----</p>	1,2, 11-26, 35-51

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/24795

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 46-51 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
1, 2, 25, 26 and partially 11-24, 35-51

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 2, 25, 26 and patially 11-24, 35-51

Streptococcal polypeptide EmaA comprising SEQ ID NO:2, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:1 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

2. Claims: 3, 4, 27, 28 and partially 11-24, 35-51

Streptococcal polypeptide EmaB comprising SEQ ID NO:4, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:3 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

3. Claims: 5, 6, 29, 30 and partially 11-24, 35-51

Streptococcal polypeptide EmaC comprising SEQ ID NO:6, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:5 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

4. Claims: 7, 8, 31, 32 and partially 11-24, 35-51

Streptococcal polypeptide EmaD comprising SEQ ID NO:8, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:7 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 9, 10, 33, 34 and partially 11-24, 35-51

Streptococcal polypeptide EmaE comprising SEQ ID NO:10, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:9 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

6. Claims: 52-54

Streptococcal Ema polypeptide comprising SEQ ID NO:23 and nucleic acid encoding it

7. Claims: 55-57

Streptococcal Ema polypeptide comprising SEQ ID NO:26 and nucleic acid encoding it.

8. Claims: 58, 59

Streptococcal Ema polypeptide comprising SEQ ID NO:37 and nucleic acid encoding it.

9. Claims: 60-62

Enterococcal Ema polypeptide comprising SEQ ID NO:29 and nucleic acid encoding it.

10. Claims: 63-65

Corynebacterium Ema polypeptide and nucleic acid encoding it.

11. Claims: 66, 67 and partially 71

Polypeptide comprising SEQ ID NO:34

12. Claim : 68 and partially 71

Polypeptide comprising SEQ ID NO:35

13. Claims: 69, 70 and partially 71

Polypeptide comprising SEQ ID NO:36

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No

PCT/US 01/24795

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
W0 0012132	A	09-03-2000	AU 5696699 A	21-03-2000
			CA 2341177 A1	09-03-2000
			EP 1121149 A1	08-08-2001
			JP 2002523474 T	30-07-2002
			NO 20010981 A	26-04-2001
			US 2002159997 A1	31-10-2002
			WO 0012132 A1	09-03-2000
-----				
W0 9838312	A	03-09-1998	AU 2192497 A	18-09-1998
			CA 2247072 A1	03-09-1998
			EP 0942982 A1	22-09-1999
			JP 2001505061 T	17-04-2001
			WO 9838312 A1	03-09-1998
-----				